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The tumor suppressor p53 is the most well-studied gene in biology. The majority 
of studies have focused on the ability of p53 to control cell cycle arrest, cellular 
senescence, and apoptosis. Surprisingly, recent studies in mice that retain p53-
mediated metabolic regulation and DNA damage repair but lack these three canonical 
functions exhibit significant tumor suppression. However, the effects of nutrient 
availability on p53 and p53-mediated metabolic regulation require additional study. 
Importantly, we have previously shown that ribosomal proteins bind to MDM2, the 
primary negative regulator of p53, stabilizing p53 in response to stress. Studies of mice 
deficient in ribosomal protein-Mdm2 binding demonstrated that p53 regulates lipid 
catabolism in the liver during starvation. These ribosomal protein-Mdm2 binding-
deficient mice were then evaluated in response to high fat diet feeding. p53 was 
similarly activated in a ribosomal protein dependent manner, but surprisingly p53 
activation promoted energy storage in the adipose tissue through altered regulation of 
Glut4 and Sirt1. Therefore, p53 responds to various levels of nutrient availability to 
regulate lipid metabolism in multiple tissues. 
In my dissertation work, I mined a previously published mRNA microarray in 
order to determine potential mechanisms for the metabolic phenotypes that were 
	 iv	
observed in the previous mouse studies. From this work, I identified two novel p53 
target genes associated with metabolism. Interestingly, the peroxisomal gene carnitine 
O-octanoyl transferase (CROT) was identified and is known to regulate very long chain 
fatty acid (VLCFA) metabolism. Further study completed by me established CROT as a 
novel p53 target gene in multiple human cancer cell lines. I completed additional 
experiments that suggest that CROT expression affects cellular signaling by modulating 
lipid raft formation through VLCFA-containing sphingolipids. A rate limiting enzyme in 
glycolysis, 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), was also 
identified from this p53 microarray, and further studies using mouse embryonic 
fibroblast cells along with human cancer cell lines demonstrated that p53 regulates 
glucose metabolism to facilitate nucleotide production in response to DNA damage. In 
summary, I have identified two novel p53 target genes by which p53 regulates cellular 
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CHAPTER 1: INTRODUCTION1 
Cell growth and proliferation are two fundamental processes essential for both 
sustaining cell viability and yielding successive progeny. As a part of a larger gene 
regulatory system, there exists tight coupling between these two processes to facilitate 
homeostasis. Cell cycle regulation, an inherent function of proliferation, is affected by 
the activity of tumor protein p53 (TP53 or p53). Emerging evidence is revealing that 
signaling pathways converge on p53 to connect protein synthesis, the driving force 
behind cell growth, to the regulation of the cell cycle by which cell division and 
proliferation is governed. In addition to the tight regulation between cell growth and 
proliferation, proper conversion of template DNA to ribosomal RNAs (rRNAs) and 
messenger RNAs (mRNAs) must also be preserved along with the maintenance and 
rapid turnover of ribosomes. The ribosome is the cellular organelle responsible for the 
coordination of mRNA transcripts and charged tRNA molecules, to form the peptide 
bonds required for the synthesis of proteins, which are the primary effector molecules of 
the cell. Given the central role that protein synthesis plays in cell growth and division, it 










of signaling to the p53 stress response pathway, which modulates metabolism and cell 
growth to facilitate cell survival. The roles of ribosomal proteins as nutrient sensors and 
the metabolic regulation exerted by p53 will be the focus of the following work with 
particular emphasis on the implications of this pathway in the treatment of cancer.  
INTRODUCTION TO BASIC RIBOSOME STRUCTURE, FUNCTION, AND 
ASSEMBLY 
Cells are made up of countless small molecules including sugars, lipids, and 
nucleic acids, but the most ubiquitous and influential materials in the cell are proteins, 
which can only be synthesized by other proteins organized into specific arrangements to 
form ribosomes. As mentioned previously, protein synthesis is essential for translating 
the genetic code into functional units of the cellular machinery. At the core of this 
process is the ribosome, a complex comprised of ribosomal proteins, auxiliary factors, 
and ribosomal RNA (rRNA). Eukaryotes express 79 ribosomal proteins that combine 
with rRNAs to form the large and small subunits of the mature 80S ribosome (Boisvert 
et al., 2007). The early studies of the ribosome utilized these sedimentation coefficients, 
which represent protein precipitation in response to forces generated using a centrifuge, 
to differentiate between the subunits (40S, 60S) and the mature ribosome (80S) 
(Kazemie, 1974). The balance between rRNA and ribosomal protein synthesis is 
complex and energetically demanding as ribosome biogenesis requires a significant 
portion of cellular resources. In yeast, and presumably in mammalian cells, upwards of 





Ribosome biogenesis occurs in the nucleolus, a condensed non-membrane 
bound section of the nucleus that contains a number of uncharacterized proteins and 
chromosomal DNA (McStay, 2016). The lack of a membrane barrier between the 
nucleolus and the nucleoplasm is unique among organelles, as it allows for the free 
exchange of molecules between these two compartments. An estimated 30% of 
nucleolar proteins are involved in ribosome biogenesis, marking the nucleolus as the 
central location for ribosome assembly (Boisvert et al., 2007). Prior to transcription of 
ribosomal genes, tandem repeats of chromosomal rDNA genes are arranged in the 
nucleolar organizing regions (NOR). Upon establishment of the NOR, the 47S precursor 
rRNA is then transcribed by RNA polymerase I (POLRI) in the fibrillar center of the 
nucleolus and then further processed to form the mature 18S, 28S, and 5.8S rRNAs 
(Boisvert et al., 2007). In contrast, the gene encoding the 5S rRNA is transcribed by 
RNA polymerase III (POLRIII) prior to export from the nucleolus to the cytoplasm where 
it binds ribosomal protein L5 (RPL5) and ribosomal protein L11 (RPL11) to form the 5S 
ribonucleoprotein (5S RNP) (Szymanski et al., 2003). Ribosomal proteins can only be 
transcribed by RNA polymerase II (POLRII) before being exported from the nucleus for 
translation. The majority of ribosomal proteins demonstrate basic isoelectric points, 
which facilitates their association with the rRNA molecules found in the ribosome 
(Lempiainen and Shore, 2009).  After translation in the cytoplasm, the nascent 
ribosomal proteins are then imported back into the nucleolus for assembly of the large 
60S and small 40S ribosomal subunits.  
In the absence of sufficient rRNA, many ribosomal proteins are hypothesized to 
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form negative feedback loops to prevent their own transcription and translation thus 
avoiding the aberrant accumulation of ribosomal proteins. For example, several 
ribosomal proteins including ribosomal protein S14 (RPS14), RPL30, and RPL12 in 
model organisms, along with RPS13 in humans have been shown to inhibit their own 
transcription or mRNA splicing thereby forming negative feedback loops (Macias et al., 
2008; Malygin et al., 2007; Mitrovich and Anderson, 2000; Tasheva and Roufa, 1995). 
Similarly, RPL2 and RPS28 both shorten the half-lives of their own mRNA transcripts 
(Warner and McIntosh, 2009). The discovery of these feedback loops suggests that 
ribosomal protein levels need to be tightly controlled by the cell for viability and growth. 
RNA interference has been utilized in the study of various proteins after it was initially 
discovered that introduction of short double stranded RNAs silenced genes containing 
the homologous sequence in C. elegans (Fire et al., 1998). The result of this 
observation is that short interfering RNAs (siRNA) of approximately 21-22 nucleotides 
can be introduced to cells to specifically decrease expression of a gene using the cell’s 
own machinery to degrade the double stranded RNA complexes created by siRNA 
binding to specific mRNA transcripts (Elbashir et al., 2001). Consistent with these 
observations, siRNA mediated suppression of a single ribosomal protein within the 
small subunit of the ribosome in HeLa cells can cause the concomitant suppression of 
the expression of other RPS proteins while having no effect on the expression of RPL 
proteins. The decreased expression of subunit-specific ribosomal proteins was also 
observed for siRNA-mediated knockdown of RPL protein expression, suggesting that 
feedback inhibition can prevent the accumulation of subunit-specific ribosomal proteins 
and avoid stoichiometric imbalances (Robledo et al., 2008). Importantly, the translation 
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of mRNA in general, as well as specific transcripts, is inhibited by free subunits of RPL7 
and RPL13a, further supporting the importance of maintaining ribosomal protein 
stoichiometry (Mazumder et al., 2003; Neumann et al., 1995). This method of auto-
regulation could play an important role in maintaining normal translation activity and 
preventing the activation of the p53-mediated stress response pathway that will be 
covered later in this work. 
RIBOSOME BIOGENESIS IS POSITIVELY REGULATED BY ONCOGENES 
Cancer cell proliferation requires high levels of protein synthesis and 
correspondingly high levels of ribosome biogenesis. A number of oncogenes such c-
MYC, protein kinase B (AKT) and extracellular signal-regulated kinases (ERK) have 
been shown to upregulate ribosome biogenesis through various mechanisms (Figure 
1.1). 
c-MYC is a general transcription factor that regulates the transcriptional activity of 
all three RNA polymerases (POLRI, POLRII and POLRIII). Briefly, c-MYC co-localizes 
with its binding partner Max to E-box sequences found within the promoter region of 
rDNA, resulting in an increase in POLRI transcriptional activity (Grandori et al., 2005). c-
MYC also activates POLRIII transcriptional activity through its direct association with 
transcription factor III B (TFIIIB). The association between c-MYC and TFIIIB is 
observed within the promoter regions of both 5S rRNA and tRNA codons; moreover, 
this association correlates with increased transcription of these genes (Gomez-Roman 
et al., 2003). c-MYC regulation of POLRII-mediated transcription, the RNA polymerase 
responsible for the transcription of ribosomal proteins and other proteins associated with 
ribosome biogenesis, is evident based on the increased presence of c-MYC within 
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POLRII promoter regions (Menssen and Hermeking, 2002). Recent studies have shown 
that c-MYC also regulates POLRII-mediated transcription by increasing the rate at 
which previously assembled complexes initiate transcription, which is known as pause 
and release regulation (Rahl et al., 2010). Furthermore, c-MYC driven increases in 
ribosome biogenesis play a central role in c-MYC driven tumorigenesis as deletion of 
one allele of RPL24 or RPL38 inhibits the development of Eμ-MYC driven lymphoma 
(Barna et al., 2008). Therefore, c-MYC activation is connected to each component of 
the transcriptional machinery required for ribosomal biogenesis, and insufficient levels 
of certain ribosomal proteins are capable of ablating c-MYC-mediated proliferation. 
The mechanistic target of rapamycin (mTOR) is an atypical serine/threonine 
protein kinase that regulates cell proliferation and survival through two complexes 
named mTORC1 and mTORC2 (Laplante and Sabatini, 2012). The PI3K-AKT-mTORC1 
pathway directly regulates ribosomal protein and rRNA synthesis through the activation 
of ribosomal S6 kinase (S6K), which phosphorylates RPS6. In non-Hodgkins 
lymphoma, RPS6 phosphorylation is associated with increased translation of 5’ terminal 
oligo-pyrimidine (TOP) genes, which include ribosomal proteins, splicing factors, and 
translation elongation factors (Hagner et al., 2011). mTORC1 also associates with either 
TIF-IA or upstream binding factor (UBF), a necessary cofactor in the initiation of 
transcription by POLRI, to upregulate rRNA transcription. mTORC1 is further involved in 
the processing and maturation of rRNA in the nucleolus (Mayer and Grummt, 2006). In 
addition to mTOR, AKT can also upregulate rRNA synthesis and consequently, 
ribosome biogenesis in coordination with c-MYC, with some portion of c-MYC-mediated 
ribosome biogenesis actually being dependent upon AKT activation (Chan et al., 2011).  
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The Ras-ERK oncogenic pathway coordinates with the c-MYC and AKT signaling 
axes to form a complex network of oncogenes that positively regulate ribosome 
biogenesis. The Ras-ERK pathway has also been shown to increase the activity of 
ribosomal S6 kinase, which functions in a similar manner as mTOR-activated S6K to 
increase ribosome biogenesis (Roux et al., 2007). All in all, oncogene activation controls 
ribosomal biogenesis through diverse mechanisms suggesting that rapid turnover of 
ribosomes could be a central component of cancerous growth. 
RIBOSOME BIOGENESIS IS REPRESSED BY TUMOR SUPPRESSORS 
In contrast to oncogenes, which upregulate ribosome biogenesis, tumor 
suppressors primarily inhibit this process (Figure 1.1). Increased expression of the 
tumor suppressor Rb directly inhibits ribosome biogenesis through its association with 
UBF in the nucleolus thereby preventing the proper assembly of the POLRI transcription 
complex responsible for precursor 47S rRNA synthesis in mouse fibroblast cells 
(Hannan et al., 2000). Similar to Rb, p53 also binds selective factor 1 (SL1), a member 
of the UBF transcription complex, in the nucleolus to inhibit POLRI activity (Zhai and 
Comai, 2000). Other studies have shown that p53 also inhibits POLRIII through direct 
binding of TFIIIB, which results in the sequestration of TFIIIB from active transcription 
complexes (Cairns and White, 1998).  
The tumor suppressor ARF has been shown to inhibit ribosome biogenesis 
through multiple mechanisms. ARF can potently activate p53 by binding and inhibiting 
mouse double minute 2 (MDM2); however, ARF can also inhibit ribosome biogenesis 
through p53-independent mechanisms (Zhang et al., 1998). ARF also inhibits the 
phosphorylation of UBF independent of its ability to bind MDM2 (Ayrault et al., 2006). 
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Moreover, ARF inhibits rRNA processing by promoting the degradation of the 
nucleophosmin (NPM)/B23 complex, a multifunctional complex in the nucleolus that 
plays a central role in ribosome biogenesis (Itahana et al., 2003). 
Another tumor suppressor that inhibits ribosome biogenesis is the PTEN 
phosphatase, which dephosphorylates phosphatidylinositol-3,4,5-triphosphate resulting 
in the inhibition of the PI3K-AKT pathway (Li et al., 2014b). PTEN has also been shown 
to inhibit ribosome biogenesis in a more direct manner by blocking SL1-UBF complex 
recruitment to rDNA promoter regions (Zhang et al., 2005). Current data suggest that 
cytoplasmic and nuclear pools of PTEN can coordinate the inhibition of ribosome 
biogenesis through two distinct mechanisms, further demonstrating the importance of 
monitoring flux through the ribosome biogenesis pathway. Altogether, tight regulation of 
ribosome biogenesis is accomplished by oncogenes and tumor suppressor genes that 
appear to focus primarily on the two signaling nodes S6K and UBF. 
RIBOSOME BIOGENESIS AND DISEASE 
Mutations in ribosomal proteins, or proteins associated with ribosome biogenesis, 
are associated with a number of phenotypes and developmental deficiencies classified 
as ribosomopathies. Generally speaking, most conditions arising from ribosomopathies 
cannot simply be explained by decreased protein synthesis. For example, Diamond–
Blackfan anemia (DBA), one of the earliest and most well-studied ribosomopathies, is 
characterized by a decrease in the viability of erythroid progenitor cells that often 
presents early in infancy. Genetic mapping of DBA patients found that 25% of DBA 
patients exhibit RPS19 deletions (Draptchinskaia et al., 1999). Mutations that impair the 
stability or localization of additional ribosomal proteins including RPS7, RPS10, RPS17, 
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RPS24, RPS26, RPL5, RPL11, and RPL35A have also been associated with the 
manifestation of DBA (Boria et al., 2010). Furthermore, DBA patients commonly show 
diverse physical malformations suggesting that the effects of DBA extend beyond 
erythroid progenitors (Gazda et al., 2008). Interestingly, not all ribosomal protein 
mutations exert identical phenotypes, with cells harboring mutations in RPL11 exhibiting 
delayed differentiation and increased apoptosis compared to cells harboring the more 
common RPS19 mutations. Decreased cell proliferation and increased p53 activity were 
also observed in response to shRNA knockdown of RPL11 and RPS19, implicating 
excessive p53 activity as a potential contributor to DBA. Consistent with this notion, 
shRNA against p53 partially rescues the DBA phenotype (Moniz et al., 2012). Analysis 
of the North American DBA patient registry further supports the connection between 
DBA and p53 by revealing that DBA patients are at higher risk of developing various 
forms of cancer than the general population, suggesting a correlation between altered 
ribosome biogenesis and cancer, which could be mediated by p53 (Vlachos et al., 
2012). More specifically, DBA patients display an increased risk of acute myeloid 
leukemia (AML), colon carcinomas, and osteogenic sarcomas (Vlachos et al., 2012). 
Conversely, a separate study using human TF1 cells suggested that, independent of 
p53 activation, depleted expression of RPS19, RPL5, and RPL11 caused cells to be 
more susceptible to oxidative stress, leading to decreased cell proliferation (Aspesi et 
al., 2014). Thus, while a number of studies and the increased likelihood of cancer 
development both suggest that DBA may be dependent upon ribosomal protein 
mutations and p53 activation, the exact mechanism of DBA remains to be fully 
elucidated. 
	 10	
5q-syndrome is another well-studied ribosomopathy that is characterized by the 
World Health Organization as a myelodysplastic syndrome associated with the deletion 
of chromosome 5 between q21 and q32. 5q-syndrome presents with macrocytic 
anemia, increased platelet counts, and increased megakaryocyte levels; yet, the 
number of erythroblasts in the bone marrow is less than 5% of normal (Vardiman et al., 
2002). The deleted region on chromosome 5 was observed to contain 40 genes, but 
only shRNA-mediated depletion of RPS14 recapitulated the 5q-syndrome phenotype in 
hematopoietic progenitor cells. Importantly, lentiviral expression of RPS14 in CD34+ 
cells rescues the differentiation of erythroid progenitor cells from 5q-syndrome patients. 
The depletion of RPS14 caused an accumulation of 30S precursor rRNA, a hallmark of 
ribosomal stress, and patients show significant response to the chemotherapeutic 
lenalidomide through an unknown mechanism that may involve p53 (Ebert et al., 2008; 
Wei et al., 2013). Furthermore, 5q-syndrome patients show a higher likelihood of 
developing acute myeloid leukemia, strengthening the connection between 5q-
syndrome and the tumor suppressor p53 (Ebert et al., 2008; Van den Berghe et al., 
1985).  
Ribosomopathies are not restricted to mutations in genes that encode ribosomal 
proteins, as mutations in factors that facilitate proper rRNA processing and subunit 
maturation are associated with Shwachman-Diamond syndrome (SDS) and Treacher-
Collins syndrome (TCS) (Freed et al., 2010). TCS is caused by mutations that result in 
early termination of the TCOF gene, which encodes the Treacle protein (Valdez et al., 
2004; Wise et al., 1997). Treacle has been shown to colocalize with UBF, the same 
signaling node used by tumor suppressors to regulate ribosome biogenesis. Preliminary 
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studies using siRNA against Treacle in HeLa cells and TCOF+/– MEF cells show that 
Treacle expression is necessary for rRNA production (Valdez et al., 2004). TCS patients 
exhibit varying degrees of craniofacial disorder because of increased neuroepithelial 
apoptosis during early development. This phenotype is recapitulated in TCOF+/– mice, 
and the observed apoptosis in neuroepithelial cells can be blocked through injections of 
the p53 inhibitor pifithrin-alpha. Furthermore, knockout of p53 in TCOF+/– mice rescues 
the craniofacial phenotype, suggesting that TCS is p53 dependent (Jones et al., 2008). 
SDS patients show a diverse array of phenotypes including pancreatic insufficiency, 
short stature, anemia, skeletal abnormalities and endocrine abnormalities along with 
defects in T- and B-cell function (Shimamura, 2006). SDS patients commonly show 
mutations in the SBDS gene, which participates in the maturation and export of the 60S 
subunit, that results in truncated protein production (Ganapathi et al., 2007). RNAi-
mediated knockdown of SBDS in human fibroblasts and SDS patient samples both 
display decreased rRNA synthesis, in addition to increased Fas-mediated apoptosis 
(Ganapathi et al., 2007; Rujkijyanont et al., 2008). As Fas is a known p53 target gene, 
the SDS phenotype is likely to be driven by ribosomal stress-mediated activation of p53 
(Owen-Schaub et al., 1995). 
Cartilage hair hypoplasia (CHH) is a ribosomopathy associated with short-limbed 
dwarfism and immune cell deficiencies. CHH patients commonly show mutations in the 
RMRP gene that encodes a ribonucleoprotein responsible for pre-rRNA cleavage and 
maturation (Ridanpaa et al., 2001). Analysis of the CHH patient database in Finland 
revealed that CHH patients exhibit a seven-fold higher likelihood of developing non-
Hodgkin’s lymphoma at an early age and a ten-fold increased likelihood of developing 
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basal cell carcinoma compared to the non-CHH population (Taskinen et al., 2008). 
Given the similarity of CHH to other ribosomopathies, this increase in cancer risk could 
be due to increased mutational pressure on p53, but additional studies on CHH and p53 
are needed. 
Ribosomal proteins have also been implicated in multiple diseases such as 
Alzheimer’s and type 1 diabetes. Studies have demonstrated that RPL10 binds 
Presenilin-1, a regulator of β-amyloid peptides, the accumulation of which is associated 
with Alzheimer’s disease. RPL10 binding to Presenilin-1 appears to further modulate c-
Jun transcriptional activity; however, whether this interaction plays a role in the 
development of Alzheimer’s disease has not been confirmed (Imafuku et al., 1999). 
Studies using large-scale integrative genomics to analyze human liver tissue have 
shown that reduced expression of RPS26 is associated with increased susceptibility to 
type 1 diabetes through a currently unknown mechanism (Schadt et al., 2008).  
The tight regulation of ribosome biogenesis by both oncogenes and tumor 
suppressors suggests that this pathway is connected to cancerous growth. Indeed, 
model organisms with alterations in ribosome biogenesis show an increased risk of 
cancer (MacInnes et al., 2008; Watson et al., 1992). In human tumors, ribosomal 
proteins are often overexpressed in breast, prostate, cervical, esophageal and liver 
cancers when compared with normal tissues (van Riggelen et al., 2010). The 
deleterious effects of many ribosomopathies, particularly DBA and 5q-syndrome, 
correlate with increased p53 activation, and lenalidomide can be used to treat at least 
one ribosomopathy through a mechanism that is poorly understood but may involve the 
destabilization of p53 (Wei et al., 2013). The connection between ribosomopathies and 
	 13	
p53 activation may also explain the observed increase in cancer risk because chronic 
p53 activation may induce mutational pressure on p53, which could then facilitate 
cancer.  
In conclusion, ribosomopathies are associated with a wide array of phenotypes 
that cannot be fully explained by a decrease in protein synthesis. Thus, this class of 
diseases provides valuable physiological evidence of extraribosomal functions for 
ribosomal proteins and other factors involved in ribosome biogenesis. 
EXTRARIBOSOMAL FUNCTIONS OF RIBOSOMAL PROTEINS 
The fundamental role of ribosomal proteins is primarily structural in that 
ribosomal proteins are the building blocks of the small and large ribosome subunits, but 
ribosomal proteins have also been reported to be involved with additional processes 
including pre-ribosomal particle assembly, rRNA folding, stabilization, processing, and 
transport (Tschochner and Hurt, 2003). Although many of these functions are inherent 
to ribosome assembly, maturation, and function, ribosomal proteins have been reported 
to have a number of extraribosomal functions related to cell growth and division, as well 
as cell death (Lindstrom, 2009).  
One of the central processes of extraribosomal protein function identified is the 
regulation of cell growth and proliferation. As mentioned previously, mTOR is a key 
master regulator of cell growth, and phosphorylation of RPS6 via mTOR signaling 
modulates the rate of protein synthesis. Knock-in mice containing a non-
phosphorylatable allele of Rps6 surprisingly show increased rates of protein synthesis 
and cell division at the expense of normal cell growth, indicating the importance of Rps6 
in driving optimal growth conditions (Ruvinsky and Meyuhas, 2006). Interestingly, 
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conditional deletion of Rps6 in mouse hepatocytes has no effect on mitogenic 
stimulated growth, but does inhibit proliferation (Volarevic et al., 2000). These 
observations are similar to T-cell-specific Rps6 knockout mice in which monoallelic 
depletion is sufficient to inhibit proliferation and biallelic deletion completely inhibits T-
cell maturation (Sulic et al., 2005). The results show the importance of RPS6 in 
coordinating the growth-promoting effects of mTOR with cell-cycle dynamics. 
Early studies of ribosomal proteins focused on RNA binding related 
extraribosomal functions. RPS1 associates with a bacteriophage Qβ peptide and 
endogenous peptides EF-Tu and EF-Ts to form the bacteriophage Qβ replicase 
(Blumenthal and Carmichael, 1979). Subsequent studies have shown that bacterial 
ribosomal proteins RPS10 and RPS4 exhibit anti-termination effects on specific mRNAs 
when associated with the NUS complex after lambda phage infection (Luo et al., 2008; 
Torres et al., 2001). RPL22 has been shown to bind to EBER-1 RNA of the Epstein-Barr 
virus; however, it remains unclear whether ribosomal proteins regulate viral RNA 
transcript stability or vice versa (Fok et al., 2006). The fact that ribosomal proteins 
exhibit RNA binding is not unsurprising given that the central component of ribosome 
function requires mRNA and rRNA association, but the fact that multiple ribosomal 
proteins have been implicated in RNA biology independent of the ribosome suggests 
that ribosomal proteins are not as well-understood as previously thought. 
In addition to RNA binding, ribosomal proteins also regulate gene transcription. 
For instance, the transcription factor CHOP (GADD153) is upregulated during erythroid 
differentiation and regulates activity of CEB/P to control a subset of genes contributing 
to robust differentiation. RPS3a can bind to CHOP to alter CHOP–CEB/P transcriptional 
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activity and inhibit erythroid lineage progression (Cui et al., 2000). Similarly, RPS3 has 
further been shown to exert a non-ribosomal function through its DNA endonuclease 
activity associated with the processing of UV-induced DNA damage (Kim et al., 2006). 
Other studies of RPS3 have shown that this protein also functions as a critical 
component of the NF-ΚB transcription complex in response to cellular stresses. The KH 
domain, which is present in many proteins that bind single-strand DNA or RNA, of RPS3 
facilitates many of these extra-ribosomal activities (Wan et al., 2007). Studies using 
endogenous RPL7 in human lymphoma cells and overexpression in yeast showed that 
through its basic N-terminus, RPL7 associates with and inhibits the transcriptional 
regulation of the nuclear receptors that bind vitamin D and retinoic acid (Berghofer-
Hochheimer et al., 1998). In another study, RPL4 was shown to bind to RNase E to 
modulate its activity in response to cellular stress (Singh et al., 2009). Additionally, 
RPL11 binds and inhibits peroxisome proliferator-activated receptor-alpha, a 
transcription factor associated with various metabolic targets (Gray et al., 2006). RPL22 
has also been shown to bind histone H1 in Drosophila melanogaster, which could have 
implications in a variety of diseases, as histones are central regulators of gene 
transcription. Furthermore, the expression levels of RPL22 inversely correlate with 
overall mRNA transcription, as overexpression of RPL22 mimics the gene repression 
observed upon overexpression of histone H1 (Ni et al., 2006). The binding of nuclear 
receptors, histones, and RNases is an important component of ribosomal protein 
biology that has only recently been recognized, and further studies will likely identify 
similar extraribosomal functions that affect various diseases. 
Ribosomal protein functions are not limited to protein synthesis and transcription, 
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as multiple studies suggest that ribosomal proteins also function as regulators of cellular 
signaling. RPL11 has been shown to reduce cell proliferation through decreased 
ribosome biogenesis by inhibiting c-MYC-dependent transcription (Dai et al., 2007). 
RPL23 has also been shown to bind and sequester NPM from Miz1, a known inhibitor of 
c-MYC-dependent cell proliferation, to facilitate cell proliferation (Wanzel et al., 2008). 
RACK1, a protein that was identified primarily for its role in cell signaling, has been 
shown to associate with the small subunit of the ribosome (Sengupta et al., 2004). 
RACK1 is one of the few ribosomal proteins in which its non-ribosomal functions have 
been more thoroughly studied than its role as part of the ribosome (Warner and 
McIntosh, 2009). RACK1 functions as a scaffold protein that associates with a diverse 
array of binding partners including kinases, phosphatases, and G proteins among 
others to regulate a number of cellular processes, which inherently connects RACK1 to 
cancer development (Li and Xie, 2014). RPS3 and RPS6 bind HSP90, a protein 
chaperone, to prevent their own proteasomal degradation. Similarly, increased 
expression and nuclear localization of RPS3 appears to be involved in the induction of 
apoptosis in a caspase-dependent manner (Jang et al., 2004); however, this function 
may involve p53 activation mediated by the RP-MDM2-p53 pathway that will be 
discussed later in this work. Overexpression of RPS29 causes an increase in apoptosis 
in non-small cell lung cancer cells, which coincides with increased expression of p53 
and the pro-apoptotic p53 target gene Bax (Khanna et al., 2003). RPL10 binds and 
inhibits the proto-oncogene c-Jun, a member of the AP-1 transcription factor and 
downstream target of both the WNT and MAP kinase pathways (Monteclaro and Vogt, 
1993; Nateri et al., 2005). Additional functions ascribed to ribosomal proteins include 
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modulation of DNA repair (Hegde et al., 2004a, b; Yadavilli et al., 2007), cell migration 
and invasion (Liu et al., 2007; McDonald et al., 2008; Yang et al., 2013), and regulation 
of cell differentiation (Duan et al., 2011; Uechi et al., 2008; Uechi et al., 2006; Yadav et 
al., 2014). As research progresses, the identification of additional extraribosomal 
functions will likely extend to more cellular processes and further emphasize the 
importance of ribosomal protein biology. Regardless, one central component of both 
ribosomopathies and extraribosomal functions is that many are associated with p53 
activation. 
p53 SURVEILLANCE OF NUCLEOLAR STRESS 
A number of studies have alluded to “nucleolar stress” as the key event capable 
of inducing the ribosomal protein (RP) – MDM2 – p53 stress response. Within this 
context, nucleolar stress specifically refers to perturbations of ribosome biogenesis and 
the subsequent breakdown of nucleolar structure, resulting in p53 activation (Bursac et 
al., 2014). Nucleolar stress and subsequent p53 activation is observed in response to a 
variety of stresses. DNA damage also activates p53 through a similar mechanism as 
demonstrated by altered nucleolar structure following severe stress and highlighted by 
the disruption of nucleolar caps that form from condensation and segregation of 
nucleolar proteins and rRNA. Hypoxia, heat shock, and growth factor deprivation all 
disrupt nucleolar structure in a similar manner to DNA damage (Boulon et al., 2010; 
James et al., 2014). These observations, in part, have led to the hypothesis of the 
nucleolus as a central stress response regulator for activation of p53 (Rubbi and Milner, 
2003). 
Perturbations to rRNA synthesis, processing, and posttranslational modification 
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can all disrupt ribosome biogenesis to trigger nucleolar stress and activate a p53-
dependent response. Pharmacological inhibition of POLRI by the antineoplastic 
compound actinomycin D (ActD) disrupts synthesis of 47S rRNA precursor and results 
in p53 stability (Blattner et al., 1999; Iapalucci-Espinoza and Franze-Fernandez, 1979; 
Sobell et al., 1971). Importantly, low levels of ActD (~5 nM) inhibit rRNA transcription 
independent of the DNA damage that is observed with higher concentrations of ActD 
(Iapalucci-Espinoza and Franze-Fernandez, 1979).  
In similar fashion, rRNA transcription is impaired through misincorporation of 
nonfunctional nucleotide analogues into nascent transcripts. The metabolite of 5-
fluorouracil (5-FU), which misincorporates into DNA in place of uracil increases p53 
activation (Longley et al., 2003; Sun et al., 2007). Another example is mycophenolic 
acid (MPA), a compound that inhibits inosine monophosphate dehydrogenase, resulting 
in depletion of guanine nucleotide pools and depletion of rRNA synthesis (Huang et al., 
2008). Loss of POLRI function, by pharmacological or chemical inhibition, has also been 
shown to induce nucleolar stress. Mouse embryonic fibroblasts (MEFs) lacking 
expression of TIF1A, a member of the POLRI transcription complex, show attenuation 
of rRNA transcription, elevation of p53, and activation of apoptosis (Yuan et al., 2005). 
Moreover, depletion of additional cofactors essential for rRNA transcription have been 
shown to elevate nucleolar stress. Loss of the U3 small nucleolar RNA-containing RNP 
complex protein, BAP28, triggers p53-dependent apoptosis in zebrafish (Yuan et al., 
2005). Likewise, inhibition of UBF (Ayrault et al., 2006), TIF-IA (Parlato et al., 2008), or 
SL1 complex recruitment (Zhang et al., 2005) to rDNA promoters activate p53-
dependent responses through mechanisms that may include decreased rRNA 
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transcription. 
Ribosomal protein imbalances resulting from individual protein depletion induce 
p53 accumulation and transactivation. Knockdown of either the 40S small subunit 
protein, RPS9 (Lindstrom and Zhang, 2008), or the 60S large subunit RPL29 (Liu et al., 
2006) impacts cell-cycle kinetics, proliferation, and differentiation in human cell lines. 
Partial imbalances achieved through siRNA knockdown of RPL11 (Bhat et al., 2004), 
RPL5 (Dai and Lu, 2004), RPS7 (Zhu et al., 2009), and RPS3 (Yadavilli et al., 2009) 
were found to be important for achieving p53 stabilization in response to nucleolar 
stress, but otherwise had little effect in the absence of any additional form of stress. The 
observations are different for RPL23 knockdown, in which p53 is activated even in the 
absence of an exogenous stressor, indicating that not all protein imbalances exert equal 
contributions to p53 regulation (Jin et al., 2004). Novel insights to ribosomal protein 
imbalances have also been gleaned from in vivo studies. For instance, ablation of Rps6 
in T cells of mice inhibits T-cell development and subsequent accumulation in the 
spleen and lymph nodes in a manner dependent on p53 (Sulic et al., 2005). Like Rps6, 
depletion of Rpl22 was identified to selectively block lineage progression of αβ	T cells 
by inducing p53-dependent cell-cycle arrest (Anderson et al., 2007). In the liver of mice, 
hepatocytes deficient for Rps6 also activate p53 via a mechanism dependent on Rpl11 
(Fumagalli et al., 2009). RPS6 haploinsufficency in developing frog oocytes leads to 
perigastrulation lethality as a result of p53-mediated apoptosis (Panic et al., 2006). 
Additional phenotypes displaying gene-specific characteristics are reduced body size in 
Rps19-/- and Rps20-/- mice, as well as hyperpigmentation of the skin owing to 
exacerbated p53-dependent expression of the melanocyte-specific KIT ligand 
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(McGowan et al., 2008). This is also seen in Belly Spot and Tail (BST) mice, in which a 
spontaneously occurring point mutation in Rpl24 confers skin hyperpigmentation, as 
well as congenital malformations of the eye and skeleton, although absolute p53 
dependence has not been clearly shown (Oliver et al., 2004; Tang et al., 1999). The in 
vivo connection between ribosomal biogenesis and p53 stress response is supported by 
gene-specific knockout models, but the understanding of the impact of ribosomal protein 
imbalances on nucleolar function is still incomplete. 
Preservation of posttranscription rRNA fidelity is a key function for maintaining a 
pool of competent ribosomes. Genetic models investigating the perturbation of rRNA 
processing factors have highlighted the essential nature of these components in 
surveillance of nucleolar integrity. BOP1 is part of a multicomponent complex essential 
for correct pre-rRNA processing by mediating cleavage at the internal transcribed 
spacers ITS1 and ITS2 to generate 25S and 5.8S rRNA (Strezoska et al., 2002). 
Inhibition of Bop1 in mouse 3T3 cells via expression of a dominant-negative mutant 
blocks production of mature rRNA transcripts, thereby inhibiting ribosome biogenesis 
and activating p53 (Pestov et al., 2001). Further, disruption of Wrd12, a binding partner 
of Bop1, has been shown to render similar effects on the cell cycle by activating p53 in 
an ARF-independent manner (Holzel et al., 2005; Sugimoto et al., 2003). Deficiency of 
other processing factors like RNA-binding motif protein 19 (Rbm19) in mice disrupts 
embryonic development in a manner dependent on p53-induced apoptosis (Zhang et 
al., 2008). In addition, depletion of Wrd36 in zebrafish perturbs 18S rRNA processing to 
induce p53-dependent activity (Skarie and Link, 2008).  
In actively dividing cells, the translation of ribosomal proteins in the cytoplasm 
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places significant strain on nuclear import machinery to transport ribosomal proteins into 
the nucleolus for the proper assembly of the ribosomal subunits. Correspondingly, a 
transient decrease in the expression of Importin 7 in human cancer cells inhibits 
ribosome biogenesis, disrupts nucleolar structure and activates p53 in an RPL11-
dependent manner (Golomb et al., 2012). Interestingly, 5.8S rRNA was shown to 
covalently bind p53 at a phosphoserine residue near the N-terminus over twenty years 
ago, further linking p53 to ribosome biogenesis; however, the in vivo role and 
significance of this interaction remains unknown (Fontoura et al., 1992). The weight of 
evidence supports the notion that insufficient yields of mature rRNA, improper subunit 
assembly, or accumulation of unprocessed intermediates triggers a nucleolar stress 
response along with p53 activation. 
CHARACTERIZATION OF RIBOSOMAL PROTEIN–MDM2 INTERACTIONS 
The connection between ribosome biogenesis and p53 is clear, but the 
mechanism of this association needed clarification. Studies by a number of labs have 
demonstrated that p53 activation in response to ribosomal stress is dependent upon 
RP-MDM2 binding. The earliest identification of ribosomal protein binding to MDM2 can 
be traced back to some of the original reports identifying MDM2 itself. MDM2 was first 
identified in the 3T3DM tumorigenic mouse cell line, in which amplification of the MDM2 
gene was thought to directly contribute to the transforming potential of the cell 
(Fakharzadeh et al., 1991). Further characterization of MDM2 using a number of rat and 
mouse cell lines suggested that MDM2 binding inhibits p53 transactivation (Momand et 
al., 1992). Continued studies in 3T3DM cells have shown that immunoprecipitation of 
MDM2 consistently pulls down p53, as well as a 34-kDa protein that corresponded to 
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ribosomal protein L5 (RPL5). Northern blot analysis of the immunoprecipitated MDM2 
further revealed that MDM2 – p53 complexes also bind with 5S rRNA (Marechal et al., 
1994). Initially, the ubiquitous expression of ribosomal proteins and rRNAs led to their 
being mislabeled as contaminants in many early experiments delaying the study of the 
RP–MDM2 interactions. It would then take a decade to fully realize the implications of 
these interactions. 
Similar to RPL5, RPL11 also binds MDM2 in HeLa cells, and this association was 
independent of RNA, as shown by RNAse A treatment in U2OS cells. Moreover, RPL11 
was shown to stabilize p53 by binding the central acidic domain of MDM2 independent 
of RPL5, and RPL11–MDM2 association was increased after treatment with low levels 
of ActD (Zhang et al., 2003). This study suggested that RPL11, not RPL5, is the major 
facilitator of ribosomal protein-mediated p53 stabilization. Further investigations have 
shown that simultaneous depletion of large and small subunit proteins results in an even 
greater stabilization of p53 than single subunit inhibition, suggesting that the 
mechanisms behind p53 stabilization in response to small subunit inhibition and large 
subunit inhibition are independent. The p53 stabilization mediated by inhibition of both 
ribosomal subunit assemblies preferentially results in a cell-cycle arrest phenotype, 
rather than the apoptotic response that would be expected with such high levels of p53 
stabilization, through an unknown mechanism (Fumagalli et al., 2012). Numerous 
studies have implicated RPL5 and RPL11 as central mediators of the RP–MDM2–p53 
pathway; however, RPS3 (Yadavilli et al., 2009), RPS7 (Chen et al., 2007), RPS14 
(Zhou et al., 2013), RPS15 (Daftuar et al., 2013), RPS20 (Daftuar et al., 2013), RPS25 
(Zhang et al., 2013b), RPS26 (Cui et al., 2014), RPS27 (Xiong et al., 2011), RPL23 (Jin 
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et al., 2004), RPL26 (Zhang et al., 2010), and RPL37 (Daftuar et al., 2013) have all 
been shown to bind MDM2 as well. The independent functions and contributions of 
each ribosomal protein, if any, are in the early stages of exploration.  
As mentioned previously, 5S rRNA was immunoprecipitated with MDM2 as early 
as 20 years ago (Marechal et al., 1994), but the role of 5S rRNA and the 5S 
ribonucleoprotein (RNP) in the MDM2–p53 pathway has only recently been 
investigated. RPL5 and RPL11 association with MDM2 and subsequent p53 activation 
was shown to require 5S rRNA in a recent study in which siRNA against TFIIIA, a 
component of the POLRIII transcription complex, was used to deplete U2OS cells of 5S 
rRNA (Donati et al., 2013). This finding suggests that 5S rRNA plays a more significant 
role in RPL5 and RPL11 association with MDM2 than previous studies have suggested. 
Additionally, RPL5, RPL11, and 5S rRNA are all required for maintenance of p53 
stability in both stressed and unstressed conditions. The association of 5S rRNA was 
further shown to require RPL5 and RPL11 association as an MDM2 point mutant that 
abrogates RPL5 and RPL11 association does not bind 5S rRNA (Sloan et al., 2013). 
Interestingly, the 5S RNP complex was also shown to be necessary for p14ARF 
stabilization of p53, which supports previous studies in which RPL11 was deemed 
necessary for p14ARF-mediated p53 activation (Dai et al., 2012; Sloan et al., 2013). 
The crystal structure for the yeast ribosome illustrates a central location for the 
RPL5/RPL11/5S RNP complex at the interface of the 60S and 40S subunits. This is a 
key position necessary for ribosome ratcheting, a shift in conformational state that is 
required for proper translational function of the ribosome (Ben-Shem et al., 2011). The 
essential nature for all three components of the 5S RNP complex to bind to MDM2 
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could suggest a mechanism, whereby p53 continuously monitors ribosomal translation 
fidelity. Given the central location of the complex at the subunit interface, it may be the 
most likely first responder to ribosomal stress. Therefore, the RP–MDM2 pathway may 
receive stress signals from oncogenic overproduction of ribosomal proteins, liberation of 
ribosomal proteins from the nucleolus, or the release of ribonucleoproteins from 
disassembly of mature ribosomes. Since ribosomal proteins play irreplaceable roles in 
protein synthesis and the p53 stress response, it is unsurprising that deletion of RPS6, 
RPS19, or RPL11 is embryonic lethal in a number of model organisms (Liu and Zhang, 
2014). However, RPL24 heterozygosity in p53-/- mice results in embryonic lethality, 
which suggests that another layer of complexity exists in the interplay between 
ribosomal proteins, the p53 stress response, and survival (Barkic et al., 2009).   
Ribosomal proteins can also activate p53 through mechanisms independent of 
MDM2 association, thus increasing the complexity by which p53 is regulated. For 
example, RPL26 binds to the untranslated regions of p53 mRNA and augments 
translation through the inhibition of the translation inhibitory nucleolin-p53 mRNA 
association (Chen et al., 2012; Takagi et al., 2005). Moreover, RPL11 has been shown 
to bind p53 response elements upon low levels of ActD treatment, which results in an 
increase in p53-mediated transcription through the recruitment of the p53 co-activator 
p300/CBP (Mahata et al., 2012). Given the numerous and diverse connections between 
ribosome biogenesis, p53 stress response, and disease further study of this interaction 
is needed. Yet, in order to study the effects of the RP-MDM2-p53 on cell physiology and 
cancer biology, the development of appropriate model systems in which RP-MDM2-p53 
can be manipulated was required. It is also equally important that other functions of 
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ribosomal proteins and p53 remain intact in such a system.  
RPL11- and RPL5-MDM2 association occurs primarily in the central zinc finger 
domain of MDM2 and partially overlaps with the binding region of the tumor suppressor 
ARF (Honda and Yasuda, 1999). In vitro studies of cancer-associated MDM2 mutations 
located in the zinc finger domain revealed that a portion of RP-MDM2 binding is 
abrogated (Lindstrom et al., 2007). Based on these observations and the fact that 
several human tumor mutations selectively target the central zinc finger of MDM2, the 
C305F mutation was selected for further study and has been shown to selectively 
prevent RPL5 and RPL11 binding to MDM2 (Lindstrom et al., 2007). Furthermore, the 
development and analysis of the Mdm2C305F knock-in mouse model has been useful in 
extending our understanding on the role of the RP-MDM2-p53 pathway in vivo. 
Importantly, in the Mdm2C305F mouse, the p53 response to DNA damage remains intact; 
however, ribosomal stress induced by low-levels of ActD, MPA, 5-FU, or starvation is 
unable to activate p53 because of the inability of MDM2 C305F to bind RPL5 and 
RPL11. Since c-MYC increases ribosome biogenesis via activation of all three RNA 
polymerases (Gomez-Roman et al., 2003; Grandori et al., 2005; Rahl et al., 2010), the 
Mdm2C305F mouse model was then combined with an Eµ-MYC-driven lymphoma model 
in order to understand the role of the RP–MDM2–p53 pathway in tumorigenesis. This 
study showed that the RP–MDM2–p53 pathway acts in an independent, but relevant 
manner, with the tumor suppressor ARF because oncogenesis is increased in the 
absence of RPL5- and RPL11-mediated p53 activation (Macias et al., 2010). Additional 
studies on the Mdm2C305F mouse model have also shown that the RP-MDM2-p53 
pathway is vital in sensing nutrient deprivation and activating lipid catabolism pathways 
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in the mouse liver in response to acute starvation stress (Liu et al., 2014). Thus, the 
C305F mouse model represents a unique opportunity to directly study the physiological 
role of the RP-MDM2-p53 pathway in vivo. 
Ribosomal proteins have not been shown to bind directly to murine double 
minute 4 (MDM4; aka MDMX), but a recent study suggests that RPL11 association with 
MDM2 also modulates MDMX stability to promote p53 activation. The additional layer of 
regulation on MDMX is necessary during ribosomal stress because neither MDMX nor 
p53 is phosphorylated to inhibit the protein–protein interactions that block p53 
transactivation. In support of this observation, MDMX overexpression was sufficient to 
mitigate ribosomal stress induced by 5-FU and ActD (Gilkes et al., 2006). Therefore, a 
number of ribosomal proteins are capable of increasing p53 activation through multiple 
mechanisms, but RPL5 and RPL11 are considered to be central components of the RP-
MDM2-p53 pathway. 
MDM2-p53 OVERVIEW 
Across all forms of cancer, p53 is the most commonly mutated gene, with 
mutations observed in approximately 50% of tumors and even higher rates of mutation 
being observed in ovarian, lung, head, and neck cancers (Kandoth et al., 2013; 
Vogelstein et al., 2000). Interestingly, p53 was initially characterized as an oncogene 
because the initial clone was actually mutant p53, which has been shown by more 
recent studies to harbor oncogenic gain-of-function activities (Oren and Rotter, 2010; 
Rivlin et al., 2011). Once WT p53 was cloned and studied, p53 was reclassified as a 
tumor suppressor and named “Guardian of the Genome” for its role in DNA damage 
repair (Lane, 1992). p53 tumor suppression activity is best exemplified by the 
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observation that p53-/- mice are susceptible to early onset lymphomas compared to wild 
type (WT) mice (Donehower et al., 1992). One of the most unique findings across 
biology is that elephants are considerably more resistant to cancer than humans even 
though elephants contain many, many more cells capable of developing tumors than 
humans do. A recent study supporting the tumor suppressive function of p53 found that 
elephants possess 40 alleles of TP53 compared to the two alleles that humans carry 
and accordingly, elephants are considerably more sensitive to DNA damage induced 
apoptosis (Abegglen et al., 2015). 
As mentioned previously, MDM2 is the primary negative regulator of p53 through 
its ability to bind the N-terminal domain of p53 which physically prevents p53 
association with DNA. Furthermore, MDM2 acts as an E3 ubiquitin ligase that catalyzes 
the ubiquitination of p53, which leads to the nuclear export and subsequent proteasomal 
degradation of p53 (Pei et al., 2012). The importance of MDM2-dependent regulation of 
p53 is evident in the fact that p53 activation requires the inhibition of MDM2-p53 
association. DNA damage-mediated activation of the ATR-Chk1 or ATM-Chk2 pathways 
results in the phosphorylation of MDM2 and p53 in key residues that prevent their 
association (Chao et al., 2000; Saito et al., 2002; Siliciano et al., 1997). MDM2 
inactivation can also be triggered by oncogene activation, many of which increase the 
transcription of ARF, which binds MDM2 and inhibits p53 association (Hu et al., 2012). 
p53 acetylation can also prevent MDM2-p53 binding and modulate p53 transcription 
through mechanisms that are not yet well understood (Li et al., 2012).  
The p53 stress response pathway results in the stabilization of p53 by inhibiting 
MDM2-p53 association (Figure 1.2). Stabilized p53 is then capable of binding DNA 
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among the promoter regions of numerous target genes that generally serve to suppress 
sources of genomic damage and tumor development (Bieging et al., 2014). The majority 
of TP53 mutations are located in the DNA binding domain of p53 and abolish p53-
mediated transcriptional regulation (Freed-Pastor and Prives, 2012). One of the most 
well-characterized target genes of p53 is actually MDM2, which importantly forms a 
negative feedback loop to rapidly turn off p53 stress response once the activating stress 
is alleviated and p53-MDM2 binding is restored (Barak et al., 1994). The importance of 
tightly regulated p53 is best exemplified by the numerous phenotypes of the 
ribosomopathies discussed previously, as many of these conditions are the result of 
persistent p53 activation.  
The canonical functions of p53 are cell cycle arrest, apoptosis, and senescence. 
However, a recent knock-in mouse model harboring mutations that inhibit the 
acetylation of p53 has illustrated that the p53 exerts significant tumor suppression 
through less well-studied p53 functions such as DNA damage repair, metabolic 
regulation, or reactive oxygen species (ROS) regulation (Li et al., 2012). p53 enacts 
diverse transcriptional programs that vary according to the intensity of the cellular 
stress. For example, although p53 activation induces cell cycle arrest relatively quickly 
in response to several stresses, p53 upregulation of pro-apoptotic genes only occurs in 
response to the most severe forms of stress. Moreover, studies have shown that the 
particular p53 transcriptional response can be altered depending on the duration of p53 
stabilization (Purvis et al., 2012). The presence of hundreds of known p53 target genes 
combined with the fact that p53 responds to various stresses through unique 
transcriptional responses has complicated the study of p53 and prevented p53-centric 
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therapeutics from being used in the clinic. However, further study of p53 and its target 
genes is needed to identify therapeutic targets that can either be manipulated to 
activate p53, such as ribosome biogenesis, or act independently of p53.  
As cancer cells require a high rate of ribosome biogenesis and because 
approximately 50% of tumors retain wild-type p53, targeted inhibition of ribosome 
biogenesis could represent a valuable therapeutic option for cancer patients. Drugs that 
specifically inhibit POLRI can reactivate wild-type p53 through the ribosomal stress 
pathway while simultaneously inhibiting ribosome biogenesis required for rapid cell 
growth. This two-fold tumor suppressive effect may be more effective than some current 
therapies. The small molecule CX-5461 inhibits SL1, which is a necessary cofactor for 
the POLRI transcription complex and correspondingly for rRNA transcription (Drygin et 
al., 2011). The small molecule BMH-21 promotes the proteasome dependent 
degradation of RPA194, which is a member of the POLRI initiation complex, thereby 
inhibiting ribosome biogenesis without triggering the DNA damage response (Peltonen 
et al., 2014). The effectiveness of these compounds in tumors expressing wild-type p53 
is currently unknown, and further studies on this potential therapeutic avenue are 
needed. 
P53 TARGET GENES ARE INVOLVED IN MANY IMPORTANT PATHWAYS 
p53 regulates 100’s of target genes involved in nearly all facets of biology, an 
exhaustive review of which is beyond the scope of this dissertation; however, a 
discussion of p53 target genes involved in the areas of research that will be discussed 
in later chapters is important. One of the first effects of p53 stress response discovered 
was the arrest of cell cycle progression associated with p53 transcriptional regulation. 
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CDKN1A (cyclin-dependent kinase inhibitor 1A), the gene from which p21 is 
transcribed, is likely the most well-studied and influential target gene of p53 (el-Deiry et 
al., 1993). As the gene name suggests, p21 inhibits cyclin-dependent kinases that are 
necessary for cell cycle progression, and Cdkn1a-/- mice exhibit increased spontaneous 
tumor formation by 16 months, suggesting that p21 acts as a tumor suppressor (Martin-
Caballero et al., 2001). p21 has also been implicated in the regulation of apoptosis, 
differentiation, senescence, and DNA damage repair (Kreis et al., 2015). Furthermore, 
p21 expression is regulated both transcriptionally and through E3-mediated 
ubiquitination by p53-dependent and p53-independent mechanisms. For the remainder 
of this dissertation, p21 will be used primarily as a read-out of p53-mediated 
transcriptional activity, but it is important to acknowledge that similar to p53, p21 elicits 
many diverse effects dependent upon upstream signals and cellular context. By 
studying the p53 response elements (p53REs) located within the promoter of CDKN1A, 
a consensus binding sequence for p53 was elucidated to have the following structure 
RRRCWWGYYY / RRRCWWGYYY (where R = A or G, W = A or T, Y = C or T, and / = 
variable length spacer from 0-13 base pairs) (el-Deiry et al., 1992). Genome wide 
studies using ChIP-seq technology have further supported this model, and while subtle 
differences in p53RE sequence between activating and repressing genes have been 
suggested, no significant change to this sequence structure has been established 
(Nikulenkov et al., 2012). 
The second most well-characterized effect of p53 stress response is 
programmed cell death through apoptosis, which can be induced from within the cell 
(intrinsic) or in response to extracellular signals (extrinsic). p53 target genes are 
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involved in both the intrinsic and extrinsic apoptosis pathways. Extrinsically-induced 
apoptosis primarily depends upon tumor necrosis family receptors, including the p53 
target genes FAS and TNFRSF10B, binding extracellular FAS ligand or TNF-α. The 
intrinsic apoptosis pathway is controlled even more tightly by the p53 target genes BAX, 
BBC3 (PUMA), APAF1, and PMAIP1 (NOXA) to release cytochrome c from the 
mitochondria (Fischer, 2017). Cytoplasmic cytochrome c then forms the apoptosome 
leading to increased caspase cleavage and cell death (Kim et al., 2005). Compared to 
the regulation of p21 and MDM2, p53 apoptotic target genes are “late-acting” in the 
sense that p53 needs to be activated either for an extended period or to a significant 
intensity to trigger apoptotic target gene transcription. It is possible that this delay in 
apoptosis allows the cell to recover from the p53-inducing stress prior to committing 
suicide through apoptosis. As apoptosis is considered one of the canonical functions of 
p53 stress response numerous comprehensive reviews are available for further study.  
In addition to cell-cycle arrest and apoptosis, p53 also regulates the permanent 
removal of the cell from the cell cycle known as senescence. As cancer is primarily a 
disease centered upon unwarranted cell proliferation, the tumor suppressive effects of 
senescence are intuitive; however, senescence also plays a role in aging and longevity 
through unknown mechanisms. In addition to a lack of cell cycle progression, senescent 
cells display altered metabolism and increased levels of p16INK4a or β-galactosidase, 
markers which are commonly used to identify senescent cell populations. p53-
dependent regulation of CDKN1A and PML are involved in the induction of senescence 
along with significant crosstalk to the Rb pathway. The occurrence of senescence in 
normal cells was originally identified by Hayflick and the implications of senescent cell 
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secretion in tumorigenesis and aging are currently being investigated by numerous labs. 
 In coordination with cell-cycle arrest, p53 regulates several target genes 
associated with DNA damage repair including the nucleotide excision repair genes XPC 
and DDB2 (Adimoolam and Ford, 2002; Hwang et al., 1999). p53 also regulates 
deoxynucleotide triphosphate (dNTP) pools, which are necessary for replacing 
damaged nucleotides, through the regulation of p53R2 (Tanaka et al., 2000). p53-
mediated DNA damage repair is clearly a tumor suppressive function, as tumors 
commonly accumulate genomic mutations that facilitate increased cell proliferation; 
conversely, once cancer-driving mutations are incorporated, DNA damage repair can 
facilitate tumor survival by decreasing the efficacy of chemotherapy or radiation. p53-
mediated DNA damage repair, nucleotide pools, and metabolic regulation will be 
discussed at greater length in chapter 4.  
Recent studies suggest that p53 regulates multiple metabolic pathways in 
response to diverse forms of cell stress such as nutrient deprivation or DNA damage 
(Figure 1.3). p53 represses the glucose transporters GLUT1 and GLUT4 to decrease 
glucose uptake and glycolysis (Schwartzenberg-Bar-Yoseph et al., 2004b). Moreover, 
p53 activates the transcription of TP53-inducible glycolysis and apoptosis regulator 
(TIGAR) to decrease fructose 2,6-bisphosphate levels, PFK1 activity, and glycolysis 
(Bensaad et al., 2006). Downstream of glycolysis, p53 positively regulates oxidative 
phosphorylation in the mitochondria through several target genes including cytochrome 
C oxidase assembly protein (SCO2) (Matoba et al., 2006). p53 also directly regulates 
the metabolic regulator AMP-activated protein kinase (AMPK) (Feng et al., 2007). 
Lastly, p53 regulation is not limited to glucose metabolism as p53 also regulates the 
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transcription of glutaminase 2 (GLS2) to convert glutamine to glutamate and increase 
oxidative phosphorylation by producing alpha-ketoglutarate (Hu et al., 2010). Moreover, 
breast cancer samples harboring mutant p53 exhibit increased expression of glycolytic 
enzymes and glycolytic flux as measured by extracellular acidification rates (Harami-
Papp et al., 2016). Broadly, p53 increases oxidative phosphorylation and mitochondria 
function at the expense of glycolysis, which fits well with the tumor suppressor function 
of p53 because glycolysis is commonly upregulated many forms of cancer.  
GLUCOSE METABOLISM AND CANCER 
The earliest observation about cancer cell metabolism was made decades ago 
by Otto Warburg. He observed that regardless of oxygen levels, cancer cells 
predominantly utilize glycolysis to generate energy (Warburg, 1956). This finding has 
been confirmed by numerous labs in the years since, but whether increased glycolysis 
is a cancer driver or result of cancer development has never been established. Recent 
work suggesting that glycolysis is utilized in normal endothelial cells to facilitate rapid 
growth for vessel sprouting supports the idea that glycolysis could be a driver of 
cancerous growth rather than a passenger effect (De Bock et al., 2013). This preference 
of glycolysis over the more efficient oxidative phosphorylation pathway suggests that 
the various biomolecules produced with glycolytic intermediates are more important for 
growth than ATP levels alone. Further strengthening the link between glycolysis and 
cancer is the fact that labeled glucose is commonly used diagnostically through PET 
scans to identify potential tumors (Zhu et al., 2011). However, the therapeutic use of this 
glucose dependence has remained elusive. Compounds targeting the glucose 
transporter GLUT 1 to prevent glucose uptake exhibit significant preclinical effects, but 
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the lack of specificity for tumor cells could lead to clinically relevant side effects, as all 
cells express glucose transporters (Ganapathy-Kanniappan and Geschwind, 2013). The 
second step in glycolysis involving hexokinase activity has also been targeted 
successfully in preclinical studies using lonidamine and 2-deoxyglucose (2-DG); yet, 
neither compound has exhibited clear efficacy in clinical trials and further study of 2-DG 
suggests that the mechanism of action extends beyond the inhibition of glycolysis 
(Cervantes-Madrid et al., 2015; Kurtoglu et al., 2007; Zhang et al., 2014; Zhong et al., 
2008). The possibility of combining these compounds with standard chemotherapy or 
radiation is currently being explored. Other therapies targeting enzymes involved in later 
steps of glycolysis have been developed and tested using preclinical models, but the 
use of any inhibitor of glycolysis as a single agent against cancer seems unlikely due to 
the normal cell toxicity observed at concentrations necessary for tumor cell death.  
As the earliest identified and most well-studied component of cancer metabolism, 
it is discouraging that compounds targeting glycolysis have yet to exhibit significant 
therapeutic impact. Glycolytic enzymes are commonly overexpressed or genetically 
amplified rather than expressing a cancer specific point mutation such as the V600E 
BRAF mutation that can be specifically targeting using compounds such as vemurafenib 
(Joseph et al., 2010). A separate complicating factor for targeting glycolytic enzymes is 
that increased mRNA expression does not faithfully predict the activity of metabolic 
enzymes when compared to measuring metabolite levels directly (Hakimi et al., 2016). 
Furthermore, glycolytic intermediates are commonly diverted or supplied by other 
metabolic pathways such as the pentose phosphate pathway (PPP) suggesting that 
inhibiting glycolysis at different steps may result in unique outcomes. The pentose 
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phosphate pathway is particularly interesting as it diverts glucose into forming the 
nucleotide precursor ribose-5 phosphate and NADPH, which can then be utilized in 
lipogenesis or to combat ROS (Patra and Hay, 2014). Therefore, inhibiting enzymes 
involved in the later stages of glycolysis could facilitate cancer cell survival through 
increased PPP flux. Specifically, the increased production of nucleotides could protect 
cancer cells from DNA damage inducing chemotherapy. Interestingly, p53 exerts 
complex regulation over the PPP. During unstressed conditions p53 inhibits the PPP by 
directly binding glucose-6-phosphate dehydrogenase (G6PD) (Figure 1.3), the rate-
limiting enzyme, while in the cytoplasm; however, in response to stress such as 
doxorubicin-induced DNA damage, p53 is predominantly localized in the nucleus and 
unable to bind G6PD (Jiang et al., 2011). Moreover, nuclear p53 regulates the 
transcription of TP53-inducible glycolysis and apoptosis regulator (TIGAR) to promote 
PPP flux by inhibiting glycolysis and increasing glucose-6-phosphate levels (Bensaad et 
al., 2006). Similarly, our work has demonstrated that in response to UV-induced DNA 
damage p53 also represses the transcription of 6-phosphofructo-2-kinase/fructose-2,6-
bisphosphatase 3 (PFKFB3) to inhibit glycolysis and increase PPP production of 
NADPH and ribonucleotides. p53 regulation of PFKFB3, glycolysis, and the PPP will be 
discussed in greater detail in chapter 4. This complex regulation of the PPP by p53 
suggests that this is an important pathway for tumorigenesis and potentially a target for 
cancer therapeutics especially in combination with DNA damaging agents.  
Early experiments using mammary carcinoma bearing mice demonstrated the 
potential efficacy of combining 6-aminonicotinamide (6-AN), an inhibitor of the PPP, with 
radiation treatment. The tumor growth delay was increased from 34.5 days in mice 
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treated with radiation alone to 57 days in mice treated with 6-AN and radiation 
treatment. It is also important to note that in this study 6-AN treatment alone only 
delayed tumor growth for 4.3 days, suggesting significant synergy for 6-AN with 
radiation-induced DNA damage (Koutcher et al., 1996). This finding was further 
supported by studies using mice bearing Ehrlich ascites tumors and the combination 
treatment of 2-DG, 6-AN, and radiation to achieve a cure rate of approximately 75% 
(Varshney et al., 2004). This group then used a panel of cancer cell lines to 
demonstrate that this combination treatment increased ROS through mitochondrial 
dysfunction to activate kinase driven apoptosis (Bhardwaj et al., 2012; Bhardwaj et al., 
2011; Sharma et al., 2012). Unfortunately, the IC50 of 6-AN is in the micromolar range 
and treatment with therapeutically relevant doses leads to side effects limiting the use of 
6-AN; however, multiple groups are working to identify novel G6PD inhibitors for 
additional studies and potential use in the clinic (Gupte, 2008; Preuss et al., 2013). The 
synergy between radiation-induced DNA damage and small molecule inhibitors that 
exert minimal toxicity on their own is called radiosensitization, and this is an attractive 
therapeutic option because off-target effects on a patient’s normal cells should be 
minimized as radiation treatment has become technically more advanced to limit 
collateral tissue damage (Muschel et al., 1998). 
Radiosensitization is not limited to targeting the PPP, as small molecule inhibitors 
of pro-survival or activators of apoptosis have also shown therapeutic benefit. As p53 is 
a positive regulator of apoptosis, the small molecule activator of p53, nutlin-3, has been 
extensively evaluated using preclinical models (Vassilev et al., 2004). Lung cancer cell 
lines treated with nutlin-3 exhibited an increased sensitivity to radiation treatment that 
	 37	
was surprisingly dependent upon increased senescence rather than the expected 
increase in apoptosis (Luo et al., 2013). Further work using nutlin-3 has demonstrated 
radiosensitization that is both independent and dependent of p53 in prostate cancer cell 
lines and tumor xenografts (Supiot et al., 2008; Tovar et al., 2011). Since nutlin-3 
exhibits poor pharmacokinetics for clinical usage, multiple groups have developed 
improved MDM2-p53 inhibitors. AMG232, a MDM2-p53 inhibitor developed by Amgen, 
exhibited synergy with radiation treatment in mouse tumor xenografts using human 
cancer cell lines derived from 4 separate tissues (Werner et al., 2015). Recently, MI-
219, another MDM2 inhibitor, was used to demonstrate that MDM2 inhibition synergizes 
with androgen-deprivation and radiation therapy in a p53 dependent manner using 
mouse tumor xenografts with multiple prostate cancer cell lines (Feng et al., 2016). 
While initial results in preclinical models are encouraging, targeting wild type p53 
presents a number of serious issues. First, non-tumor cell toxicity is a concern as p53 is 
a potent activator of apoptosis and is present in the patient’s normal cell population. 
Secondly, it is important to note that the target of these compounds is MDM2 rather 
than p53. Since MDM2 is one of the strongest p53 regulated genes, a side effect of the 
compound is to increase the amount of MDM2, causing a decrease in the 
compound/target ratio and p53 activation to be relatively short. This effect can be 
overcome by continually increasing the MDM2 targeting compound; however, this 
method is not likely to be feasible in the clinic (Purvis et al., 2012). Considering these 
complications, it is likely that targeting p53 regulated target genes rather than the p53-
MDM2 interaction will be a better therapeutic strategy in the future. 
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LIPID METABOLISM AND CANCER 
The metabolic alterations of cancer cells are not limited to glucose metabolism. 
Many forms of cancer exhibit significant increases in the process required for novel 
synthesis of lipids, called lipogenesis (Swinnen et al., 2006). Lipids are one of the 
biomolecules mentioned previously that can be generated from the acetyl-CoA 
molecules generated by glycolysis, and as lipids are the primary component both 
organelles and cell membranes, the demand for lipids in growing cancer cells is thought 
to be higher than in normal tissue. Indeed, tumors exhibiting significant lipid 
accumulation in the form of subcellular lipid droplets often correlate with chemotherapy 
resistance and poorer prognosis (Beloribi-Djefaflia et al., 2016). On the molecular level, 
the expression of lipogenesis promoting factors including fatty acid synthase (FASN), 
ATP citrate lyase (ACLY), and acetyl-CoA carboxylase (ACC) are increased in multiple 
cancers to facilitate this lipogenic phenotype (Flavin et al., 2010; Wang et al., 2015; 
Wang et al., 2012). Inhibitors targeting these genes have been developed and tested in 
various cancers.  
FASN is a particularly interesting target, as FASN expression has been shown to 
increase in an inverse manner with tumor stage and patient survival (Nguyen et al., 
2010; Notarnicola et al., 2012; Witkiewicz et al., 2008). Preclinical studies have found 
that TVB-3166, a small molecule inhibitor of FASN developed by 3-V Biosciences, 
decreased tumor xenograft growth when used as a monotherapy in various human 
cancer cell lines; however, this monotherapy response was notably weaker than 
treatments with chemotherapeutic agents such as gemcitabine or paclitaxel (Ventura et 
al., 2015). Importantly, 3-V Biosciences has developed an analog of TVB-3166 that is 
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orally available in humans, which is currently in phase 1 clinical trial for dose escalation 
tolerance in advanced stage solid tumor bearing patients (ClinicalTrials.gov Identifier: 
NCT02223247). In the event that this TVB analog is found to be safe, it will likely be 
combined with standard chemotherapy for future clinical use as the preclinical effect of 
the monotherapy was relatively modest. Interestingly, treatment with either sunitinib or 
sorafenib anti-angiogenic therapy reduces tumor growth during treatment; however, 
upon removal of the compound the tumors exhibit visible lipid droplet accumulation and 
rapid regrowth along with increased metastatic potential. Co-treatment with the FASN 
inhibitor orlistat blocked the observed lipid accumulation and regrowth of tumor 
xenografts treated with either sunitinib or sorafenib, suggesting that FASN activity is 
partially responsible for the observed resistance to anti-angiogenic therapy and 
subsequent recovery (Sounni et al., 2014). It is possible that better FASN inhibitors 
could be useful in targeting anti-angiogenic resistance in future studies. In addition to 
FASN inhibitors, researchers at the SALK Institute have recently targeted lipogenesis by 
identifying an allosteric ACC inhibitor that blocks xenograft growth of non-small cell lung 
cancer and exhibits synergy with the chemotherapeutic carboplatin (Svensson et al., 
2016). As mentioned previously, the future clinical utility of these and other metabolic 
compounds is likely to be in combination therapy with agents targeting other pathways. 
Unfortunately, as with most phenotypes in cancer significant heterogeneity exists 
within a single tissue type and especially between different tissue types with regards to 
lipid metabolism. Increased lipogenesis is the most commonly observed phenotype, but 
certain tumors with elevated lipogenesis or lipid scavenging surprisingly exhibit high 
rates of fatty acid oxidation (FAO) (Kamphorst et al., 2013). Less surprisingly, cancer 
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cells that do not exhibit significant increases in glycolysis such as prostate 
adenocarcinoma and certain diffuse large B-cell lymphomas commonly exhibit high 
rates of FAO for energy generation (Caro et al., 2012; Liu et al., 2010). This increase in 
FAO is hypothesized to be the result of decreased glucose availability in the tumor 
environment, but further study is needed to understand the heterogeneity in FAO 
activity between different forms of cancer. 
P53-MEDIATED LIPID METABOLISM 
With the intention of identifying novel therapeutic targets for cancer treatment 
and combination therapies, our lab has spent significant resources studying p53-
mediated metabolic regulation with a particular focus on lipid metabolism. This research 
was spurred on by the observation that in the previously described Mdm2C305F mouse, 
where ribosomal protein-MDM2 association is lost along with p53 activation in response 
to nutrient deprivation, significant hepatic lipid accumulation was observed during 
starvation in the mutant mouse. This finding suggests that normal p53 activation leads 
to increased lipid clearance, presumably through fatty acid oxidation. Further study of 
this mouse during starvation led to the identification of the novel p53 target gene 
malonyl-CoA decarboxylase (MLYCD) a known activator of mitochondrial lipid 
catabolism (Liu et al., 2014). Malonyl-CoA decarboxylase catalyzes the breakdown of 
malonyl-CoA to acetyl-CoA and carbon dioxide. This enzymatic activity is an important 
function for mitochondrial FAO because carnitine palmitoyl transferase 1 enzymes 
(CPT1A-C), which are located on the cytoplasmic side of the mitochondrial membrane, 
are allosterically inhibited by malonyl-CoA. Since fatty acids require carnitine 
conjugation and carnitine acylcarnitine translocase (CACT) activity to pass through the 
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mitochondrial membrane, CPT1 enzymes are considered the rate-limiting enzymes for 
FAO of the most abundant long chain fatty acid species (Schreurs et al., 2010). 
Therefore, p53 regulates the degradation of long chain fatty acids by regulating MLYCD 
expression to indirectly modulate CPT1A activity in response to nutrient deprivation. 
This increased lipid catabolism was further shown to be pro-survival by preventing 
muscle wasting in the mice during starvation (Liu et al., 2014). Similarly, p53 regulates 
CPT1C in response to nutrient stress in a panel of cancer cell lines along with mouse 
embryos to facilitate tumor cell survival in a mechanism that is also dependent up on 
AMPK (Sanchez-Macedo et al., 2013). It is important to mention that the CPT1A-C 
enzymes are expressed in a tissue dependent manner suggesting that p53 may 
regulate either CPT1A or CPT1C to promote increased FAO and survival in response to 
stress in diverse tissues.  
p53-mediated lipid metabolism extends beyond the MLYCD-CPT1 pathway to a 
number of other target genes including additional transcription factors involved with 
lipogenesis and energy expenditure. p53 induces the transcription of LPIN1 in response 
to starvation. LPIN1 is an enzyme that catalyzes the conversion of phosphatidic acid to 
diacylglycerol; moreover, LPIN1 binds to peroxisome proliferator-activated receptor 
alpha (PPARα) and PPAR gamma coactivator 1 alpha (PGC-1α) to modulate the 
transcription of lipid metabolism genes (Finck et al., 2006). Similar to p53, the PPAR 
family of transcription factors have a significant number of target genes that vary 
depending upon the activating stress or tissue of origin, which both extend the potential 
effects of p53 activation and complicate the delineation of p53 direct target genes. 
Nonetheless, the effects of PPAR and PGC1α activation are widely considered to be 
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indicative of increased lipid metabolism and oxidative phosphorylation corresponding to 
the observed phenotypes of p53 activation and further strengthening this connection 
(Grygiel-Gorniak, 2014; Kruiswijk et al., 2015; LeBleu et al., 2014). Lastly, both p53 and 
LPIN1 modulate adipose differentiation, suggesting that p53-mediated lipid regulation 
extends from the cellular to organismal level (Molchadsky et al., 2013; Nadra et al., 
2012).  
In addition to activating FAO and affecting adipose differentiation, p53 negatively 
regulates the lipogenesis regulator sterol response element binding protein 1C (SREBP-
1c) (Yahagi et al., 2003). The dual regulation of FAO and lipogenesis is not unique to 
p53 as the lipogenesis promoting acetyl-CoA carboxylase 2 (ACC2) enzyme 
simultaneously increases lipogenesis and inhibits FAO through malonyl-CoA 
production. Further supporting the specificity of this dual regulation, ACC2 is localized to 
the outside of the mitochondrial membrane such that its activity modulates local 
malonyl-CoA levels to bind and inhibit CPT1 enzymes also localized on the outside of 
the mitochondrial membrane (Abu-Elheiga et al., 2000). The previously mentioned 
direct inhibition of G6PD by p53 indirectly inhibits lipogenesis through decreased levels 
of NADPH, which is necessary for lipid biosynthesis (Stanton, 2012). Therefore, after 
considering the literature available on p53-mediated lipid metabolism, a central theme 
that p53 upregulates lipid catabolism and inhibits the synthesis of fatty acid chains 
becomes apparent. Conversely, this model is limited to the synthesis/degradation of 
fatty acid chains rather than the effects of p53 on various lipid species because fatty 
acid chain length is only a portion of what makes a lipid species unique. The effects of 
p53 on complex lipids containing unique linkages or head groups such as 
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triacylglycerides, phospholipids, and sphingolipids is less well understood. 
Nevertheless, this portion of p53-mediated lipid metabolism is potentially even more 
important to cell signaling and cancer than our current understanding of p53-mediated 
fatty acid catabolism.  
With this in mind, we set out to identify novel p53 target genes associated with 
lipid metabolism. From this work, which will be discussed at length in chapter 3, we 
identified carnitine O-octanoyltransferase (CROT) as a novel p53 target gene. CROT 
was shown to be the rate-limiting step in the peroxisomal beta-oxidation of very long 
chain fatty acids (>C20, VLCFA), which is the only mechanism capable of degrading 
VLCFA (Le Borgne et al., 2011). Peroxisomal beta-oxidation is vital. In the progression 
of Zellweger syndrome, the loss of functional peroxisomes and the mutation of lipid 
transporters on the peroxisomal membrane in adrenoleukodystrophy both result in 
increased VLCFA levels in the serum and lipotoxicity in the central nervous system 
(Engelen et al., 2012; Steinberg et al., 2006). Since p53 target genes commonly exert 
tumor suppressor activity, we sought to determine whether patients with decreased 
VLCFA catabolism exhibit altered tumorigenesis, but sadly the symptoms of these 
disorders are too severe to make any significant correlation to cancer prevalence. 
CROT regulates the degradation of specific lengths of fatty acid chains along with 4,8-
dimethylnonanoyl-CoA, a product of phytanic and pristanic acid degradation 
(Ferdinandusse et al., 1999; Violante et al., 2013). While CROT regulation of fatty acid 
degradation is similar to p53 regulated CPT1A activity, the substrates regulated by 
CROT are less prevalent within the cell than those of CPT1A and VLCFAs are enriched 
in complex lipids such as sphingolipids, which affect cell signaling pathways (Heipertz et 
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al., 1977; O'Brien and Rouser, 1964). Therefore, to understand the potential effects of 
p53-mediated CROT expression, an understanding of the various families of complex 
lipids and their connection to cancer is needed.  
COMPLEX LIPIDS, LIPID RAFTS, CELL SIGNALING, AND CANCER  
Complex lipids are a diverse, but important family of hundreds of unique 
molecules in which fatty acid chains of various lengths are combined with organic 
molecules including glycerol, sphingosine, and sugars. The most common type of 
complex lipid is triacylglycerol (TAG), which is the combination of glycerol and 3 fatty 
acid chains. Fatty acid chains are stored and transported in this neutral TAG form 
(Voshol et al., 2009). Similarly, TAGs can be converted to glycerophospholipids by 
substituting a phosphate molecule and various head groups in place of the 3rd fatty acid 
chain. These glycerophospholipids are the primary constituents of the cell’s plasma 
membrane, and in addition to this structural role, many glycerophospholipids are 
involved in various cell signaling pathways depending on the head group and activity of 
phospholipases (Hishikawa et al., 2014). Sphingolipids exhibit significant diversity, but 
all family members contain the 18-carbon acyl chain with one unsaturated carbon-
carbon bond (C18:1) known as sphingosine. Importantly, the diversity of sphingolipids is 
derived both from the various fatty acid chains bound to the amino linker and the unique 
head groups that can bind via the terminal hydroxyl group. Specifically, ceramides are 
the combination of sphingosine with a fatty acid chain of any length through the amide 
linkage. The addition of either phosphocholine or phosphoethanolamine to the terminal 
hydroxyl group of a ceramide converts the molecule into a sphingomyelin, which is the 
most abundant form of sphingolipid in mammalian cells (Futerman and Hannun, 2004). 
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Sphingomyelins are found predominantly in the plasma membrane and are even further 
enriched in the myelin sheaths encircling nerve axons (Gielen et al., 2006). Ceramides 
can also be combined with either a single sugar to form cerebrosides, which are most 
abundant in neural tissue, or an oligosaccharide linkage to form gangliosides. Since the 
oligosaccharide extends off from the surface of the cell, it is hypothesized that 
gangliosides are involved in cell-cell communication. For example, anti-ganglioside GD3 
antibodies were shown to inhibit epithelial morphogenesis by blocking GD3 expressed 
on the surface of neighboring mesenchymal tissue (Sariola et al., 1988). Lastly, the 
most well-known complex lipid are the sterols, which exhibit a unique structure 
independent of the fatty acid chain structure observed for the other complex lipid 
classes discussed here. Cholesterol is perceived negatively by the public, but the 
presence of cholesterol within the plasma membrane is essential for multiple signaling 
pathways essential for the cell that may also contribute to cancer (Mullen et al., 2016). 
All of the previously described lipid families are involved in diverse cellular signaling 
cascades and studies have shown that altered complex lipid content can drive 
numerous phenotypes.  
Considering the structural diversity of complex lipids discussed previously, it is 
unsurprising that altered levels of various complex lipids exhibit distinct phenotypes 
from one another. Treatment of multiple cancer cell lines with exogenous ceramides or 
genetic inhibition of ceramidases caused clear decreases in cell growth and increased 
levels of apoptosis (Morales et al., 2007; Selzner et al., 2001). Further study 
demonstrated that the effects of exogenous ceramide treatment may be due to cellular 
starvation as cells exhibited decreased levels of nutrient transporters with these effects 
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being rescued by supplementation with the cell permeable methyl pyruvate as an 
alternate carbon source (Guenther et al., 2008). On the other hand, increased 
sphingosine-1-phosphate (S1P) levels or increased sphingosine kinase (SK) expression 
is associated with increased cell survival and resistance to chemotherapy; moreover, 
S1P binds to S1P-receptors to modulate cell motility and activate ERK-dependent 
signaling. Importantly, multiple cancer cell lines treated with SK inhibitors exhibit 
increased sensitivity to chemotherapy (Pyne and Pyne, 2010). The effects of cholesterol 
on cancer development are unclear because studies have shown both positive and 
negative effects related to cholesterol levels in various forms of cancer. Similarly, 
statins, a class of cholesterol synthesis inhibitors, have also shown mixed results in 
clinical trials and epidemiological studies assessing their effects on cancer development 
(Boudreau et al., 2010; Demierre et al., 2005). With their high level of diversity and 
potential tissue dependent effects, it is not unexpected that the effects of complex lipids 
on cancer are unclear. Yet, as metabolomics and lipidomics technologies continue to 
improve, our understanding of the role of lipids in cancer is expected to expand 
significantly. 
One area where complex lipids are particularly important is the lipid raft, which 
was defined by its insolubility in nonionic detergents such as 1% Triton X-100. Lipid 
rafts can therefore be isolated from cellular lysates using a combination of nonionic 
detergents, sucrose gradients, and centrifugation because the buoyancy of the lipid raft 
and associated proteins causes it to rise during ultracentrifugation (Gajate and 
Mollinedo, 2017). It is important to note that these detergent resistant membranes 
(DRMs) are enriched in lipid rafts, but do not exclusively represent lipid rafts, as other 
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insoluble components can be co-purified by this method. A second complicating factor 
in the study of lipid rafts is that the proteins associated with the isolated DRMs are 
partially dependent upon the detergent used to isolate them (Wang and Paller, 2006). 
Additionally, when using Triton X-100, the insolubility of the DRMs is only apparent at 
4°C, rather than 37°C. This finding suggests that the combination of low strength 
detergent and low temperature could be responsible for generating the observed DRMs, 
which may not exist at the higher temperatures within living cells (Lingwood and 
Simons, 2007). Considering these difficulties, the presence of a lipid raft microdomain 
within the plasma membrane has been debated extensively over the last two decades, 
but a consensus is beginning to emerge from this debate. Specifically, technologies 
including Förster resonance energy transfer (FRET) and single molecule tracking 
suggest that lipid raft microdomains do exist within the plasma membrane of cells, but 
that these microdomains are smaller than originally hypothesized, with average 
diameters of approximately 50 nm (Lagerholm et al., 2005). Moreover, lipid raft 
microdomains are dynamic and relatively short-lived, which when combined with their 
small size makes directly observing lipid rafts very difficult (Wang and Paller, 2006). 
Since the existence of lipid raft microdomains have become more certain many labs 
have worked on defining the composition of lipid raft microdomains in an effort to more 
fully understand the biological role of these microdomains.  
From these additional studies, it is well established that the main component of 
many lipid raft microdomains is cholesterol (Simons and Ehehalt, 2002). The presence 
of cholesterol leads to increased hydrophobic interactions and a more stable portion of 
the plasma membrane (Li et al., 2006). The second most common component of lipid 
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rafts are sphingolipids including a partial enrichment of very long chain fatty acid-
containing sphingolipids (Brown and Rose, 1992). The cholesterol and sphingolipid 
enriched microdomains have been shown to contain cell signaling proteins including 
GPCRs, G-proteins, urokinase-type plasminogen activator receptor, and Src-family 
kinases, which can explain the significant role of lipid rafts in cell growth and the 
potential pro-cancer effects of increased lipid raft composition (Wang and Paller, 2006). 
Beyond signaling pathways, structural proteins such as caveolin-1, flotillin 1 (FLOT1), 
and flotillin 2 (FLOT2) are significantly enriched in various forms of lipid raft 
microdomains (Staubach and Hanisch, 2011). Interestingly, expression of FLOT1 is 
increased in lung cancers compared to normal lung tissue and further increases in 
FLOT1 expression correlate with tumor size, grade, and decreased overall survival in 
non-small cell lung cancer, suggesting that FLOT1 enriched lipid rafts may contribute to 
lung cancer development (Li et al., 2014a). Similar findings have been shown for FLOT1 
expression in hepatocellular carcinoma, supporting the idea that FLOT1 and by 
association lipid raft microdomains affect cancer development in multiple tissues (Zhang 
et al., 2013a). The complexity and unique functions of caveolin or flotillin enriched lipid 
raft microdomains are only partially understood.  
As mentioned previously, lipid raft microdomains also contain signaling 
molecules including multiple oncogenes, the study of which may be useful in 
determining any lipid raft-mediated effects on cancer (Wang and Paller, 2006). 
Interestingly, the different isoforms of the Ras oncogene exhibit unique associations 
with lipid raft microdomains, and this isoform-dependent lipid raft localization is 
presumably mediated by the unique mechanisms that each isoform utilizes for 
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membrane association. For example, H-Ras co-localizes with lipid raft microdomains in 
its inactive state (Prior et al., 2001). Contrary to this, N-Ras forms nanoclusters in the 
plasma membrane that co-localize with lipid raft markers, which is hypothesized to 
facilitate signaling by bringing together the upstream proteins required for N-Ras 
activation. Furthermore, constitutively active mutant N-Ras nanoclusters can be 
inhibited through cholesterol depletion, showing dependence of activated N-Ras upon 
cholesterol enriched lipid raft microdomains (Roy et al., 2005). Surprisingly, neither K-
Ras isoform co-localizes with lipid raft microdomains, and thusly, cancers that are 
dependent upon K-Ras mutation are unaffected by cholesterol depletion, suggesting 
that K-Ras functions independent of lipid raft microdomains (Prior et al., 2003). In 
addition to Ras, AKT is a second oncogene that is directly affected by lipid raft 
microdomains, further strengthening the connection between lipid rafts and cancer. AKT 
activation is downstream of EGFR, the activity of which is directly affected by lipid raft 
localization, and PI3K, which has also been shown to localize in lipid raft microdomains 
(Gao et al., 2011; Irwin et al., 2011; Zhang et al., 2016). Beyond the lipid raft localization 
of the upstream activators of AKT, the disruption of lipid raft integrity by targeting 
cholesterol is sufficient to block AKT activation even in the presence of PI3K-EGFR 
association, suggesting that AKT is directly affected by lipid raft microdomains in certain 
cellular contexts (Calay et al., 2010). This study also demonstrates that cells can 
become sensitized to chemotherapeutic agents by disrupting lipid raft microdomains 
through cholesterol modulation, a response which is presumably dependent upon the 
observed decrease in AKT-mediated survival signaling. Lipid raft microdomains have 
been linked to additional cell signaling cascades that contribute to cancer, but for the 
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purposes of this work, lipid raft-mediated AKT activation will be the central focus. 
However, additional proteomic analysis will likely reveal novel cell signaling pathways 
that are affected by CROT expression and lipid raft microdomains.  
Altogether, this work will seek to elucidate the mechanisms by which p53 is 
activated by ribosomal proteins in response to varied nutrient status and to further 
characterize novel p53 target genes that elicit a portion of p53-mediated metabolic 
regulation of both glycolysis and lipid metabolism. This increased understanding of p53-
regulated metabolic pathways may identify novel pathways that can be targeted 




(1.1) Model of oncogene and tumor suppressor regulation of ribosome 
biogenesis.  
Oncogenes (Yellow) and tumor suppressors (Red) regulate ribosome biogenesis 



















(1.2) Model of p53 activation.  
In the absence of stress p53 (Blue) and is inhibited by MDM2 (Dark Gray). In response 
to stress, MDM2-p53 interaction is interrupted and tetrameric p53 binds response 


















(1.3) p53 regulates multiple genes affecting metabolic pathways.  
p53 regulates multiple target genes affecting mitochondrial oxidative phosphorylation 
(Left), glycolysis (Center-Right), and the pentose phosphate pathway (Right). Target 
genes upregulated by p53 are shown in green and target genes repressed by p53 are 
shown in red. Metabolic molecules (Light blue) were limited for simplicity. Green arrows 






CHAPTER 2: PROTECTION AGAINST HIGH-FAT DIET INDUCED OBESITY IN 




The transcription factor p53 is a tumor suppressor, and previous studies 
underscore the importance of p53 in inhibiting cancer development (Vousden and 
Prives, 2009). As a mediator of cellular stress response, p53 plays a central role in 
sensing and responding to a variety of stresses including genotoxic damage, oncogene 
activation, hypoxia, and nutrient deprivation (Horn and Vousden, 2007). The eventual 
outcome of p53-mediated stress response depends on the cell type and context as well 
as the extent, duration, and origin of the stress (Purvis et al., 2012). Aside from the 
conventional functions of p53 including cell cycle arrest, senescence, and apoptosis, 
new roles for p53 in regulating cell metabolism have received increasing attention with 
regards to tumor suppression (Berkers et al., 2013; Li et al., 2012). For instance, p53 
regulates various targets to affect insulin resistance and to reduce glucose metabolism 
through glycolysis, a metabolic pathway that favors tumor growth (Jiang et al., 2011; 







Obesity contributes to numerous systemic diseases, reduces quality of life, and 
shortens life expectancy (Stewart et al., 2009). Previous studies have demonstrated that 
moderate obesity reduces life expectancy by 2-3 years and morbid obesity a further 8-
10 years (Whitlock et al., 2009). High-fat diet (HFD) treated animals from several 
studies have shown that p53 is induced by HFD in various tissues (Derdak et al., 2013; 
Minamino et al., 2009; Yokoyama et al., 2014). Surprisingly, pharmacologic inhibition of 
p53 in mice fed with HFD inhibits body weight gain and hepatosteatosis (Derdak et al., 
2013). Similarly, genetic ablation of endothelial p53 increased insulin sensitivity and 
prevented the excess fat accumulation commonly observed under HFD feeding 
(Yokoyama et al., 2014). These studies demonstrate that p53 activation in mice during 
HFD feeding regulates global metabolism and directly contributes to HFD-induced 
obesity. However, how p53 is activated in response to HFD treatment and 
correspondingly regulates fatty acid metabolism is not fully understood.   
Ribosomal biosynthesis is the most energetically demanding process in cells. As 
such, fluctuation of energy status at organismal and cellular levels will exert a profound 
impact on the overall capacity for ribosomal biosynthesis (Warner, 1999). Extracellular 
nutrient availability is a central contributor to cellular energetics and variation in nutrient 
availability is a common physiological stress affecting ribosomal biosynthesis 
(Deisenroth and Zhang, 2011). Inhibition of ribosomal biosynthesis causes ribosomal 
stress and activates p53 through ribosomal protein (RP) mediated suppression of 
MDM2 (Zhang and Lu, 2009). Multiple RPs have been identified that interact with 
MDM2 to mediate a RP-MDM2-p53 signaling pathway that links ribosomal biogenesis to 
p53 stress response (Kim et al., 2014).  
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We have recently demonstrated that mice carrying a cysteine to phenylalanine 
substitution at residue 305 of MDM2, which specifically disrupts MDM2 binding to 
RPL11 (Lindstrom et al., 2007), exhibited accelerated onset of oncogenic c-MYC 
induced lymphomas (Macias et al., 2010; Meng et al., 2015). Moreover, the 
Mdm2C305F/C305F (Mdm2C305F hereafter) mice showed impaired p53 regulation of lipid 
metabolism in response to nutrient depletion (Liu et al., 2014). Here we studied the 
Mdm2C305F mice fed with a HFD ad libitum and, surprisingly, we found that the mutant 
mice are resistant to HFD-induced obesity and obesity-associated illnesses.   
 
RESULTS 
Mdm2C305F mice are metabolically comparable to WT mice on a normal chow diet 
When maintained under a normal chow (NC) diet ad libitum, the Mdm2C305F mice 
exhibited similar lifespan along with a slight decrease in body weight compared to WT 
mice (Figure 2.1 A) (Macias et al., 2010). Gross metabolic comparisons between WT 
and Mdm2C305F mice found no significant difference in food intake (Figure 2.2 A), body 
weight gain per unit of food consumed (Figure 2.2 B), total excretion of fecal matter 
(Figure 2.2 C) or fecal lipid content (Figure 2.2 D). Furthermore, no differences in the 
levels of blood glucose or triglycerides were detected between the WT and Mdm2C305F 
mice (Figures 2-2 E and F). Glucose and insulin tolerance tests (GTT and ITT) were 
carried out to analyze glucose homeostasis in the mice. The GTT and ITT revealed no 
differences between the WT and Mdm2C305F mice (Figures 2.3 A and B). Histological 
analysis also demonstrated no obvious differences in sections of adipose tissues 
(Figure 2.3 C) and livers (Figure 2.3 D) of the WT and Mdm2C305F mice. Thus, loss of 
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the RPL11-MDM2 interaction by the MDM2C305F mutation appears to exert no significant 
metabolic effect in mice maintained on a NC diet.  
 
Mdm2C305F mice are resistant to HFD-induced obesity 
To investigate the effects of HFD treatment, a cohort of six-week old WT and 
Mdm2C305F male mice were fed ad libitum a diet containing 60% fat. Interestingly, the 
Mdm2C305F mice displayed resistance to HFD-induced obesity, and their body weight 
gain was significantly slower than the WT mice with an approximately 20% lower 
average body weight than that of WT mice after 20-weeks of HFD feeding (Figures 2.1 
A and B). We analyzed body composition of the mice and found that HFD-fed 
Mdm2C305F mice had a significantly lower percentage of total body fat (Figure 2.1 C) and 
a correspondingly higher proportion of lean mass (Figure 2.1 D) than that of WT mice, 
suggesting that the reduced body weight of the Mdm2C305F mice is primarily because of 
the difference in total body fat. Further study revealed that the epididymal white fat pads 
were approximately 50% smaller in the Mdm2C305F mice than that of WT mice (Figures 
2.4 A and B). To determine if the reduction in size of the fat pad was due to fewer cell 
numbers or smaller adipocytes, we examined adipose tissue sections and found that 
the average size of adipocyte was smaller in the Mdm2C305F adipose tissues than the 
WT adipose tissues (Figure 2.4 C). A comparison between the average size of 
adipocytes (Figure 2.4 D) and the average fat-pad weight (Figure 2.4 E) suggested that 
the reduced total fat accumulation in Mdm2C305F mice is primarily due to reduced size of 
the adipocytes.  
We also evaluated the Mdm2C305F mice for obesity-associated ailments such as 
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hepatosteatosis. The livers of WT mice after 20 weeks of HFD feeding were paler and 
markedly enlarged compared with those of Mdm2C305F mice (Figure 2.5 A), though the 
liver weight relative to body weight remained unchanged (Figure 2.5 B). Histological 
examination of hematoxylin and eosin (H&E) stained liver sections revealed the 
development of severe steatosis and clear lipid accumulation in the livers of WT but not 
Mdm2C305F mice (Figure 2.5 C). Oil-red-O staining showed that large lipid droplets 
accumulated diffusely in the liver of WT but not Mdm2C305F mice (Figure 2.5 D). These 
data indicated that the Mdm2C305F mice are resistant to HFD induced fatty liver disease. 
Furthermore, non-fasting blood glucose (Figure 2.6 A) and blood triglyceride (Figure 2.6 
B) levels were lower in HFD-treated Mdm2C305F mice than WT mice. Obesity-associated 
insulin resistance, as determined by ITT, was significantly decreased in Mdm2C305F mice 
as compared to WT mice (Figure 2.6 C). Correspondingly, GTT revealed that the 
Mdm2C305F mice exhibited improved glucose clearance compared to WT mice (Figure 
2.6 D). We also evaluated long-term effects of HFD treatment on the mice. We placed a 
cohort of 6-week-old WT and Mdm2C305F male mice on HFD and monitored their 
lifespan. As shown in Figure 2.6 E, both mean and maximum lifespan were significantly 
extended in the HFD-fed Mdm2C305F mice compared to HFD-fed WT mice. Together, 
these data suggest that the MDM2C305F mutation, which disrupts RPL11-MDM2 
interaction, is sufficient to protect mice from HFD-induced, obesity-associated ailments, 
including fatty liver disease, insulin resistance, and glucose intolerance.  
 
Mdm2C305F mice demonstrate increased energy expenditure  
To begin to understand the mechanisms underlining the observed phenotypes of 
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the HFD-fed Mdm2C305F mice, we first measured the mice for several metabolic 
parameters. Food consumption was measured to determine whether the reduced body 
weight gain of the Mdm2C305F mice was due to a reduced food intake. We did not 
observe differences in daily food intake between the WT and Mdm2C305F mice at either 
the beginning (week 1) or later (week 20) stages of HFD treatment, although daily food 
intake decreased significantly for all mice as HFD feeding continued (Figure 2.7 A). 
Equal food intake was also observed through cumulative food intake measurements 
using a metabolic chamber over a 72 h period (Figure 2.8 A). Total excretion of fecal 
matter and lipid content in the excretion were measured to determine whether the 
Mdm2C305F mice had increased steatorrhoea—the presence of excess fat in the feces, a 
potential mechanism for decreased lipid storage during HFD feeding. No significant 
differences in either total feces excretion or lipid content were observed (Figures 2.8 B 
and C). Hence, the combination of decreases in body fat gain and equal food intake and 
feces excretion suggests that the rate of energy expenditure in the HFD-fed Mdm2C305F 
mice might be altered. 
We therefore measured the feed efficiency, which is a measure of the efficiency 
in converting feed mass into body mass, of the mice from the time that the body weight 
begins to diverge at 5 weeks of HFD feeding (Figure 2.1 A). Interestingly, feed efficiency 
was reduced by approximately 50% in Mdm2C305F mice compared to WT mice (Figure 
2.7 B). Correspondingly, fat gain efficiency (fat accumulation per unit of food consumed) 
was also reduced approximately 50% in HFD-fed Mdm2C305F mice (Figure 2.7 C). These 
results indicate that the energetic balance of HFD-fed Mdm2C305F mice is shifted 
towards increased energy expenditure. Total energy expenditure in animals is a sum of 
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energy utilization during external physical activity and internal heat production. To 
determine if Mdm2C305F mice exhibit increased physical activity, we monitored locomotor 
activity in mice at 4 weeks of HFD treatment, prior to the development of the obesity 
phenotype, and found no differences in total moving distance during either day or night 
(Figures 2.8 D-F). Thus, the increased energy expenditure in the HFD-fed Mdm2C305F 
mice is likely because of increased internal heat production. Indeed, indirect calorimetry 
analysis using the comprehensive laboratory animal monitoring system (CLAMS) 
showed that the heat production was significantly increased in HFD-fed Mdm2C305F mice 
during both day and night compared to WT mice (Figure 2.9 A). Correspondingly, total 
volume of carbon dioxide production (Vol. CO2) and oxygen consumption (Vol. O2) were 
significantly higher in HFD-fed Mdm2C305F mice than WT mice (Figures 2.9 B and C). 
Since no differences were observed in food intake or spontaneous physical activity, we 
therefore concluded that higher energy expenditure in the form of heat production in 
HFD-fed Mdm2C305F mice is the primary mechanism facilitating their resistance to 
adiposity and body weight gain.  
 
HFD-driven p53 induction is attenuated in Mdm2C305F mice  
Since the only alteration in the Mdm2C305F mice is the MDM2C305F mutation 
disrupting RPL11 binding, we reasoned that the metabolic alterations in the HFD-fed 
Mdm2C305F mice are likely a consequence of blocked signaling that is dependent upon 
this interaction. Previous studies have shown that excessive calorie intake increases 
expression of p53 in mouse adipose tissues (Minamino et al., 2009), and that HFD 
treatment can cause overexpression of c-MYC in mice (Kim et al., 2013; Liu et al., 
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2012b). We therefore investigated the effects of HFD on c-MYC expression and p53 
activation in Mdm2C305F mouse adipose tissues. When maintained under NC diet, the 
expression of c-MYC was low in mouse adipose tissues of both WT and Mdm2C305F 
mice (Figure 2.10 A). HFD feeding increased c-MYC expression in adipose tissues, and 
the increase was similar for both WT and Mdm2C305F mice (Figure 2.10 A). HFD also 
increased RPL11 expression, likely a result of c-MYC overexpression because c-MYC 
can directly upregulate ribosomal biogenesis (van Riggelen et al., 2010), to similar 
levels in WT and Mdm2C305F mice (Figure 2.10 A), indicating that the MDM2C305F 
mutation does not affect HFD mediated induction of c-MYC and expression of RPL11. 
Conversely, HFD mediated induction of p53 expression and p53 transcriptional activity 
were attenuated in Mdm2C305F mouse adipose tissues (Figures 2.10 B and C). No 
previous reports demonstrate MDM2 detection by western blot in mouse adipose 
tissues presumably because the levels of MDM2 in the adipose are too low, and 
correspondingly, we were unable to detect MDM2 or MDM2-RPL11 binding from 
adipose tissue lysates. Nevertheless, given that the MDM2C305F mutation disrupting 
RPL11 binding had been shown both in vitro (Lindstrom et al., 2007) and in vivo 
(Macias et al., 2010), we considered it probable that the diminished p53 induction in the 
HFD-fed Mdm2C305F mouse adipose tissues was due to the inability of the MDM2C305F 
mutant to interact with RPL11 and transduce RPL11-MDM2 dependent stress signals to 
p53.  
In order to determine whether differentiated p53 regulation between WT and 
Mdm2C305F mice extends to the liver, as the liver is involved in converting excess 
nutrients into fatty acids to be exported and stored in adipose tissue, we tested the 
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expression of RPL11, p21, and p53 in mouse livers. However, we did not observe any 
difference between WT and Mdm2C305F mice either with or without HFD treatment 
(Figure 2.11). c-MYC expression could not be detected in liver tissue likely due to low 
levels of expression and/or poor antibody specificity. These data suggest that the RP-
MDM2-p53 pathway response to nutrient excess is tissue specific. The physical 
changes observed in the liver of Mdm2C305F mice after HFD feeding in Figure 2.5 could 
be indirect consequences of alterations in the adipose tissue as less energy expenditure 
in adipocytes may cause increased glucose and lipid accumulation in the liver of HFD-
fed WT mice (Figures 2.9 A-C).  
To further investigate the mechanisms behind the specific metabolic alterations 
observed after HFD feeding in Mdm2C305F mice, we performed real-time quantitative 
polymerase chain reaction (qRT-PCR) to evaluate additional p53 target genes with 
particular interest in genes associated with metabolism in adipose tissue (Berkers et al., 
2013; Kruiswijk et al., 2015; Liang et al., 2013). Since obesity is commonly associated 
with increased inflammation, we analyzed the expression of p53-regulated genes linked 
to inflammation and detected lower levels of proinflammatory cytokines such as Ccl2, 
Tnfa, Cxcl10 and Cd68 (Figure 2.12 A) in Mdm2C305F mice. This finding is consistent 
with the hypothesis that the secretion of proinflammatory cytokines by adipose tissue 
exacerbates insulin resistance (Hotamisligil et al., 1993; Weisberg et al., 2003), which is 
correspondingly lower in the Mdm2C305F mice (Figure 2.6 C). Moreover, we observed 
increased expression of p53 down-regulated targets associated with glucose 
metabolism (Glut4) and energy expenditure (Ppargc1a, Ppargc1b and Sirt1) in the 
adipose tissue of Mdm2C305F mice compared to HFD-fed WT mice (Figure 2.12 B). 
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Surprisingly, no significant changes were detected in the levels of p53 regulated Glut1 
or Tigar, which are both involved in glycolysis, suggesting that Glut4 may be specifically 
regulated by p53 in response to HFD rather than p53 generally inhibiting glycolysis 
(Figure 2.12 B). Similarly, decreased levels of Pgm2 and Igfbp3, p53 regulated genes 
associated with glycolysis, were observed in the Mdm2C305F mice further showing that 
Glut4 expression may be independent of glycolysis. Increased expression of lipid 
metabolism genes such as Pck1 and Lipin1 were also observed in the Mdm2C305F mice, 
which is surprising as both genes are positively regulated by p53 suggesting that their 
expression after HFD feeding may be due to other factors. Generally, the Mdm2C305F 
mice exhibit decreased inflammatory cytokines along with increased levels of p53 
repression targets Glut4, Sirt1, Ppargc1a, and Ppargc1b associated with metabolism 
and energy expenditure. 
 
HFD-induced p53 regulates energy expenditure via the GLUT4/SIRT1 network 
The glucose transporter GLUT4, a p53 repression target (Schwartzenberg-Bar-
Yoseph et al., 2004b), plays a critical role in the maintenance of glucose homeostasis, 
and its deregulation has profound effects on diet-induced obesity and diabetes in 
humans (Shepherd and Kahn, 1999); similarly, its down-regulation in mice leads to 
increased risk of obesity and diabetes (Abel et al., 2001; Carvalho et al., 2005). We 
confirmed that in adipose tissues isolated from mice maintained on NC diet the levels of 
GLUT4 expression was similar between WT and Mdm2C305F mice. Interestingly, the 
levels of GLUT4 were on average 50% higher in HFD-fed Mdm2C305F mouse adipose 
tissues as compared to those of WT mouse adipose tissues (Figure 2.13 A). qRT-PCR 
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analysis demonstrated that Glut4 mRNA was similarly expressed in NC-fed WT and 
Mdm2C305F mice, but expressed at higher levels in the HFD-fed Mdm2C305F mice than 
HFD-fed WT mice (Figure 2.13 B), consistent with increased p53 activity (Figure 2.10) 
suppressing GLUT4 expression (Schwartzenberg-Bar-Yoseph et al., 2004b). This is 
also consistent with the observation that WT and Mdm2C305F mice are phenotypically 
similar when maintained on NC diet (Figure 2.2), but different after HFD treatment 
(Figure 2.1). 
Recent studies have established a link between lower levels of GLUT4 and 
increased nicotinamide N-methyltransferase (NNMT) in HFD-fed WT mouse adipose 
tissues (Kraus et al., 2014). NNMT controls energy expenditure through modulating the 
levels of two essential metabolic intermediates S-adenosylmethionine (SAM) and 
nicotinamide (a precursor of NAD+) (Kraus et al., 2014; Shlomi and Rabinowitz, 2013; 
Ulanovskaya et al., 2013). Consistent with these findings, Nnmt expression was lower in 
adipose tissues of HFD-fed Mdm2C305F mice, where GLUT4 expression was higher, 
than that of HFD-fed WT mice, where GLUT4 expression was lower (Figure 2.13 C). 
Lower Nnmt expression in HFD-fed Mdm2C305F mouse adipose tissues resulted in 
increased NAD+ (Figure 2.13 D) and a higher NAD+/NADH ratio (Figure 2.13 E) 
compared to HFD-fed WT mice.  
The NAD-dependent deacetylase SIRT1 is a critical sensor and regulator of 
cellular energy status (Chalkiadaki and Guarente, 2012). SIRT1 expression can be 
suppressed by p53-mediated induction of hypermethylated in cancer 1 (HIC1) (Chen et 
al., 2005) and microRNA-34a (Lee et al., 2010; Raver-Shapira et al., 2007). 
Consistently, in HFD-fed Mdm2C305F mouse adipose tissues, where p53 activity was 
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lower, the levels of both SIRT1 protein and mRNA were higher as compared to those of 
HFD-fed WT mouse adipose tissues, where the p53 activity was higher (Figures 2.14 A 
and B). SIRT1 can regulate cellular energy metabolism by promoting transcription of 
nicotinamide phosphoribosyltransferase (NAMPT) (Chang and Guarente, 2013), a rate-
limiting enzyme in the NAD+ salvage pathway (Yang et al., 2007). In line with the higher 
levels of SIRT1 in HFD-fed Mdm2C305F adipose tissues, the levels of Nampt transcript 
were higher compared to HFD-fed WT adipose tissues (Figure 2.14 C). Furthermore, 
the transcript levels of SIRT1 targets Cd36, Cat, and Mlycd, all of which promote energy 
expenditure (Alcendor et al., 2007; Derdak et al., 2013; Liu et al., 2012a; Wu et al., 
2011), were also higher in HFD-fed Mdm2C305F mouse adipose tissues than in WT 
mouse adipose tissues (Figures 2.14 D-F). It has been shown that increased NAD+ 
levels can enhance the catalytic activity of SIRT1 (Revollo et al., 2004). Thus, higher 
levels of NAD+ and an increased NAD+/NADH ratio in the adipose tissues of HFD-fed 
Mdm2C305F mice could promote further SIRT1 activity. Ppargc1a and Ppargc1b are 
transcription factors associated with energy expenditure and increased mitochondrial 
biogenesis (Jornayvaz and Shulman, 2010). Consistent with higher expression levels of 
Ppargc1a and Ppargc1b (Figure 2.12 B), we detected increased mitochondrial DNA 
content in the adipocytes of Mdm2C305F mice compared to WT mice after HFD-fed, 
which correlates well with the increased energy expenditure observed in the Mdm2C305F 
mice (Figure 2.14 G). Together, our data indicate that HFD feeding leads to stabilization 
of p53 and downregulation of GLUT4, SIRT1, Ppargc1a and Ppargc1b in WT mouse 
adipose tissues, resulting in decreased energy expenditure and increased energy 
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storage. Disruption of RPL11 binding by MDM2C305F mutation attenuates p53 activation, 
leading to increased energy expenditure and decreased energy storage.  
To further determine the role of p53 regulation of GLUT4 and SIRT1 in 
adipocytes, we evaluated the expression of p53 regulated metabolism genes in mouse 
3T3-L1 adipocytes. After we induced the 3T3-L1 cells to differentiate into adipocytes 
(Figure 2.15 A), we treated these cells with 10 µM nutlin-3, which activates p53 by 
inhibiting the interaction between MDM2 and p53, or 5 nM actinomycin D (ActD), which 
activates p53 by inducing ribosomal stress (Figure 2.15 B). Consistent with the previous 
observations in mouse adipose tissue and other publications (Chen et al., 2005; Sahin 
et al., 2011; Schwartzenberg-Bar-Yoseph et al., 2004b), p53 induction in 3T3-L1 
adipocytes suppressed the expression of Glut4, Glut1, Sirt1, Ppargc1a and Ppargc1b 
as well as SIRT1 targets Nampt, Mlycd, Cat and Cd36 indicating that p53 regulates 
these genes in the adipose tissue of mice (Figure 2.16). 
Compared to WT mice, Mdm2C305F mice exhibit improved insulin resistance and 
glucose tolerance after HFD treatment. In order to determine whether liver or adipose 
tissue is responsible for this improved phenotype, we examined the levels of phospho-
AKT (S473), which is a critical effector of the insulin signaling pathway. Interestingly, 
phospho-AKT levels were consistently higher in the adipose tissue of Mdm2C305F mice 
compared to WT mice (Figure 2.17). This suggests that increased insulin signaling in 
the adipose tissue rather than the liver mediates the observed improvement in insulin 
resistance and glucose tolerance because no observable change in phospho-AKT 





p53+/- mice demonstrate similar HFD-induced phenotype as the Mdm2C305F mice 
To further determine whether the observed phenotype of HFD-fed Mdm2C305F 
mice is a consequence of reduced p53 function, we fed a cohort of 6-week old p53+/- 
male mice with the same HFD ad libitum and recorded their body weight compared to 
HFD-fed WT mice. The body weight of the p53+/- and WT mice started to diverge after 7 
weeks of HFD feeding and the p53+/- mice demonstrated a slower increase in body 
weight than the WT mice (Figure 2.18 A), a trend that is similar to what was observed 
with HFD-fed Mdm2C305F mice. The non-fasting blood glucose and triglyceride levels 
were lower in HFD-fed p53+/- mice than in HFD-fed WT mice (Figure 2.18 B and C). The 
epididymal white adipose tissues were smaller in HFD-fed p53+/- mice than in HFD-fed 
WT mice (Figure 2.18 D). Histological analysis also demonstrated that the average size 
of each adipocyte was smaller in the p53+/- adipose tissues than the WT adipose tissues 
(Figure 2.18 E and F). As expected, p53 activity (as indicated by the levels of p21 
mRNA) was lower in HFD-fed p53+/- mouse adipose tissues (Figure 2.18 G). Lower p53 
activity in the p53+/- mice led to higher protein levels of GLUT4 and SIRT1 (Figure 2.19 
A-C). Accordingly, qRT-PCR analysis revealed higher mRNA levels of Glut4, Sirt1, 
Ppargc1a, Ppargc1b and Cat (Figures 2.19 D-H) along with lower mRNA levels of Nnmt 
(Figure 2.19 I) in adipocytes of p53+/- mice compared to WT. Thus, the observations 
from HFD-fed p53+/- mice mimic the findings from the HFD-fed Mdm2C305F mice 
suggesting that the resistance to obesity and metabolic disorder observed in the HFD-
fed Mdm2C305F mice is p53 dependent.  
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DISCUSSION 
Our results support a role for the RPL11-MDM2-p53 pathway as an intrinsic 
stress response mechanism linking c-MYC expression to ribosome biosynthesis and 
regulation of energy homeostasis. Studies have shown that c-MYC is induced in 
response to HFD treatment in various animal models (Kim et al., 2013; Liu et al., 
2012b). Chronic nutrient abundance leads to obesity and a corresponding increase in 
amino acid concentration in the serum (Caballero et al., 1988; Newgard et al., 2009). 
Elevated intracellular amino acids have been shown to activate the mammalian target of 
rapamycin complex 1 (mTORC1), promoting global protein synthesis and increased 
expression of c-MYC (Gera et al., 2004; Wullschleger et al., 2006). The transcription 
factor c-MYC regulates multiple components of ribosomal biosynthesis including 
ribosomal RNA, ribosomal protein, gene products required for the processing of 
ribosomal RNA, nuclear exporters of ribosomal subunits, and factors involved in the 
initiation of mRNA translation (van Riggelen et al., 2010). The data presented here 
suggest that nutritional excess enhances c-MYC expression and engages the RPL11-
MDM2-p53 pathway to promote nutrient storage, which shortens the mouse lifespan 
through obesity-linked metabolic alterations. Mice with the MDM2C305F mutation 
disrupting RPL11 binding demonstrate alleviated p53 activation, reduced obesity, 
decreased metabolic disorder, and extended lifespan. Our result is consistent with a 
recent study showing c-MYC haploinsufficient mice (c-Myc+/-) exhibit decreased body 
mass, higher metabolic rate, and longer lifespans compared to the WT mice (Hofmann 
et al., 2015). Moreover, mice with reduced p53 expression, such as p53+/- mice, 
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respond to HFD feeding similarly as the Mdm2C305F mice, suggesting that the unique 
phenotype of the HFD-fed Mdm2C305F mice is because of reduced p53 activity. 
 
Energy expenditure controlled by p53 regulation of GLUT4 and SIRT1  
GLUT4 plays a major role in glucose uptake into muscle, heart, and adipocytes in 
response to rising insulin levels after feeding. In both humans and rodents with type 2 
diabetes and obesity GLUT4 is selectively down regulated in adipose tissues (Shepherd 
and Kahn, 1999). Experiments with altered expression of Glut4 in mouse adipocytes 
have shown that GLUT4 plays an essential role in type-2 diabetes and associated 
metabolic alterations (Abel et al., 2001; Carvalho et al., 2005). As we have observed in 
the adipose tissue of HFD-fed WT, but not Mdm2C305F mice, there is an increase in p53 
activity leading to decreased expression of GLUT4 and increased expression of 
nicotinamide N-methyltransferase (NNMT) (Figure 6). This finding corresponds with a 
recent study demonstrating that the levels of NNMT are reciprocally regulated with the 
levels of GLUT4 (Kraus et al., 2014). In mouse adipose tissues, NNMT decreases the 
levels of the two metabolic intermediates, NAD+ and S-adenosylmethionine (SAM), 
which have been shown to also affect histone methylation, polyamine flux and SIRT1 
signaling (Kraus et al., 2014; Shlomi and Rabinowitz, 2013; Ulanovskaya et al., 2013).  
This NAD+ dependent increase in energy expenditure is at least partially 
mediated through the NAD+-dependent deacetylase SIRT1, a metabolic regulator that is 
activated by increased NAD+ levels (Canto et al., 2009). Our results show that HFD-fed 
Mdm2C305F mice exhibit increased SIRT1 expression in adipose tissue corresponding to 
the previously discussed decrease in p53 activation and increased NAD+ levels. This is 
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consistent with previous findings showing that transgenic mice that moderately 
overexpress SIRT1 or treated with SIRT1 activators are protected from developing liver 
steatosis or insulin resistance after HFD feeding (Banks et al., 2008; Feige et al., 2008). 
Moreover, multiple studies have demonstrated that increase of NAD+ biosynthesis by 
introducing nicotinamide mononucleotide intermediates or the NAD+ precursor 
nicotinamide riboside protects mice from HFD-induced metabolic abnormalities (Canto 
et al., 2012; Yoshino et al., 2011). Based on these previous studies and our current 
data, we propose that excess nutrient availability, such as feeding with HFD, promotes 
c-MYC expression and RPL11 dependent p53 activation, which inhibits p53 target 
genes including Ppargc1a, Ppargc1b, GLUT4 and SIRT1 to reduce NAD+ levels and 
energy expenditure, leading to obesity. Disruption of RPL11 binding by MDM2C305F 
mutation blocks HFD-induced p53 activation leading to increased energy expenditure 
and improved resistance to the development of obesity (Figure 2.20). 
 
The role of RPL11-MDM2-p53 pathway in energy expenditure  
A previous study from our lab has demonstrated that fasted Mdm2C305F mice 
exhibit attenuated oxidative respiration and increased fatty acid accumulation in the 
liver, suggesting that the RPL11-MDM2-p53 pathway is involved in stimulating fatty acid 
oxidation in response to nutrient deprivation (Liu et al., 2014). Surprisingly, under 
conditions of nutrient abundance, the RPL11-MDM2-p53 pathway is necessary for fat 
accumulation in the liver and adipose tissue. Collectively, we propose that the RPL11-
MDM2-p53 pathway is essential in balancing energy expenditure and storage in 
response to nutrient availability (Figure 2.21). p53 stress response is considered to be 
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one of the central stress response pathways in mammalian biology, with its effects 
being most obvious in the study of cancer; however, recent studies suggest that p53 
regulates metabolism. The ability of p53 to maintain nutrient homeostasis may have 
developed as the earliest form of stress response as all organisms face uncertain 
nutrient availability. The obese phenotype of HFD-fed WT mice maintaining normal p53 
function seems counterintuitive to the established pro-survival effects of p53; yet, 
sustained periods of nutrient abundance have only become common for humans 
recently, and are rarely observed in nature. Thus, the RP-MDM2-p53 pathway is 
activated in response to various nutrient conditions to maintain energy homeostasis and 
efficiency in nutrient utilization. We speculate that in the past this pathway could have 
facilitated fitness and survival in adverse conditions such as a harsh winter or drought in 
the wild, but may contribute to the development of obesity with the excess food 
available in modern society. The ability of p53 to regulate energetic homeostasis when 
presented with varied nutrient availability at both the cellular and organismal levels 
supports the hypothesis that p53 acts as a metabolic regulator facilitating the survival of 
the organism. Furthermore, our results implicate that the RPL11-MDM2-p53 pathway is 
involved in the development of diet-induced obesity and diabetes, which is a rapidly 




Wild type and Mdm2C305F mice were bred and maintained on a 12h light and 12h 
dark cycle with lights on from 7:00am to 7:00pm. All mice were given standard food 
pellets (normal chow, NC) and water ad libitum. Cohorts of age-matched male mice 
were used for the study. Body weight and food intake were measured weekly. For high-
fat diet (HFD) feeding experiments, mice were fed with HFD (Research Diet, D12492) 
beginning at the age of 6 weeks. The Institutional Animal Care and Use Committee 
(IACUC) at the University of North Carolina Animal Care Facility approved all studies 
using animals (protocol 10-045). 
 
Mouse calorimetry 
Age-matched male mice were housed individually in metabolic chambers of an 
Oxymax system (Columbus Instruments). The first readings were taken after a 24 h 
acclimation period. Heat production, physical activity, oxygen consumption rate (VO2) 
and carbon dioxide production (VCO2) rates were determined. VO2, VCO2, and heat 
were measured every 26 min during a 48 h period and were normalized to the body 
weight. Physical activity was determined by measuring interruptions in the infrared 
beams (Breaks X-beam total and Breaks Y-beam total). 
 
Mouse whole-body composition and fecal lipid excretion 
EchoMRI-100 quantitative magnetic resonance whole body composition analyzer 
(Echo Medical Systems) was used to measure whole-body water, fat, and lean mass. 
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Each value was normalized to body weight. To analyze fecal lipid excretion, lipid 
content of feces was extracted using chloroform:methanol (2:1) and air dried in a fume 
hood. 
 
Glucose and Insulin tolerance tests 
Glucose homeostasis was examined via intra-peritoneal glucose tolerance test 
(IP-GTT) and intra-peritoneal insulin tolerance test (IP-ITT). IP-GTT and IP-ITT were 
performed following 15 weeks and 16 weeks, respectively, of HFD feeding. For IP-GTT, 
after 6 h fasting, mouse body weight was measured and a drop of blood was collected 
from tail vein to measure basal blood glucose level (t=0) using a glucometer (Roche, 
ACCU-CHEK® Aviva). Then D-glucose (2mg/g) was injected to the mice 
intraperitoneally followed by measurements of blood glucose level at 15, 30, 60, and 
120 min. For IP-ITT, insulin (Gibco, #12585-014) was injected at the dosage of 1 U/kg in 
place of D-glucose. All other procedures were same as IP-GTT. The area under the 
curve (AUC) was calculated by the trapezoidal method. 
 
Triglyceride and NAD+ measurement 
Serum triglyceride was measured with Stanbio Triglyceride Liquicolor® 
colorimetric kit (Stanbio Laboratory, 2100-430) as instructed by the manufacturer. NAD+ 
and NADH levels were determined with the NAD+/NADH Quantification Colorimetric Kit 





Histology and Oil Red O staining 
Mouse liver and white adipose tissues were fixed in 10% neutral formalin in PBS 
for 24 h, and stored in 70% ethanol until they were transferred to the Histology 
Research Core Facility at UNC. H&E staining and Oil red O staining were conducted 
according to the standard protocol used in the Histology Research Core Facility at 
University of North Carolina (UNC). 
 
qRT-PCR analysis of mRNA expression 
Total RNA was prepared from mouse tissues using Trizol® Reagent (Invitrogen, 
#15596-026). RNA concentration was determined with a NanoDrop spectrophotometer 
(Thermo Scientific, NanoDrop™ 2000c) and quality was assessed by agarose gel 
electrophoresis. cDNA was synthesized using Superscript III reverse transcriptase 
(Invitrogen, 18080-051). qRT-PCR was performed with SYBR Green probes using the 
Applied Biosystems 7900HT Fast Real-Time PCR system. Results were expressed as 
the fold-change in transcript levels.  
For mitochondrial DNA copy quantification, total DNA were isolated from adipose 
tissue by using Puregene Core Kit B (Qiagen) following the manufacture’s instruction. 
Relative amounts of nuclear DNA and mtDNA were determined by qRT-PCR. We used 
NADH dehydrogenase flavoprotein 1-coding gene for quantification of nuclear DNA and 
mitochondrial cytochrome	c	oxidase 2-coding gene, mitochondrial D-loop for 




For western blotting, proteins were extracted from tissues as previously 
described (Macias et al., 2010). Briefly, mouse tissue was homogenized and lysed in 
0.5% NP-40 lysis buffer. Results detected by using either Pico or Dura enhanced 
chemiluminescence (ECL) systems (Thermo Scientific, SuperSignal™ West Dura 
Substrate). Antibodies: Rabbit polyclonal c-MYC (N262; Santa Cruz); p53 (NCL-505; 
Novocastra); Rabbit polyclonal SIRT1 (#2028; Cell Signaling); Rabbit polyclonal GLUT4 
(H61; Santa Cruz); Rabbit polyclonal AKT (#9272; Cell Signaling); Rabbit Monoclonal 
Phospho-AKT (Ser473) (#3787; Cell Signaling); Rabbit polyclonal antibodies to p21 
were gifts from Dr. Yue Xiong (UNC-Chapel Hill). Rabbit polyclonal antibodies to L11 
were made in house and previously described (Macias et al., 2010). 
 
Statistical analysis 
Results are represented as mean ± standard error of the mean. The survival 
curve was evaluated for significance using the Log-rank (Mantel–Cox) test. Quantitative 
PCR data and immunohistochemistry quantifications were evaluated for significance 
using the two-tailed student’s t-tests. A p value <0.05 was considered significant for all 
analyses. Significant differences between experimental groups were: *P < 0.05, **P < 











(2.1) Mdm2C305F mice are refractory to HFD-induced body fat gain. 
(A) Body weights of WT (n=10) and Mdm2C305F (n=12) male mice fed with normal chow 
(NC), and body weights of WT (n=30) and Mdm2C305F (n=23) male mice fed a high-fat 
diet (HFD) for 20 weeks.  
(B) Picture of mice after 10 weeks HFD-feeding. WT: wild type mouse; 305: Mdm2C305F 
mouse.  
(C and D) Body composition of WT and Mdm2C305F mice after 6 weeks HFD treatment 






(2.2) Mdm2C305F exhibit no significant phenotypic alterations during normal chow 
feeding 
(A) Food intake was measured at different ages as indicated (n=5 each group).  
(B) WT and Mdm2C305F mice exhibited similar feed efficiency (n=5 each group)  
(C) Total excreted feces and (D) fecal lipid content were measured (n=4 each group). 
(E) Blood glucose and (F) triglycerides levels from 3 month old mice were measured 
(n=5 each group).  
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(2.3) Mdm2C305F exhibit no significant phenotypic alterations during normal chow 
feeding. 
(A) Glucose tolerance test (GTT) and (B) insulin tolerance test (ITT) between WT and 
Mdm2C305F mice, areas under the curve (AUC) were determined (n=5 each group).  
(C) Sections from adipose tissues were imaged to determine adipocyte size.  
(D) Liver sections were stained by hematoxylin and eosin (H&E). WT: wild type mice; 






(2.4) Mdm2C305F mice are refractory to HFD-induced body fat gain. 
(A) Weights and (B) picture of epididymal white adipose tissue (EWAT) after 10 weeks 
of HFD treatment (n=5 per group). (C) Sections from epididymal adipose tissues from 
WT and Mdm2C305F mice stained by haematoxylin and eosin (H&E). Scale Bar 50µm.  
(D) Relative quantified size of adipocytes from (C).  
(E) Relative weight of epididymal white adipose tissue from 20 weeks HFD-fed WT and 








(2.5) Mdm2C305F mice are resistant to HFD-induced obesity associated metabolic 
alterations. 
(A) Pictures were taken of livers of WT or Mdm2C305F mice after 20 weeks HFD 
treatment. Scale Bar 2mm. 
(B) Liver weight in percentages of body weight for WT or Mdm2C305F mice fed HFD for 
20 weeks. 
(C) H&E staining of the liver sections of WT and Mdm2C305F mice on HFD. Scale bar 
5µm. (D) Oil-Red-O staining for lipid droplets in livers from HFD-fed WT and Mdm2C305F 
mice. Scale bar 50µm. 
  




(2.6) Mdm2C305F mice are resistant to HFD-induced obesity associated metabolic 
alterations and exhibit longer lifespan. 
(A) Blood glucose and (B) triglycerides were measured in 10 weeks HFD-fed WT and 
Mdm2C305F mice.  
(C) Insulin tolerance test (ITT) and (H) glucose tolerance test (GTT) in WT and 
Mdm2C305F mice on HFD for 15 weeks (n=5 each group). AUC: area under the curve.  
(D) Mdm2C305F mice exhibited longer lifespans than WT mice upon long-term HFD 
feeding. Error bars, ±SEM; *P<0.05; **P<0.01. 
  
D 




(2.7) Mdm2C305F mice demonstrate increased energy expenditure. 
(A) Average food intake for HFD-fed WT and Mdm2C305F mice at different ages as 
indicated (n=5 each group). 
(B and C) Feed efficiency as indicated by body-weight gain (B) and body fat gain (C) 
per gram high-fat food consumed in WT and Mdm2C305F mice for 5 weeks. 
  
B C A 
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(2.8) WT and Mdm2C305F exhibit similar food intake, excretion and physical activity 
during HFD Feeding. 
(A) 3 days of food intake from WT and Mdm2C305F mice were measured in metabolic 
chambers (n=3 each group).  
(B) Total feces excreted and (C) fecal lipid content in WT and Mdm2C305F mice after 4 
weeks HFD treatment (n=5 each group).  
(D-F) Locomotor activity was measured by comprehensive laboratory animal monitoring 
system (CLAMS) (n=4 each group). 
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(2.9) Mdm2C305F mice demonstrate increased energy expenditure. 
(A-C) After 4 weeks of HFD treatment, the comprehensive laboratory animal monitoring 
system (CLAMS) measured heat generation (A), CO2 production (B), and O2 
consumption (C); bar graphs indicate average O2 consumption, CO2 or heat production 







(2.10) Mdm2C305F mice demonstrate attenuated HFD-induced p53 activation.  
(A) Cell lysates from epididymal adipose tissues of WT and Mdm2C305F mice were 
analyzed by immunoblotting for c-MYC and RPL11. NC: normal chow; HFD: 10 weeks 
HFD treatment. 
(B) Adipose tissue lysates were analyzed by immunoblotting for expression levels of 
p53 and p21 (left). Quantification analysis by Image J was shown to the right (3 mice 
each group). 







(2.11) WT and Mdm2C305F mice exhibit similar levels of p53 activation in the liver 
during HFD feeding. Cell lysates from livers of WT and Mdm2C305F mice were analyzed 





(2.12) Mdm2C305F mice demonstrate attenuated HFD-induced p53 activation.  
(A-B) qRT-PCR analysis for expression of p53 targets associated with inflammation (A), 
or p53 targets associated with metabolism (B) in 10 weeks HFD-fed mice adipose 






(2.13) Mdm2C305F mice demonstrate increased GLUT4 expression in adipose 
tissues. 
(A) Cell lysates from epididymal adipose tissues of WT and Mdm2C305F mice (n=3 each 
group) were analyzed by immunoblotting for GLUT4 expression. NC: normal chow; 
HFD: 10 weeks HFD treatment. Quantification analysis by Image J was shown to the 
right.  
(B and C) qRT-PCR analysis of the expression of Glut4 and Nnmt in adipocytes from 
WT or Mdm2C305F mice treated with NC or HFD for 10 weeks.  
(D) NAD+ level and (E) NAD+/NADH ratio measured in adipose tissues from WT or 
Mdm2C305F mice treated with NC or HFD for 10 weeks. 
  




(2.14) Mdm2C305F mice demonstrate increased energy expenditure in adipose 
tissues. 
(A) Immunoblotting analysis for SIRT1 protein expression. NC: normal chow; HFD: 10 
weeks HFD treatment. Quantification analysis by Image J was shown to the right. 
(B and C) The mRNA expression levels of Sirt1 and Nampt in adipose tissues from WT 
or Mdm2C305F mice treated with NC or HFD.  
(D-F) qRT-PCR measurement of Cd36 (D), Cat (E), and Mlycd (F) in response to HFD 
treatment.  
(G) Mitochondrial DNA (mt-DNA) content in WT and Mdm2C305F mice in response to 
HFD treatment. mt-D, mitochondrial DNA D-loop; mt-Co1, mitochondrial 
cytochrome	c	oxidase 2 gene; data normalized by nuclear DNA coding NADH 
dehydrogenase flavoprotein 1 (Ndufv1). Error bars, ±SEM; *P<0.05; **P<0.01. 
  







(2.15) Adipocyte-like 3T3-L1 cells exhibit normal p53 activation and inhibition of 
previously identified p53 suppression targets.  
(A) Mouse preadipocyte 3T3-L1 cells were induced to differentiate into adipocytes. 
Picture were taken for cells in bright field (left) and cells stained with Lipidtox Red 
(right).  
(B) qRT-PCR analysis for the expression of p21 and Mdm2 in differentiated adipocytes 
treated with or without actinomycin D (5nM) or nutlin-3 (10µM) for 24 hours respectively. 
(C) qRT-PCR analysis of the expression of p53 targets associated with metabolism in 
differentiated adipocytes treated with or without actinomycin D (5nM) or nutlin-3a 






(2.16) Adipocyte-like 3T3-L1 cells exhibit normal p53 activation and inhibition of 
previously identified p53 suppression targets.  
qRT-PCR analysis of the expression of p53 targets associated with metabolism in 
differentiated adipocytes treated with or without actinomycin D (5nM) or nutlin-3a 




(2.17) Mdm2C305F mice exhibit higher levels of phospho-AKT levels in adipose 
tissue but not in liver after HFD feeding.  
Cell lysates from livers and adipose tissues from WT and Mdm2C305F mice were 





(2.18) HFD-fed p53+/- mice display similar phenotype as the HFD-fed Mdm2C305F 
mice.   
(A) WT and p53+/- mice (n=7 per group) were fed with HFD for 12 weeks; body weights 
are shown. 
(B and C) Blood glucose and triglycerides were measured after 12 weeks of HFD 
treatment.  
(D) Weights of epididymal white adipose tissue (EWAT) after 12 weeks HFD treatment 
(n=5 per group).  
(E) Picture of epididymal EWAT from WT and p53+/- mice after 12 weeks of HFD 
treatment.  
(F) Relative quantified size of adipocytes from (E).  
(G) qRT-PCR measurements of p21.  
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(2.19) HFD-fed p53+/- mice display similar phenotype as the HFD-fed Mdm2C305F 
mice.   
(A-C) Immunoblotting analysis for GLUT4 and SIRT1 protein expression for lysates 
from adipose tissue after 10 weeks HFD treatment (n=3 per genotype). Quantification 
analysis by Image J was shown to the right. 
(D-I) qRT-PCR measurements of Glut4 (D), Sirt1 (E), Ppargc1a (F), Ppargc1b (G), Cat 
(H) and Nnmt (I) in adipose tissues from HFD-fed WT and p53+/- mice Error bars, ±SEM; 









(2.20) RPL11-MDM2-p53 pathway senses nutrient availability and regulates 
energy expenditure. 
During nutrient abundance, c-MYC is activated and promotes ribosomal protein 
biosynthesis including RPL11, which can interact with and inhibit the E3 ligase function 
of WT MDM2 (Blue), to stabilize and activate p53. Activation of p53 will transcriptionally 
repress the expression of Glut4, Sirt1, Ppargc1a and Ppargc1b; consequently, 
mitochondrial biogenesis and NAD+ biosynthesis are inhibited, decreasing energy 
expenditure. In Mdm2C305F mice, where RPL11 does not bind MDM2 (Teal), p53 is not 
induced and energy expenditure is increased during conditions of nutrient abundance. 
The size of the circles and the thickness of the lines and arrows indicate levels of 




(2.21) RPL11-MDM2-p53 responds to various nutrient states to facilitate survival 
A model depicting the role of the RPL11-MDM2-p53 pathway in regulation of energy 





CHAPTER 3: CROT:  A NOVEL LINK BETWEEN P53 STRESS RESPONSE, LIPID 
METABOLISM, AND CELLULAR SIGNALING 
 
INTRODUCTION 
Initial studies on p53 unknowingly used mutant p53 clones, leading to p53 being 
mislabeled as an oncogene; however, after decades of research by countless labs, p53 
is considered to be a central tumor suppressor earning the nickname “Guardian of the 
Genome” along the way (Lane, 1992). It is therefore unsurprising that p53 is the most 
commonly mutated gene across multiple types of cancer (Ciriello et al., 2013). p53 
regulates the transcription of numerous target genes in response to various forms of 
stress such as DNA damage or inhibition of ribosome biogenesis. Importantly, not all 
target genes of p53 are regulated in response to every form of stress, and the dose or 
duration of stress also affects p53 transcriptional regulation (Purvis et al., 2012). The 
most well characterized tumor suppressive functions regulated by p53 are cell cycle 
arrest, senescence, and apoptosis. Yet, a recent study using knock-in mutant p53 mice 
incapable of transcriptionally regulating certain target genes and, a separate study using 
knockout mice deficient for three of the same target genes, suggest that p53 exhibits 
significant tumor suppression in the absence of these canonical functions (Li et al., 
2012; Valente et al., 2013). Importantly, one of these studies further demonstrated that 
p53-mediated metabolic regulation remained intact suggesting that p53 regulation of 
metabolic genes could exert significant tumor suppressive effects. p53 inhibits multiple 
	 98	
glycolytic target genes and upregulates genes that promote oxidative phosphorylation, 
but p53 regulation of lipid metabolism is less well understood. Therefore, I mined a 
previously described p53 target gene microarray to identify novel target genes 
associated with lipid metabolism and identified the peroxisomal gene carnitine O-
octanoyltransferase (CROT) as a putative p53 regulated target.  
CROT expression was previously shown to be the rate-limiting step of very long 
chain fatty acid (VLCFA) catabolism in HepG2 cells (Le Borgne et al., 2011). The 
peroxisomal localization of CROT is an important component of this activity because 
VLCFAs can only be catabolized in the peroxisome. As one might expect, the 
symptoms of many peroxisomal disorders such as adrenoleukodystrophy are due to 
increased VLCFA content (Singh and Pujol, 2010). Interestingly, CROT is under-
expressed in esophageal, kidney, and colorectal cancers suggesting a possible tumor 
suppressor function. In this study, I seek to validate CROT as a novel target gene of 
p53 and elucidate any tumor suppressive effects of CROT expression. 
RESULTS 
CROT is a novel p53 target gene 
A previously published mouse embryonic fibroblast (MEF) cell microarray utilizing 
a tamoxifen sensitive p53-estrogen receptor (p53ER) fusion protein was mined to 
identify the novel p53 target gene carnitine O-octanoyltransferase (CROT), a 
peroxisomal enzyme associated with VLCFA degradation (data not shown). Specifically, 
CROT regulates the exchange of coenzyme-A (CoA) for carnitine on medium chain fatty 
acids (C8-C14), which is the rate-limiting step in the peroxisomal beta-oxidation of 
VLCFAs. Carnitine-conjugated medium chain fatty acids can then be further catabolized 
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in the mitochondria through oxidative phosphorylation, a pathway promoted by p53 
activation, that is commonly repressed in many types of cancer.  
To determine whether p53 regulates CROT in humans, liver derived HepG2 and 
breast derived MCF7 cancer cell lines retaining WT p53 were treated with low levels (~5 
nM) of actinomycin D (ActD) to stabilize p53. Importantly, CROT expression was 
increased along with the known p53 targets p21 and MDM2 in both cell lines (Fig 3.1 A). 
Interestingly, long term ActD treatment (~96 h) caused CROT expression to continually 
increase throughout the time-course in HepG2 cells, whereas the p53 target gene 
MDM2 expression increased for 24 h before decreasing throughout the remainder of the 
time-course. This finding suggests that CROT is regulated by sustained p53 activation 
in a similar manner to “late-acting” apoptotic target genes (Fig 3.1 B). Furthermore, 
CROT expression is increased along with p21 and MDM2 in response to DNA damage 
induced by both etoposide and 5-fluorouracil (5-FU) treatment. However, CROT is 
similarly induced by the small molecule MDM2-p53 association inhibitor, Nutlin-3, 
suggesting that CROT is not a DNA damage specific target gene (Fig 3.2).  
CROT expression in response to ActD treatment is dependent upon p53 as 
HepG2 cells stably expressing shp53 constructs exhibited decreased CROT expression 
in response to ActD treatment (Fig 3.3 A). Similarly, p53 is required for increased CROT 
expression in response to ActD treatment in MCF-7 cells (Fig 3.3 B). To further 
demonstrate that p53 is necessary for CROT accumulation in response to both ActD 
and Nutlin-3 treatment independent of RNAi, HCT116 colon cancer cells in which p53 
was deleted using CRISPR-Cas9 were used. No significant increase in CROT 
expression was observed in either p53-/- HCT116 clone after ActD (Fig 3.4 A) or Nutlin-3 
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treatment (Fig 3.4 B). Exogenous p53 expression was also sufficient to increase CROT 
levels in p53-/- SaOS2 cells (Fig 3.5). Taken together, these data suggest that p53 
regulates CROT expression in response to various forms of stress in a wide array of 
tissues. 
p53 elicits multiple tumor suppressive functions primarily, but not exclusively 
through direct transcriptional regulation of target genes. The majority of p53 response 
elements (p53REs) contain the following sequence RRRCWWGYYY / RRRCWWGYYY 
(where R = A or G, W = A or T, Y = C or T, and / = variable length spacer from 0-13 
base pairs) (el-Deiry et al., 1992; Nikulenkov et al., 2012). Interestingly, TP53TG1, a 
non-protein coding gene that was named for its response to p53 activation, is located 
near the transcription start site of CROT coding in the opposite direction. Three potential 
p53REs were identified by scanning the promoter region of CROT (Fig 3.6 A). 
Chromatin immunoprecipitation (ChIP) PCR assays demonstrate that p53 binds 
p53RE1 and p53RE3 located near the CROT promoter and the p53RE from CDKN1A in 
response to nutlin-3 treatment (Fig 3.6 B). Further analysis by qPCR suggests that p53 
exhibits increased binding on p53RE3 compared to p53RE1 (Fig 3.6 C). The 
functionality of p53 binding to each p53RE can be evaluated by luciferase reporter 
assays. Both p53RE1 and p53RE3 (WT) luciferase constructs exhibit significant 
luminescence in the presence of exogenous p53 that can be ablated by mutation of the 
central CATG portion (Mut) of each response element (Fig 3.6 D). Therefore, the data 
suggest that p53 regulates CROT by direct transcriptional regulation mediated by 
binding two of the three putative p53REs located near the promoter region. 
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CROT is underexpressed in human cancers with increased CROT expression 
correlating with increased patient survival in multiple cancer types 
Since p53 is a tumor suppressor and we have demonstrated that CROT is a 
novel target gene of p53, we sought to determine the role of CROT expression in 
tumorigenesis. Importantly, CROT is underexpressed in multiple cancers including 
colorectal, esophageal, head-neck squamous cell carcinoma (HNSCC), and kidney 
cancer samples compared to normal tissue according to data available from the 
Oncomine database (Fig 3.7). Further analysis of CROT expression from patients using 
ProGGENEV2 software demonstrates that patients with CROT expression above the 
observed median correlate with increased overall survival in certain lymphoma, renal, 
breast, and brain cancers (Fig 3.8). The possibility that the observed survival benefit for 
patients with higher CROT expression is the result of these patients retaining WT p53 
cannot be ruled out from this analysis, but it is also possible that CROT mediates tumor 
suppressive activity independent of p53. Additional analysis using ProGGENEV2 shows 
that the putative CROT-mediated tumor suppression is highly context dependent 
because additional breast and brain cancer patient datasets exhibit decreased overall 
survival in patients with higher CROT expression levels (Fig 3.9). As seemingly 
contradictory as the survival data are, it is important to recognize the genetic, nutritional, 
and treatment heterogeneity among the patients involved in these data sets, limiting the 
implications of these findings. It is an intriguing starting point though, as little is known 
about the role CROT and peroxisomal beta-oxidation in cancer, but additional controlled 
experiments will be needed to elucidate any putative tumor suppressive function for 
CROT.  
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CROT exhibits tissue dependent effects on cancer proliferation and cell signaling 
In order to determine the role of CROT in cancer, we utilized shRNA-mediated 
CROT knockdown in HepG2 and MCF-7 cells. At normal oxygen levels (~20% O2), 
shCROT treated HepG2 cells exhibited slightly decreased cell proliferation compared to 
control cells (Figures 3.10 A and C). Surprisingly, shCROT treated MCF-7 cells 
exhibited no significant change in proliferation at normal oxygen levels, but exhibited 
significantly increased proliferation compared to control at hypoxic levels (~1% O2) that 
more closely mimic the tumor environment, suggesting that CROT exerts context 
dependent effects along with oxygen dependent effects on cell proliferation (Figures 
3.10 B and D). Since CROT is regulated by p53, we wanted to determine whether 
CROT affects cell survival in response to DNA damage. Altered CROT expression does 
not affect cell survival in response to DNA damage induced by UV irradiation or 
doxorubicin in MCF-7 cells (Fig 3.11). Therefore, CROT does not appear to be involved 
in some of the most well-studied aspects of p53-mediated tumor suppression.  
We then sought to determine whether CROT expression affected the activation 
of oncogenic cell signaling pathways in response to serum or epidermal growth factor 
(EGF) stimulation as p53 has been shown previously to inhibit many of these pathways 
(Bheda et al., 2008; Feng et al., 2007). MCF-7 cells treated with siCROT exhibited 
decreased AKT and SRC family kinase activation, with a slight increase in ERK 
activation in response to FBS stimulation compared to control cells (Fig 3.12). In 
agreement with our cell proliferation data, where HepG2 and MCF-7 cells exhibited 
opposite responses, HepG2 cells treated with siCROT exhibited slight increases in both 
AKT and ERK activation but no change in Src family kinase activity compared to control 
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cells in response to FBS stimulation (Fig 3.13). Importantly, decreased CROT 
expression in polyclonal CRISPR-Cas9-mediated knockout cells similarly exhibit 
increased AKT activation in response to either fetal bovine serum (FBS) or epidermal 
growth factor (EGF) stimulation, suggesting that CROT expression may antagonize 
oncogenic AKT signaling in HepG2 cells (Fig 3.14). While this finding is exciting and 
novel for CROT and peroxisomal beta-oxidation, we wanted to probe the effects of 
CROT expression on additional kinase-dependent cell signaling cascades using the 
multiplexed inhibitor beads and mass spectrometry (MIB/MS) technology pioneered in 
the Pharmacology Department at UNC (Duncan et al., 2012). Excitingly, glycogen 
synthase kinase 3 beta (GSK-3β) was found to be 5.5-fold less active in the siCROT 
treated HepG2 cells after FBS stimulation (Fig 3.15 A). This is in agreement with our 
previous data indicating that AKT is more active in cells with decreased CROT 
expression, because AKT is known to inhibit GSK-3β (Cross et al., 1995). In addition to 
GSK-3β, multiple subunits of AMP-activated protein kinase (AMPK) and casein kinases 
were found to be decreased in activity in the siCROT treated cells after serum 
stimulation, suggesting that CROT expression may affect their activation (Fig 3.15 A). In 
contrast, adenylate kinase isoenzyme 1, fructosamine-3-kinase, and ketosamine-3-
kinase are all increased in the siCROT treated HepG2 cells after FBS stimulation (Fig 
3.15 B). We were surprised to observe that altered CROT expression altered cell 
signaling of such diverse pathways, but the coverage of this initial screen was relatively 
modest and additional experiments with increased sample numbers are needed to 
comprehensively assess the effect of CROT on cell signaling cascades.  
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CROT expression affects lipid raft localization of multiple cell-signaling proteins 
CROT was shown previously to be the rate-limiting step in peroxisomal beta-
oxidation of very long chain fatty acids (Le Borgne et al., 2011). Interestingly, the 
VLCFAs regulated by CROT are commonly incorporated in sphingolipids and lipid raft 
microdomains suggesting that altered CROT expression could affect lipid raft 
composition and associated cell signaling pathways (Heipertz et al., 1977; O'Brien and 
Rouser, 1964). Therefore, we used discontinuous sucrose gradients to isolate detergent 
resistant membranes, which are enriched in lipid raft microdomains, from HepG2 cells 
but were unable to do so for MCF-7 cells (Fig 3.16). The lack of a visible lipid raft in 
MCF-7 cells could potentially be overcome by increasing the number of cells analyzed 
or by stimulating the MCF-7 cells to induce lipid raft formation in future experiments, but 
HepG2 cells were selected for the remainder of this work because of the significant 
increase in lipid raft content detected by this initial screen. 
In order to determine whether the observed changes in cell signaling in response 
to siCROT treatment are dependent upon increased VLCFA-containing sphingolipids in 
lipid raft microdomains, HepG2 cells were treated with siRNA for 72h before lipid rafts 
were isolated and analyzed for sphingolipid content by mass spectrometry. Intriguingly, 
siCROT treatment increased the concentration of certain sphingomyelins including 
those with CROT substrates C12:0 (a fatty acid chain with 12 carbons and no double 
bonds) and C24:0. This finding suggests that CROT expression does affect the 
sphingolipid composition of the lipid raft (Fig 3.17 A). The relative concentrations of both 
C12:0 and C24:0 fatty acid chains were previously shown to increase in HepG2 cells 
after siCROT treatment and decrease in response to exogenous CROT expression, 
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suggesting that these fatty acids are directly regulated by CROT (Le Borgne et al., 
2011).  Surprisingly, all ceramide species measured and sphingosine, a ceramide 
precursor, were increased in the siCROT treated samples indicating that decreased 
CROT expression may induce an increase in the amount of lipid rafts rather than altered 
lipid composition as we expected (Fig 3.18 B).   
Since the sphingolipids of lipid raft microdomains are altered in response to 
CROT expression, it is possible that these lipid raft alterations could explain the altered 
cell signaling that we observed in response to siCROT treatment. The most well-
established marker of lipid raft microdomains is flotillin-1, which was actually named for 
its ability to float with the lipid raft in sucrose gradients, and this protein was used to 
define the lipid raft fraction (Bickel et al., 1997). Additionally, LRP1 is a lipoprotein 
receptor with established roles in both lipid metabolism and cell signaling that is known 
to partially localize to lipid raft microdomains (Laudati et al., 2016). In order to quantify 
lipid raft localization, the protein from fraction 8, representing the non-lipid raft localized 
fraction of each protein (>95% of total protein), was serially diluted to allow for direct 
comparisons with the lipid raft associated signal. Quantitation of the lipid raft-associated 
protein is expressed as a percentage of the signal from fraction 8 that is visible in lipid 
raft fractions 3 and 4. As expected, siCROT treatment exhibited a modest increase in 
lipid raft localization of LRP1 (0.54% vs. 0.44% for siCtrl) and a greater shift in FLOT1 
(5000% vs. 1600% for siCtrl) in unstimulated HepG2 cells (Fig 3.18). As the CROT-
mediated increase in AKT signaling is most clear after stimulation, we wanted to 
determine whether the lipid raft localization of cell signaling proteins including LRP1 is 
also increased in response to FBS stimulation. As expected, the increase in lipid raft 
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localization of LRP1 (17.78% vs. 0.86% in siCtrl) in the siCROT treated HepG2 cells is 
exaggerated compared to the unstimulated cells, whereas the shift in FLOT1 
localization (2700% vs. 1100% in siCtrl) is similar to unstimulated HepG2 cells. 
Activated AKT exhibited partial lipid raft localization (1.80%) in response to FBS 
stimulation in the siCROT treated HepG2 cells (Fig 3.19). It is important to note that as 
opposed to FLOT1, where the majority is localized to lipid raft microdomains, the LRP1, 
AKT, and EGFR proteins are still predominantly found outside of lipid raft microdomains 
even in siCROT treated cells. These results suggest that CROT may affect AKT 
localization and activation in a lipid raft independent manner. Ectopic expression of 
adenoviral CROT noticeably decreased the lipid raft association of FLOT1 (200% vs. 
600% in adGFP), but exhibited minimal effect on LRP1 localization (1.10% vs. 1.39% in 
adGFP) in the absence of stimulation (Fig 3.20).  
As CROT is a novel target gene of p53, we then probed the effects of p53 
activation on the localization of proteins in lipid raft microdomains. We found that p53 
activation mediated by nutlin-3 treatment clearly decreased lipid raft localization of 
FLOT1 (400% vs. 5000% in DMSO), and LRP1 (1.07% vs. 1.54% in DMSO) (Fig 3.21). 
Interestingly, p53 activation also increased EGFR localization to lipid raft microdomains. 
This finding suggests that p53 activation leads to increased EGFR internalization 
because cholesterol depletion, and presumably the loss of lipid raft microdomains, 
blocks EGFR internalization (He et al., 2006). p53 activation also decreased Lyn 
expression levels in lipid raft microdomains, but because no Lyn was detected in 
fraction 8, percent lipid raft localization could not be calculated. To examine whether 
p53-mediated lipid raft regulation was dependent upon CROT, we first knocked down 
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CROT in HepG2 cells prior to p53 activation via nutlin-3 treatment. These cells were 
then starved of FBS overnight before being stimulated for 10 min with FBS prior to lipid 
raft fractionation. Under these conditions, p53 activation decreased lipid raft associated 
FLOT1 to similar extents in both control (500% vs. 4000% in DMSO) and siCROT cells 
(300% vs. 5000% in DMSO). This suggests that p53 regulation of FLOT1 lipid raft 
localization is independent of CROT. Additionally, LRP1 localization to the lipid raft was 
completely ablated in both control (0% vs. 1.00% in DMSO) and siCROT (0% vs. 2.00% 
in DMSO) treated cells in response to nutlin-3 treatment. This further suggests that p53 
may regulate lipid raft composition and localization through additional target genes (Fig 
3.22). In conclusion, both p53 and CROT affect cell signaling by modulating lipid raft 
association of various proteins including LRP1 and FLOT1. 
 
DISCUSSION 
Our current data show that p53 regulates the expression of CROT by binding 
response elements in the promoter region of CROT, which significantly expands on 
previous screens suggesting that p53 may regulate CROT mRNA (Goldstein et al., 
2012). Moreover, a completely novel connection between CROT expression and AKT 
activation was discovered by decreasing CROT expression independent of p53 
activation using multiple RNAi molecules and CRISPR-Cas9 polyclonal knockout cells. 
This connection is particularly important as increased AKT activation leads to cancer 
cell survival in many types of cancer (Altomare and Testa, 2005). Furthermore, the 
preliminary MIB/MS kinome screen indicates that CROT expression affects multiple 
signaling pathways including casein kinases and AMPK. Additionally, the loss of CROT 
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expression increased expression of the glycation-associated kinases, fructosamine-3-
kinase and ketosamine-3-kinase. This suggests that CROT affects multiple cell 
signaling pathways. Mechanistically, fructosamine and ketosamine kinases affect 
glycation levels, which is the spontaneous covalent binding of sugars to proteins, in a 
process that may serve to restore enzymatic activity to the previously glycated protein 
(Collard et al., 2003; Delpierre and Van Schaftingen, 2003). This process affects many 
protein in the plasma membrane and could link CROT expression to multiple cellular 
processes, but additional research on the biological impact of glycation and the role of 
these kinases specifically  will be needed (Van Schaftingen et al., 2007). Given the role 
of CROT in VLCFA metabolism and the association of VLCFAs with lipid raft 
microdomains, we conclude that altered lipid raft-mediated cell signaling could explain 
the increases in AKT activation (Le Borgne et al., 2011).  
Our sphingolipid profiling suggests that siCROT treatment does increase VLCFA-
containing sphingomyelins and ceramides as we expected. However, siCROT treatment 
also increased concentrations of certain sphingomyelins and fatty acid-containing 
ceramides that are not known to be regulated by CROT. This suggests that the total 
sphingolipid content per mg of protein is increased in siCROT cells (Fig 3.17). It is 
possible that rather than the hypothesized altered lipid raft composition, decreased 
CROT expression may modulate lipid raft signaling by increasing the total lipid raft 
content per cell. This hypothesis is supported by observation that FLOT1 localization to 
lipid raft microdomains is further increased by siCROT treatment compared to control 
cells, but further studies quantifying lipid raft microdomains by other methods are 
needed to further explore this possibility. Separately, the observed increase in ceramide 
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levels could potentially explain the slight growth inhibition observed in siCROT treated 
HepG2 cells (Fig 3.10 A) because increased ceramide content is associated with 
decreased cell proliferation (Alesse et al., 1998; Jayadev et al., 1995). Yet, many of 
these studies utilized exogenous ceramide treatment or measured whole cell ceramide 
levels so the connection between the modest increase in lipid raft-associated ceramides 
and HepG2 cell proliferation will require additional study.  
The combination of the observed decrease in proliferation from HepG2 cells 
expressing shCROT constructs and the lack of datasets indicating differential 
expression of CROT in the liver affects survival indicates that while HepG2 cells have 
been a valuable tool for exploring CROT expression-mediated biology, the role of CROT 
in cancer will require studies of other tissues. Importantly, our initial studies indicate that 
decreased CROT expression facilitates the growth of MCF-7 breast cancer cell lines 
cultured in hypoxic conditions (Fig 3.10D). This aligns well with the decreases in 
relapse-free or overall survival for breast cancers expressing lower levels of CROT, 
suggesting that CROT expression may exert tumor suppressive effects in breast tissue 
(Fig 3.8). In addition to breast cancer, renal cancers exhibited differential CROT 
expression between normal and cancer tissue, along with a significant increase in 
overall survival in patients expressing higher levels of CROT. These findings indicate 
that renal cancer cells may also be useful in future CROT-cancer studies.  
A key goal of cancer research is to have an impact in the clinic for improved 
patient outcomes. Although CROT expression was linked to the interesting findings from 
this study, it is unknown whether CROT enzymatic activity is even necessary for the 
effects described in this study. Taken together this makes CROT an unlikely drug target, 
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at least in the near future. However, lipogenesis is more well-studied with inhibitors of 
both ACC and FASN currently being evaluated in preclinical models (Flavin et al., 2010; 
Rohrig and Schulze, 2016; Svensson et al., 2016). Importantly, one FASN inhibitor is 
currently being evaluated in the clinic as well (ClinicalTrials.gov Identifier: 
NCT02223247). Further study of the effects of these inhibitors on lipid raft-mediated cell 
signaling would be informative for targeting pathways including AKT, but inhibition of 
lipogenesis/lipid raft signaling is unlikely to exhibit significant anti-cancer effects as a 
monotherapy (Heuer et al., 2017). Yet, targeting lipid metabolism or lipid raft-dependent 
signaling could have multiple therapeutic benefits such as the fact that inhibition of lipid 
raft signaling would target multiple pathways simultaneously. Also, inhibition of 
lipogenesis or lipid raft signaling could avoid significant normal cell toxicity because 
there is no induction of DNA damage/apoptosis and normal cells retain WT p53, a 
mediator of metabolic homeostasis. By targeting p53 regulated targets independent of 
p53 and in a non-genotoxic manner, clinicians may be able to target cancer cells in a 
more specific manner, but this goal will require years of additional study to begin testing 
this hypothesis. The identification of CROT as a p53 target gene and the novel effects 
of this peroxisomal lipid metabolism gene on cell signaling suggest that we have much 




Cell Culture and Reagents 
HepG2, MCF-7, and HCT116 cells were maintained in Dulbecco's Modified Eagle 
Medium supplemented with 10% fetal bovine serum, 100μg/ml penicillin, and 100μg/ml 
streptomycin in the presence of 5% CO2 in a humidified incubator. Cells were treated 
with 10 µM Nutlin-3 (purchased from Selleckchem) in DMSO. Cells were treated with 5 
nM ActD (purchased from Sigma) in 100% ethanol. Mammalian protein extraction was 
accomplished using either NP-40 or SDS lysis buffer. FBS or EGF stimulation was 
accomplished by treating the cells with serum-free DMEM for 12 hours prior to the 
addition of 10% FBS containing DMEM or EGF supplemented serum-free DMEM for 10 
minutes. 
 
Chromatin Immunoprecipitation Assay 
HepG2 cells expressing endogenous p53 were subjected to chromatin 
immunoprecipitation (ChIP) assays according the instructions recommended by the 
manufacturer (Quick ChIP kit, Novus Biological). Briefly, cells were treated with either 0 
or 10 µM nutlin-3 12 h before crosslinking with 1% formalin. After cell lysis, the lysates 
were sonicated (Branson) to generate ~1000-bp fragments. Goat anti-human p53 FL-
393 antibody and protein-A beads were used to immunoprecipitate p53-DNA 
complexes. Immunoprecipitated DNA was utilized as a template for PCR reactions 
consisting of 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 
minute and further analyzed with QuantStudio 6 Flex Real-Timer PCR System (Applied 
Biosystems) using the following primers: 
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P21REF 5’ – CCACTGAGCCTTCCTCACAT - 3′  
P21RER 5′ - TCTGACTCCCAGCACACACT - 3′ 
CROT RE 1 F 5’ – AGCCTCACTTCCCTTCAGGT - 3’ 
CROT RE 1 R 5’ – TATGCCGCAGCACACTACAT – 3’ 
CROT RE 3 F 5’ – GATAGCTGGGCATTTCATCTGCATAAAGC – 3’ 
CROT RE 3 R 5’ – GGGTCTCCACCCTTGAGGAGG – 3’ 
 
Plasmids and Adenovirus 
The AdEasy XL system (Stratagene) was used to generate adenovirus 
constructs according to the instructions recommended by the manufacturer. Briefly, the 
full-length CROT cDNA (ORIGENE #SC127154) was amplified by PCR, cloned into 
pShuttle-CMV, recombined with pADEASY-1 vector, and transfected into 293 QBT cells 
to generate adenovirus particles. The pGL3 basic vector was utilized to subclone the 
identified p53RE’s from CROT upstream of the firefly luciferase gene in each vector 
using the following insert oligos. The 5’ side of each forward primer and the 3’ side of 
each reverse primer had a Kpn1 RE site. The 5’ side of each reverse primer and the 3’ 
side of each forward primer had a Hind III RE site. For the mutant constructs, the 
essential CATG bases (shown in bold) in the putative p53RE were mutated according to 



























The following antibodies were purchased commercially: rabbit anti-p473 AKT 
(Cell Signaling), rabbit anti-LRP1 (Abcam), mouse anti-MDM2 2A10 (University of North 
Carolina Tissue Culture and Molecular Biology Support Facility), mouse anti-actin 
(Neomarkers), rabbit polyclonal (H300) anti-CROT (Santa Cruz), rabbit polyclonal anti-
CROT (ProteinTech), anti-p53 DO.1 (Neomarkers), rabbit polyclonal anti-Flotillin 1 
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(Protein Tech) and goat anti-p53 FL393 (Santa Cruz). Rabbit anti-p21 (C-19) was 
generously provided by Dr. Yue Xiong (UNC). 
 
Lentivirus-based shRNA and siRNA Treatment 
Lentivirus-based shRNA constructs were purchased from Open Biosystems for 
human p53 (TRCN0000003753, TRCN0000003754, TRCN0000003755, 
TRCN0000003756, and TRCN0000003757). shRNA constructs were cloned into the 
lentivirus-based pLKO.1 vector and were co-transfected into HEK293T cells along with 
the appropriate packaging vectors to produce infective virions. siRNA constructs 
targeting human CROT from Invitrogen (CROTHSS123148, CROTHSS123149) 
siCROT 8F (CROTHSS123148) 
5’ – GGACACCCUGGUUGUUGCUAUGAAA – 3’ 
siCROT 8R (CROTHSS123148) 
5’ – UUUCAUAGCAACAACCAGGGUGUCC – 3’ 
siCROT 9F (CROTHSS123149) 
5’ – GCACCAGAAAUUGCUUGAAAGAGCA – 3’ 
siCROT 9R (CROTHSS123149) 
5’ –UGCUCUUUCAAGCAAUUUCUGGUGC – 3’ 
siCROT 0F (CROTHSS123150) 
5’ –CCAGGAAUUACUAGAGACUCCAUUA– 3’ 
siCROT 0R (CROTHSS123150) 




Lipid Raft Isolation 
Detergent resistant membranes were isolated using polysome gradient buffer (20 
mM Tris-HCl pH 7.4, 140 mM KCl, 5 mM MgCl2, ddH2O) with 100 µL Triton X-100, 10 
µL of 10 mM DTT, 100 µL of 100 mM Na3VO4, 100 µL of protease inhibitor cocktail, and 
100 µL of PMSF added to make 10 mL polysome lysis buffer. 2mL of polysome lysis 
buffer were used to lyse 3 10-cm dishes of HepG2 cells per sample on ice prior to 10 
strokes with the dounce homogenizer. The homogenized lysates were then mixed with 
2 mL 80% sucrose in polysome gradient buffer. Four mL of 30% sucrose in polysome 
gradient buffer and 2 mL of 5% sucrose in polysome gradient buffer were added 
sequentially to generate the discontinuous sucrose gradient. Ultracentrifugation for 19 
hours at 37,000 RPM using a Beckmann Coulter SW-41 rotor. Fractions were taken 
from the top of the gradient in 1 mL fractions by pipet before protein extraction using 




HepG2 cells were treated with siCROT for 48 hours prior to lysis using polysome 
lysis buffer and detergent resistant membranes were isolated using the sucrose 
gradient method described previously. Fractions 3 & 4 were isolated and sent to the 
Emory Lipidomics Core Facility for extraction and analysis by mass spectrometry. 
Briefly, to each 500µl aliquot of lipid raft, 0.5 ml chloroform and 1 ml methanol were 
added and incubated at 48°C for 12 hours. The samples were cooled to the room 
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temperature and centrifuged at 3000 rpm for 10 minutes. The supernatant was 
transferred to the fresh tubes and 30 µl 1M potassium hydroxide was added. The base-
treated samples were further incubated at 37°C for 2 hours to hydrolyze the 
phospholipids. The samples were cooled to room temperature and treated with 20 µl 
glacial acetic acid to neutralize the potassium hydroxide. The neutralization was 
confirmed by a pH test strip. The samples were then treated with 2 ml of an equal 
volume of a chloroform: methanol mixture. To the solvent mixture approximately 2ml of 
water was added for phase separation. The water layer on the top was discarded and 
the remaining organic solvent was dried under a nitrogen stream. The dried samples 
were re-solvated in 500 µl methanol and injected into LC-MS.	The solvated samples 
were then analyzed using LC-MS (Exion AC-SCIEX 5500 QTRAP). The LC method was 
developed using the sphingolipid mix standard (Cer/Sph mixture II, LM-6005, Avanti 
Polar Lipids Inc.). This standard mixture was used for making a calibration curve and for 
quantification. The data were acquired using multiple reaction monitoring (MRM) mode. 
Data processing and quantification was performed using Multiquant 3.0.2 software. 
Fractions 7-10 were kept for protein extraction using methanol and chloroform prior to 
measuring for protein content, which was used as normalization for the lipid content of 
each gradient, and immunoblotted to verify CROT knockdown. 
 
MIB/MS Kinome Profiling 
HepG2 cells were treated with siCROT for 48 hours prior to introduction with 
serum free DMEM media for 12 hours. Normal media with serum was then added to the 
cells for 1 hour to stimulate cell signaling cascades. Each 10-cm dish of HepG2 cells 
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was lysed using Kinome Lysis Buffer (50 mM Hepes pH 7.5, 150 mM NaCl, 0.5% Triton 
X-100, 1 mM EDTA, 1 mM EGTA, 10 mM NaF, 2.5 mM Na3VO4, and protease inhibitor 
cocktails 2 &3 (Sigma)) and scraped to remove the total lysate. Lysates were then 
sonicated 10s @ 35% and 30s off (3 cycles) prior to centrifugation to remove additional 
cell debris. The lysate was then filtered with a .22 µM filter and transferred to the Graves 
lab for analysis. Equal protein from the various samples were then run across columns 
with multiplex inhibitor beads conjugated to kinase inhibitors to bind and isolate proteins 
that bind the kinase inhibitors. The isolated peptides were then trypsinized and analyze 





(3.1) CROT expression is induced in response to ActD treatment in WT p53 cell 
lines.  
(A) HepG2 and MCF-7 cells were treated with 5 nM ActD for 0, 24, and 48 hours prior to 
harvesting cell lysates for immunoblot analysis. 
(B) HepG2 cells were treated either with vehicle (ethanol) or 5 nM ActD for 0, 24, 48, 





















(3.2) CROT expression increases in response to multiple p53 activating stimuli.  
HepG2 cells were treated with vehicle, etoposide (5 µg/mL), 5-FU (10 µM), UV 25 J/m2, 














(3.3) Increased CROT expression in response to ActD treatment is dependent 
upon p53 expression in HepG2 and MCF-7 cells.  
(A) HepG2 cells stably infected with shp53 expressing lentivirus were treated with ActD 
for 0, 24, and 48 hours prior to cell lysis and immunoblotting. 
(B) MCF-7 cells stably infected with shp53 expressing lentivirus were treated with ActD 























(3.4) Increased CROT expression in response to ActD and Nutlin-3 treatment is 
dependent upon p53 expression in HCT116 cells.  
(A) Two CRISPR-mediated p53 knockout and WT p53 HCT116 cells were treated with 
ActD (5nM) for 0, 24, or 48 hours prior to cell lysis and immunoblotting. 
(B) Two CRISPR-mediated p53 knockout and WT p53 HCT116 cells were treated with 






















(3.5) Exogenous p53 expression increases CROT expression in p53-/- cells.  
p53-null Saos2 cells were infected with adenoviral GFP or p53 for 24 hours prior to cell 











(3.6) p53 directly binds response elements in the promoter region of CROT to 
regulate transcription.  
(A) Schematic representation of the portion of chromosome 7 containing CROT with 
p53REs and relative genes highlighted.  
(B) HepG2 cells were treated with Nutlin-3 for either 0 or 12 hours prior to crosslinking 
and immunoprecipitation using anti-p53 antibodies. The ChIP-purified DNA was then 
used as a template for PCR targeting p53REs in either the CROT or p21 promoter 
regions. 
(C) p53 binding ChIP-purified DNA was then analyzed by qRT-PCR to probe for relative 
enrichment between REs and Nutlin-3 treatment. 
(D) The putative p53REs from CROT and p21 were cloned upstream of a firefly 
luciferase gene prior to co-transfection with either vehicle or p53 plasmids in p53-null 
Saos2 cells. Luminescence is shown in log scale to more easily visualize both the p21 
and CROT mutant constructs. 
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(3.7) CROT expression is decreased in multiple cancers compared to normal 
tissue samples.  
To determine whether CROT mRNA expression is altered in tumor compared to normal 
tissue, I mined publicly available mRNA data from the Oncomine database including two 
esophageal, one HNSCC, two renal, and one colorectal cancer (Beroukhim et al., 2009; 
Cromer et al., 2004; Gumz et al., 2007; Hao et al., 2006; Hong et al., 2010; Kim et al., 


































(3.8) Increased CROT expression correlates with longer survival in patients with 
multiple cancer types.  
(A-D) We separated patients according to CROT expression levels. We then used 
PROGgene V2 software developed at Indiana University-Purdue University Indianapolis 
was used to visualize the survival of patients based on their CROT expression levels 
determined by RNA-seq (Goswami and Nakshatri, 2014).  
(E-F) Additional data including lung metastasis and relapse free survival were available 
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(3.9) Decreased CROT expression correlates with longer survival in certain 
cancers.  
(A-B) The PROGgene V2 software was used to visualize the survival of patients by 
separating CROT expression into high and low groups on either side of the median 
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(3.10) CROT expression affects cell proliferation differently depending upon 
oxygen availability.  
HepG2 cells were trypsinized and counted using the Bio-Rad TC Automated Cell 
Counter each day for growth at 20% O2 (A) or 3% O2 (C). MCF-7 cells were trypsinized 
and counted using the Bio-Rad TC Automated Cell Counter each day for growth at 20% 







(3.11) CROT expression does not affect cell survival in response to either UV- or 
Doxorubicin-induced DNA damage.  
(A) MCF-7 cells stably expressing NS or shCROT constructs were treated with either 
15J/m2 UV or doxorubicin 24h prior to fixation, DAPI staining, and counting using a plug-
in for Image J. 
(B) MCF-7 cells were infected with adenoviruses expressing GFP or CROT for 24 h 
prior to being treated with either 15J/m2 UV or doxorubicin 24h prior to fixation, DAPI 






(3.12) siCROT treated MCF-7 cells exhibit altered AKT and ERK signaling.  
MCF-7 cells were treated with control (siCtrl) or one of 3 siCROT constructs for 48 h 
prior to 12h serum starvation. The cells were then stimulated with DMEM supplemented 













(3.13) siCROT treatment increases the activation of the cellular signaling node 
AKT in HepG2 cells.  
HepG2 cells were treated with control (siCtrl) or one of 3 siCROT constructs for 48 h 
prior to 12h serum starvation. The cells were then stimulated with DMEM supplemented 














(3.14) Decreased CROT expression mediated by CRISPR-Cas9 knockdown affects 
the cellular signaling node AKT.  
Polyclonal CRISPR-Cas9-mediated knockout HepG2 cells were subjected to 12h of 
serum starvation. The cells were then stimulated with either fresh serum free media 
(FBS-), DMEM supplemented with 10% FBS (FBS+) or serum free media with 100 
















(3.15) Decreased CROT expression affects the activation of multiple cell signaling 
cascades in addition to AKT.  
(A) HepG2 cells treated were treated with either siCtrl or siCROT for 36h before serum 
starvation for 12h. Samples were then stimulated with 10% FBS-containing media for 1 
hour prior to lysis and MIBMS analysis. Casein kinase 1 isoform alpha (CSNK1A1), 
casein kinase 1 isoform delta (CSNK1D), casein kinase 2 isoform beta (CSNK2B), c-Src 
tyrosine kinase (CSK), AMPK gamma 1 (PRKAG1), AMPK beta 1 (PFKAB1), AMPK 
alpha 1 (PRKAA1), and glycogen synthase kinase 3 beta (GSK3B) peptide counts were 
all decreased in the siCROT treated samples. 
(B) Adenylate kinase 1 (AK1), cyclin G associated kinase (GAK), ketosamine 3 kinase 
(FN3KRP), fructosamine 3 kinase (FN3K), and ephrin type B receptor 4 (EPHB4) 






(3.16) Detergent resistant membranes containing lipid raft-associated Lyn kinase 
can be isolated from HepG2 cells.  
MCF-7 and HepG2 cells were lysed and subjected to a discontinuous sucrose gradient 
prior to ultracentrifugation (~230,000 x g) for 18 h. Protein was extracted using methanol 
and chloroform. Equal volumes of protein lysate from each fraction (fraction 1-top and 










(3.17) Decreased CROT expression affects the sphingolipid content of lipid rafts.  
HepG2 cells treated with either siCtrl, siCROT 8 or siCROT 9 for 72h were lysed and 
subjected to a discontinuous sucrose gradient prior to ultracentrifugation (~230,000 x g) 
for 18 h. Fractions 3 & 4 were analyzed for sphingolipid content. Briefly, 
methanol/chloroform extraction was used to isolate the lipids in the organic phase 
before analysis with mass spectrometry. The detected concentration of each 
sphingomyelin species (A) or ceramide/sphingosine (B) was normalized to protein 
concentration of fraction 8 from each sucrose gradient to account for loading differences 
between the samples. Protein from fraction 8 was extracted using methanol and 





(3.18) Decreased CROT expression increased LRP1 localization to lipid raft in 
unstimulated HepG2 cells.  
(A) HepG2 cells treated with either siCtrl or siCROT for 72h were lysed and subjected to 
a discontinuous sucrose gradient prior to ultracentrifugation (~230,000 x g) for 18 h. 
Protein was extracted using methanol and chloroform. Equal volumes of protein lysate 
from fractions 3-6 (with 1 representing the top of the gradient and 10 representing the 
bottom fraction) and serial dilutions of fraction 8 were run on an acrylamide gel and 
immunoblotted. Fraction 8 was serially diluted three times to more accurately compare 
the expression of lipid raft localized proteins to the majority of the cell’s proteins found in 
fractions 7-10. Percentages indicate the amount of lipid raft protein (fractions 4 & 5 for 
siCtrl / fractions 3 & 4 for siCROT) versus fraction 8. 
(B) 50 µg protein from fraction 8 of each gradient were immunoblotted to evaluate 




















(3.19) Decreased expression of CROT increases LRP1, p-AKT, and FLOT1 
localization to lipid rafts after stimulation with FBS for 10 min.  
HepG2 cells treated with either siCtrl or siCROT for 24h were then starved of serum for 
12h prior to 10 min of stimulation with FBS-containing media. The cells were then lysed 
and subjected to a discontinuous sucrose gradient prior to ultracentrifugation (~230,000 
x g) for 18 h. Protein was extracted using methanol and chloroform. Equal volumes of 
protein lysate from fractions 3-6 (with 1 representing the top of the gradient and 10 
representing the bottom fraction) and serial dilutions of fraction 8 were run on an 
acrylamide gel and immunoblotted. Fraction 8 was serially diluted three times to more 
accurately compare the expression of lipid raft localized proteins to the majority of the 
cell’s proteins found in fractions 7-10. Percentages indicate the amount of lipid raft 

















(3.20) Increased expression of CROT decreases FLOT1 localization to lipid rafts.  
(A) HepG2 cells treated with either adGFP or adCROT for 72h were lysed and 
subjected to a discontinuous sucrose gradient prior to ultracentrifugation (~230,000 x g) 
for 18 h. Protein was extracted using methanol and chloroform. Equal volumes of 
protein lysate from fractions 3-6 (with 1 representing the top fraction and 10 
representing the bottom fraction) and serial dilutions of fraction 8 were run on an 
acrylamide gel and immunoblotted. Fraction 8 was serially diluted three times to more 
accurately compare the expression of lipid raft localized proteins to the majority of the 
cell’s proteins found in fractions 7-10. Percentages indicate the amount of lipid raft 
protein (fractions 3 & 4) versus fraction 8. 




















(3.21) p53 activation affects lipid raft localization of LRP1, FLOT1, and LYN.  
HepG2 cells treated with either DMSO or Nutlin-3 for 72h were lysed (DMSO lysate was 
diluted to 50% to account for p53-mediated cell cycle arrest) and subjected to a 
discontinuous sucrose gradient prior to ultracentrifugation (~230,000 x g) for 18 h. 
Protein was extracted using methanol and chloroform. Equal volumes of protein lysate 
from fractions 3-6 (with 1 representing the top fraction and 10 being the bottom) and 
serial dilutions of fraction 8 were run on an acrylamide gel and immunoblotted. Fraction 
8 was serially diluted three times to more accurately compare the expression of lipid raft 
localized proteins to the majority of the cell’s proteins found in fractions 7-10. 

















(3.22) Decreased CROT expression is not sufficient to ablate p53-mediated 
regulation of LRP1 localization to the lipid raft.  
HepG2 cells treated with either siCtrl (A) or siCROT (B) for 36h were then starved of 
serum for 12h prior to 10 minutes of stimulation with FBS-containing media. The cells 
were then lysed and subjected to a discontinuous sucrose gradient prior to 
ultracentrifugation (~230,000 x g) for 18 hours. Protein was extracted using methanol 
and chloroform. Equal volumes of protein lysate from fractions 3-6 (with 1 representing 
the top fraction and 10 representing the bottom fraction) and serial dilutions of fraction 8 
were run on an acrylamide gel and immunoblotted. Fraction 8 was serially diluted three 
times to more accurately compare the expression of lipid raft localized proteins to the 
majority of the cell’s proteins found in fractions 7-10. Percentages indicate the amount 
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(C) Protein from fraction 8 of each gradient was immunoblotted to evaluate CROT 




CHAPTER 4: P53 COORDINATES DNA REPAIR WITH NUCLEOTIDE SYNTHESIS 




The transcription factor p53 regulates the expression of genes involved in many 
cellular processes, including cell cycle arrest, senescence, apoptosis, DNA damage 
repair, and metabolism (Lane and Levine, 2010; Meek, 2009; Vousden and Lane, 
2007). Despite its ability to regulate a seemingly diverse array of pathways, p53 
activation regularly exerts a net tumor suppressive effect. p53 tumor suppression is 
demonstrated by the homozygous deletion of p53 in mice, which results in the rapid 
development of tumors (Donehower et al., 1992). Consistent with its importance in 
tumor development, p53 has been confirmed as the most commonly mutated gene 
across all forms of cancer (Ciriello et al., 2013). p53 is colloquially referred to as the 
“guardian of the genome” for its role in inducing cell cycle arrest in the presence of DNA 
damage (Lane, 1992). Specifically, p53-dependent cell cycle arrest in the G1 phase 
through the induction of CDKN1A (p21) expression prevents the incorporation of 







arrest is a necessary checkpoint that allows the cell an opportunity to either repair DNA 
damage before re-entering the cell cycle or initiate apoptosis when the damaged DNA is 
beyond repair.  
One common hypothesis regarding the tumor suppressive function of p53 has 
been that the canonical effects of p53 activation (i.e., cell cycle arrest, senescence, and 
apoptosis) are more important and are thus of more interest from a clinical perspective. 
However, less well-studied p53-regulated pathways, such as metabolism and DNA 
damage repair (DDR), are gaining recognition as being equally necessary for p53-
dependent tumor suppression. These non-canonical p53-regulated pathways are 
currently being evaluated for their relative importance in p53-dependent tumor 
suppression. Multiple in vivo studies over recent years have suggested that p53 exerts 
significant tumor suppressor activity in the absence of cell cycle arrest, senescence, 
and apoptosis; therefore, efforts to further characterize non-canonical functions of p53 
are needed (Li et al., 2012; Valente et al., 2013). 
Two branches of the p53 stress response that likely contribute to its tumor 
suppressive effects are genes involved in metabolism and DDR. As a metabolic 
regulator, p53 inhibits glycolysis at multiple points by repressing the expression of 
glucose transporters GLUT1 and GLUT4 as well as pyruvate dehydrogenase kinase 2 
(PDK2) (Contractor and Harris, 2012; Kondoh et al., 2005; Schwartzenberg-Bar-Yoseph 
et al., 2004a). p53 also induces the expression of the glycolytic inhibitor TIGAR (tp53-
induced glycolysis and apoptosis regulator) (Bensaad et al., 2006). As a DDR regulator, 
p53 directly regulates the expression of the nucleotide excision repair genes XPC and 
DDB2, which contribute to the repair of DNA lesions that occur in response to UV 
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irradiation (Adimoolam and Ford, 2002; Hwang et al., 1999; Tan and Chu, 2002). 
Similarly, p53 contributes to the maintenance of the deoxyribonucleotide pool, which is 
an important component of DDR, as nucleotide shortage or imbalance can result in 
incorrect base insertion (Bester et al., 2011). Indeed, in response to DNA damage, p53 
upregulates the expression of the ribonucleotide reductase p53R2 to facilitate accurate 
nucleotide incorporation through the conversion of ribonucleotides (rNTPs) to 
deoxyribonucleotides (dNTPs) (Tanaka et al., 2000). Interestingly, despite the ability of 
p53 to increase dNTPs at the expense of rNTPs, p53 has also been reported to inhibit 
the pentose phosphate pathway (PPP), which is the biosynthetic pathway through which 
rNTP and dNTP precursors are produced (Jiang et al., 2011; Pilz et al., 1984). 
Importantly, p53-mediated inhibition of the PPP is dependent on direct binding of p53 
and glucose-6-phosphate dehydrogenase (G6PD) in the cytoplasm rather than p53 
transcriptional regulation (Jiang et al., 2011). Nonetheless, whether the p53-dependent 
regulation of metabolism could play a role in maintaining sufficient nucleotide levels 
through de novo biosynthesis in response to DNA damage remains unknown. In this 
study, we identify the PFK2 isoform 6-phosphofructo-2-kinase/fructose-2,6-
biphosphatase 3 (PFKFB3), a potent stimulator of glycolysis, as a novel p53 
suppression target and seek to determine the role of p53-PFKFB3 regulation in the 
context of p53 stress response.  
 
RESULTS 
PFKFB3 is a p53 suppression target 
To identify novel p53 target genes, we analyzed a previously described mRNA 
microarray database (Deisenroth et al., 2011), which is based on mouse embryonic 
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fibroblast (MEF) cells expressing an inducible p53-estrogen receptor (p53ER; p53ER/- 
MEF cells) fusion protein. The p53ER fusion protein is inactive in the absence of the 
tamoxifen derivative 4-hydroxytamoxifen (4-OHT), which allows for p53 activation 
independent of damage or other cellular stress. Using this system, we identified Pfkfb3 
as a novel p53 suppression target gene. PFKFB3 is a bifunctional enzyme that 
catalyzes the rate-limiting glycolysis step of generating fructose-(2,6)-bisphosphate 
(F2,6BP) through its N-terminal kinase domain, which is significantly more active than 
its C-terminal phosphatase domain. F2,6BP is a potent allosteric activator of PFK1; 
therefore, PFKFB3-mediated F2,6BP generation dramatically increases glycolytic flux 
(Hue and Rousseau, 1993; Van Schaftingen et al., 1981).  
To confirm the effect of p53 on PFKFB3 expression, we analyzed PFKFB3 
protein expression levels in Mdm2+/+;p53ER/- and Mdm2-/-;p53ER/- MEF cells in the 
presence or absence of 4-OHT. Consistent with the microarray results, Mdm2+/+;p53ER/- 
and Mdm2-/-;p53ER/- MEF cells exhibited decreased PFKFB3 protein expression in the 
presence of 4-OHT (Figure 4.1 A, lanes 4 and 6). Importantly, WT and p53-/- MEF cells 
exhibited no response to 4-OHT (Figure 4.1 A, lane 2 and 8). Moreover, quantitative 
RT-PCR (qRT-PCR) analysis showed approximately 50% decrease in Pfkfb3 mRNA 
levels after 4-OHT treatment (Figure 4.1 B). To verify that PFKFB3 down-regulation is 
directly related to p53 activation, we treated p53ER/- MEF cells with 4-OHT and 
increasing amounts of nutlin-3, a small molecule activator of p53. Consistently, we 
observed a dose-dependent decrease in PFKFB3 expression only when p53 was 
activated with 4-OHT (Figure 4.2). 
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To determine whether PFKFB3 suppression is observed in a non-p53ER system, 
we treated WT and p53-/- MEF cells with nutlin-3 and the nucleoside analog 5-
fluorouracil (5-FU), two activators of p53, and found that nutlin-3 and 5-FU induce p53-
dependent PFKFB3 suppression (Figure 4.3 A). This decrease in protein expression is 
likely dependent upon p53 transcriptional regulation, as Pfkfb3 mRNA levels were 
significantly decreased after nutlin-3 and 5-FU treatment in WT but not p53-/- MEF cells 
(Figure 4.3 B). To determine whether p53 regulates PFKFB3 in response to other forms 
DNA damage, we analyzed PFKFB3 expression in WT and p53-/- MEF cells after 
exposure to 30 J/m2 of UV irradiation. In agreement with our results after 5-FU-induced 
DNA damage, PFKFB3 protein expression decreased in WT but not p53-/- MEF cells in 
response to UV irradiation (Figure 4.4 A). Furthermore, the decrease in PFKFB3 
expression inversely correlated with increased expression of MDM2 and p21, two 
archetypal p53 transactivation targets, and increased levels of phosphorylated p53. 
Similarly, we observed a UV-induced decrease in Pfkfb3 mRNA levels and increases in 
p21 and Mdm2 mRNA levels, suggesting that p53 transcriptionally regulates Pfkfb3 in 
response to both 5-FU- and UV-induced DNA damage (Figures 4.3 B and 4.4 B).  
To determine whether p53 directly suppresses Pfkfb3, we searched the Pfkfb3 
promoter region and identified a potential p53 response element (p53RE) consistent 
with the consensus p53 binding sequence (Nikulenkov et al., 2012) (Figure 4.5 B). In 
support of a direct suppression mechanism, chromatin immunoprecipitation assays 
probing for p53 binding within PFKFB3 showed specific binding of p53 to a putative 
PFKFB3 p53RE in intron 1 (Figure 4.6 A). To test the functionality of this putative 
p53RE, we constructed a luciferase reporter under the control of the putative PFKFB3 
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p53RE. When this reporter was co-expressed with p53 in p53-null H1299 cells, we 
observed a significant (p=0.0002) decrease in luciferase signal (Figure 4.6 B). 
Moreover, when the essential central C and G nucleotides from the p53RE consensus 
sequence were mutated, the p53-dependent repression of luciferase activity was 
abolished (Figure 4.6 B). 
PFKFB3 down-regulation inhibits glycolysis 
To determine whether the p53-dependent inhibition of PFKFB3 expression 
affects the level of the PFKFB3 product F2,6BP, a potent glycolysis-promoting 
molecule, we analyzed the concentration of F2,6BP upon p53 activation. We found a 
decrease in the concentration of F2,6BP in response to p53 activation in p53ER/- MEF 
cells (Figure 4.7 A), which is consistent with reduced PFKFB3 expression (Figure 4.1A-
B). Similarly, WT MEF cells exhibited decreased levels of F2,6BP in response to UV 
irradiation, whereas p53-/- MEF cells showed a slight p53-independent increase in 
F2,6BP levels (Figure 4.7 B). The mechanism behind this p53-independent increase in 
F2,6BP is unknown, but PFKFB3 is regulated by several kinases that are likely to 
respond to UV-induced cell stress, including p38, AMPK, and PKC, which in the 
absence of p53 may play a more prominent role in F2,6BP regulation (Domenech et al., 
2015; Novellasdemunt et al., 2013; Okamura and Sakakibara, 1998). Additionally, MEF 
cells exhibited a p53-dependent decrease in lactate, which is indicative of decreased 
glycolytic production, in response to UV irradiation (Figure 4.8 B).  Previous studies 
analyzing the effects of RNAi-mediated PFKFB3 suppression reported decreased 
glycolytic flux, as indicated by decreased production of lactate (Klarer et al., 2014; Yang 
et al., 2014). Correspondingly, in response to shRNA-mediated down-regulation of 
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PFKFB3, lactate production decreased (Figure 4.8 A and C). Conversely, exogenous 
expression of PFKFB3 resulted in increased lactate production (Figure 4.8 D). 
Collectively, our results suggest that p53-mediated suppression of Pfkfb3 contributes to 
the suppression of glycolysis. 
 
PFKFB3 down-regulation facilitates DNA damage repair and survival 
The suppression of PFKFB3 and inhibition of lactate production in response to 
UV-induced DNA damage suggest that the suppression of glycolysis could play a role in 
DNA damage repair. To test this hypothesis, we analyzed the levels of the DNA 
damage marker g-H2AX in U2OS cells subjected to UV irradiation. Consistent with a 
potential role in promoting DDR, the levels of PFKFB3 showed an inverse correlation 
with g-H2AX signal. After UV irradiation, PFKFB3 levels begun to decrease between 4 
and 8 h, reached the lowest observed levels at 12 h, and recovered to basal levels by 
48 h (Figure 4.9, lanes 1-7). More importantly, upon knockdown of PFKFB3 by siRNA, 
g-H2AX levels were sharply reduced at all time points (Figure 4.9, lanes 8-14), indicating 
that down-regulation of PFKFB3 affects DNA damage accumulation. 
Immunofluorescence imaging of U2OS cells treated with UV irradiation also showed a 
direct correlation between PFKFB3 expression and g-H2AX levels (Figure 4.10 A). 
Consistently, exogenous overexpression of PFKFB3 resulted in a nearly 3-fold increase 
in g-H2AX-positive cells after UV irradiation in p53ER/- MEF cells in the absence of 4-
OHT (Figure 4.11 A). 
Next, we analyzed inducible p53ER/- MEF cells to determine the relative 
contributions of p53 activation in the context of DDR. As expected, 4-OHT-induced p53 
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activation resulted in significantly lower levels of g-H2AX (p=0.0041) after UV irradiation 
(Figure 4.12 A). Interestingly, exogenous overexpression of PFKFB3 was sufficient to 
abrogate the DNA repair function of p53 (Figure 4.12 B), suggesting that in the absence 
of PFKFB3 suppression (and hence glycolytic repression) following DNA damage, cells 
cannot effectively repair damaged DNA. Additionally, the decrease in g-H2AX foci 
associated with cells in which PFKFB3 expression was silenced correlated with a 
survival benefit in response to UV-induced DNA damage (Figure 4.10 B and Figure 
4.13). Consistently, exogenous overexpression of PFKFB3 negatively affected cell 
survival in response to UV irradiation (Figure 4.11 B). Thus, p53-mediated down-
regulation of PFKFB3 expression after UV irradiation plays an essential role in DNA 
repair and cell survival. 
 
UV irradiation induces p53-dependent down-regulation of PFKFB3 and up-
regulation of nucleotide levels 
Increased nucleotide demand is one of the stresses present after extensive DNA 
damage, such as UV irradiation, and p53 can be activated under conditions of 
nucleotide shortage (Linke et al., 1996). Our results show that PFKFB3 suppression 
occurs in response to 5-FU treatment (Figure 4.3 A and B), which inhibits nucleotide 
production (Longley et al., 2003). Therefore, we hypothesized that p53-mediated 
PFKFB3 suppression could be important when the cell requires more nucleotides. To 
test this hypothesis, we determined whether the pyrimidine synthesis inhibitor 
leflunomide could induce p53-dependent PFKFB3 repression. Consistent with our 
hypothesis, treatment with leflunomide resulted in p53 activation and PFKFB3 
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repression in WT but not p53-/- MEF cells (Figure 4.14 A). Moreover, nucleoside 
supplementation prior to UV-induced DNA damage reversed the suppression of 
PFKFB3 in both WT MEF (Figure 4.14 B) and p53 WT U2OS (Figure 4.15) cells without 
affecting p53 activation, indicating that nucleotide demand is a significant component of 
UV-induced, p53-dependent suppression of PFKFB3. Likewise, nucleoside 
supplementation prior to 5-FU treatment also reversed PFKFB3 repression in WT MEF 
cells, further supporting the hypothesis that p53 responds to nucleotide levels to repress 
PFKFB3 expression (Figure 4.14 C). Because p53 appears to respond to nucleotide 
demand in response to UV and 5-FU treatment, the effects on ribonucleotide pools 
post-UV treatment were probed using LC-MS/MS to determine individual ribonucleotide 
levels relative to untreated control cells. Surprisingly, no clear effect was observed 6 h 
post-UV treatment in either WT or p53-/- MEF cells (Figure 4.16); however, WT MEF 
cells exhibited clear increases in ribonucleotide abundance 12 h post-UV treatment 
compared with untreated control cells (Figure 4.17 A). Importantly, this increase in 
ribonucleotide abundance was not observed in p53-/- MEF cells, suggesting that p53, 
and presumably PFKFB3 regulation, play important roles in the maintenance of 
ribonucleotide pools in response to UV-induced DNA damage (Figure 4.17 B). 
 
Inhibition of PFKFB3 expression augments PPP-dependent nucleotide production 
Reduced levels of PFKFB3 have previously been shown to decrease glycolytic 
flux, thereby resulting in the diversion of glucose through the pentose phosphate 
pathway (PPP) (Yamamoto et al., 2014). In agreement with this observation, we found 
that knockdown of PFKFB3 in p53-/- MEF cells increases the NADPH/NADP+ ratio, a 
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known result of increased PPP production (Figure 4.18 A). To test whether the increase 
in DDR upon PFKFB3 suppression is dependent on the PPP, we knocked down 
PFKFB3 in U2OS cells and then treated these cells with dehydroepiandrosterone 
(DHEA), a potent inhibitor of the rate-limiting PPP enzyme G6PDH (Schwartz and 
Pashko, 2004). In support of the importance of augmenting PPP production in response 
to DNA damage, the protective effects of PFKFB3 suppression on UV irradiation were 
abrogated by DHEA treatment with respect to DNA damage repair (Figure 4.18 B) and 
cell survival (Figure 4.18 C). 
PPP products include NADPH and the nucleotide precursor ribose-5-phosphate. 
Thus, we determined whether exogenous supplementation of either component could 
rescue UV-induced DNA damage. Interestingly, only the supplementation of 
nucleosides exhibited a dose-dependent reduction of g-H2AX foci observed in UV-
irradiated U2OS cells, as supplementation with NADPH exhibited no effect (Figure 4.19 
A). Consistently, nucleoside supplementation produced a dose-dependent increase in 
cell survival upon treatment with UV irradiation (Figure 4.19 B). Moreover, knockdown of 
Pfkfb3 increased nucleotide levels by approximately 15% in p53-/- MEF cells (Figure 
4.20 A). Although PFKFB3 knockdown increased cell survival in response to UV 
irradiation, exogenous nucleoside supplementation abrogated this survival advantage, 
further supporting the idea that the enhanced survival observed after PFKFB3 
knockdown is due to increased nucleotide production (Figure 4.20 B). Conversely, 
exogenous overexpression of PFKFB3 resulted in an approximately 20% decrease in 
the relative abundance of all nucleotides (Figure 4.21 A and Figure 4.22), which is in 
agreement with reduced survival rates (Figure 4.11 B). Moreover, nucleoside 
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supplementation was sufficient to abrogate the effect of PFKFB3 overexpression on 
DNA damage-induced g-H2AX foci (Figure 4.21 B). Collectively, these results show that 
DNA damage-induced, p53-mediated PFKFB3 suppression facilitates nucleotide 
production. Our results further suggest that p53-mediated PFKFB3 suppression likely 
plays an important role in the diversion of glucose through the PPP to maintain de novo 




In this study, we mined an inducible p53 microarray dataset and identified the 
novel p53 suppression target gene Pfkfb3, which plays a critical role in the coordination 
of glycolytic metabolism with the PPP and nucleotide production. Our study establishes 
a link between p53-mediated glycolysis suppression through PFKFB3 and increased de 
novo nucleotide production to generate the nucleotides necessary for DNA repair. 
Moreover, our results suggest that despite the expression of other DNA repair target 
genes, a lack of glycolytic regulation severely impairs DNA damage repair due at least 
in part to the lack of sufficient nucleotides. 
In addition to the ability of PFKFB3 to increase F2,6BP levels, another p53-
regulated target gene, TP53-induced glycolysis and apoptosis regulator (TIGAR), 
exhibits phosphatase activity toward F2,6BP. p53-dependent induction of TIGAR results 
in decreased F2,6BP levels, reduced glycolytic flux, and increased PPP activity, as 
TIGAR primarily counteracts PFKFB3 activity (Bensaad et al., 2006). Our study 
suggests that by suppressing PFKFB3 in response to UV irradiation and inducing 
TIGAR expression in response to other types of stress, p53 maximizes its control over 
glycolysis and PPP production. Although p53 regulates both PFKFB3 and TIGAR, it is 
noteworthy that high-level expression of PFKFB1, a homolog of PFKFB3 that also 
exhibits dominant kinase activity, has been shown to reverse TIGAR-induced PPP 
activity (Bensaad et al., 2006). These results indicate that the kinase activity of PFKFB1 
could override the phosphatase activity of TIGAR, which could explain the necessity for 
p53 to suppress PFKFB3. In response to acute stress, such as UV-induced DNA 
damage, the concomitant regulation of TIGAR and PFKFB3 could be necessary to 
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rapidly and robustly produce the nucleotides required for repair. The dual regulation of 
an important rate-limiting step in glycolysis suggests that a major component of p53 
tumor suppression involves the maintenance of nucleotide homeostasis through 
metabolic regulation (Figure 6). Initially, the hypothesis that p53 is activated to 
upregulate PPP-dependent production of nucleotides seems to contradict previous 
research showing that p53 directly binds to and inhibits G6PDH, the rate-limiting 
enzyme of the PPP; however, it has also been noted that MG132- or doxorubicin-
mediated p53 activation reduces the amount of p53-G6PDH binding (Jiang et al., 2011). 
This suggests that while inactivated cytoplasmic p53 may inhibit the PPP through 
protein-protein interaction, that p53 activation via genotoxic stress results in p53 
trafficking to the nucleus to increase PPP activity through transcriptional regulation. 
Collectively, these data suggest a dynamic p53-dependent mechanism that depends on 
the sub-cellular localization of p53 protein. 
UV irradiation generates cyclobutane-pyrimidine dimers and 6-4 photoproducts in 
the affected DNA, which requires nucleotide excision repair (NER) to maintain genomic 
integrity (Marteijn et al., 2014).  NER requires more nucleotides than base excision 
repair or non-homologous end joining, which repair DNA lesions without significant DNA 
synthesis. The high demand on nucleotide levels could explain why p53 regulates 
PFKFB3 specifically in response to UV irradiation. Whether p53 regulates PFKFB3 in 
response to other DNA damaging agents that generate DNA lesions that are repaired 
by other mechanisms will need to be addressed by future studies. Moreover, a sufficient 
and balanced nucleotide pool is required for proper cell division, as DNA replication in 
the presence of insufficient nucleotides leads to replication-induced DNA damage, 
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which can result in mutations that lead to tumorigenesis (Beck et al., 2012; Bester et al., 
2011). Although a high degree of genomic fidelity is important in non-transformed cells, 
cancer cells require a degree of fidelity as well. Despite the adaptive advantages 
associated with increased genomic instability in cancer cells, too many mutations can 
be detrimental; therefore, even cancer cells must guard against mutation by maintaining 
de novo nucleotide synthesis through PPP upregulation. Consistent with the importance 
of the PPP in cancer, not only is PFKFB3 down-regulated in certain cancers but the 
rate-limiting PPP enzyme G6PDH is also commonly upregulated in cancers, suggesting 
that PPP flux is advantageous to cancer cell proliferation and survival (Du et al., 2013; 
Kuo et al., 2000). 
One specific area of therapeutic research that could benefit from our findings is 
the development of molecules that increase the efficacy of radiation treatment, known 
as radiosensitizers (Moding et al., 2013). The efficacy of cancer radiation therapy is in 
part derived from the high proliferation rate of tumor cells, which results in more 
devastating replication-induced DNA damage in cancer cells compared with normal 
tissue. Based on the results of our study, we suspect that cancer cells in which the p53 
stress response is disrupted may be especially vulnerable to PPP inhibition in 
conjunction with radiotherapy. Interestingly, multiple studies have shown that PPP 
inhibitors can sensitize cancer cells derived from difficult-to-treat tumors, such as 
gliomas and squamous carcinomas, to ionizing radiation (Manganelli et al., 2013; 
Varshney et al., 2005), suggesting that the development of additional PPP inhibitors 
could be a worthwhile endeavor. The potential value of PPP inhibitors as 
radiosensitizers is intriguing given the relative scarcity of nucleotides at any given 
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moment in the cell and the importance of maintaining nucleotide levels sufficient for 
DNA repair. Our results provide the basis for future studies developing and investigating 
the efficacy of cancer therapeutics targeting the PPP. 
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EXPERIMENTAL PROCEDURES 
Chromatin Immunoprecipitation Assay 
U2OS cells expressing endogenous p53 were subjected to chromatin 
immunoprecipitation (ChIP) assays according the instructions recommended by the 
manufacturer (Quick ChIP kit, Novus Biological). Briefly, cells were treated with either 0 
or 10 µM nutlin-3 12 h before crosslinking with 1% formalin. After cell lysis, the lysates 
were sonicated (Branson) to generate ~1000-bp fragments. Goat anti-human p53 FL-
393 antibody and protein-A beads were used to immunoprecipitate p53-DNA 
complexes. Immunoprecipitated DNA was utilized as a template for PCR reactions 
consisting of 40 cycles of 95°C for 30 seconds, 60°C for 30 seconds, and 72°C for 1 
minute and analyzed with QuantStudio 6 Flex Real-Timer PCR System (Applied 
Biosystems) using the following primers: 
P21 RE F 5’ – CCACTGAGCCTTCCTCACAT - 3′  
P21 RE R 5′ - TCTGACTCCCAGCACACACT - 3′ 
PFKFB3 RE Intron F 5’ - CCAGGCATGTTTCAGTTGAC – 3’  
PFKFB3 RE Intron R 5’ - GTAATCCCATCTGCTGAGGTAGG – 3’ 
 
Measurement of Fructose-2,6-Bisphosphate Levels 
Fructose-2,6-bisphosphate levels were determined based on the activation of 
pyrophosphate-dependent PFK1, as previously described (Yalcin et al., 2009). Briefly, 
cells were pelleted by low-speed centrifugation and resuspended in a solution 
containing 20 volumes of 50mM NaOH and 1 volume of 100mM NaOH (pH 11.0) and 
vortexed for 10 seconds. The solution was then heated at 80°C for 5 minutes before 
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being placed on ice, and the solution was neutralized to pH 7.2 with cold acetic acid in 
20mM HEPES buffer. Sample extracts were then incubated at 25°C for 2 minutes in a 
solution containing 50mM Tris, 2mM Mg2+, 1mM Fru-6P, 15μM NAD, 10 units/liter PP-
dependent PFK1 enzyme, 0.45 kilounits/liter aldolase, 5 kilounits/liter triose phosphate 
isomerase, and 1.7 kilounits/liter glycerol-3-phosphate dehydrogenase (Sigma). Then, 
0.5mM pyrophosphate was added, and the rate of change in absorbance (OD 339 nm) 
per minute was measured for 5 minutes. The F-2,6BP concentration was calculated 
based on a calibration curve ranging from 0.1 to 1.0 pmol of purified F-2,6BP (Sigma) 
and then normalized to total protein content. 
 
Cell Culture and Reagents 
U2OS cells were maintained in Dulbecco's Modified Eagle Medium 
supplemented with 10% fetal bovine serum, 100μg/ml penicillin, and 100μg/ml 
streptomycin in the presence of 5% CO2 in a humidified incubator. Primary mouse 
embryonic fibroblast (MEF) cells were isolated on embryonic day 13.5 and were grown 
in a humidified 37°C incubator in the presence of 5% CO2 and 3% O2 to simulate 
endogenous oxygen concentrations and to minimize oxidative stress. MEF cells were 
also maintained in DMEM supplemented with 10% FBS and 100μg/ml penicillin-
streptomycin. 4-hydroxytamoxifen (4-OHT) was purchased from Sigma. Mammalian 





Plasmids and Adenovirus 
The AdEasy XL system (Stratagene) was used to generate adenovirus 
constructs according to the instructions recommended by the manufacturer. Briefly, the 
full-length PFKFB3 cDNA (Open Biosystems) was amplified by PCR, cloned into 
pShuttle-CMV, recombined with pADEASY-1 vector, and transfected into 293 QBT cells 
to generate adenovirus particles. The pGL3 basic and pGL3 promoter vectors were 
utilized to subclone the identified p53RE from intron 1 of PFKFB3 upstream of the firefly 
luciferase gene in each vector using the following insert oligos. The essential C and G 
bases in the putative p53RE highlighted in Figure S2 were mutated according to the 
oligo sequences shown below to generate the PFKFB3 p53RE mutant construct. 
PFKFB3Luc-1F: 5’ -
CTAGCAGACAGAGTTTTGCTCTGTTTCCCAGGCTGGAGTGCATTGGTACAATCTCG
GCTCACTGCAACCTCTGCCTC – 3’ PFKFB3Luc-1R: 5’ - 
TCGAGAGGCAGAGGTTGCAGTGAGCCGAGATTGTACCAATGCACTCCAGCCTGGG
AAACAGAGCAAAACTCTGT CTG – 3’ PFKFB3Lucm-1F: 5’ - 
CTAGCAGACAAGTTTTGCTCTGTTTCCCAGGCTAGAGTGCATTGGTACAATCTAGG





Cells grown in a monolayer were fixed with formaldehyde, permeabilized with 
0.2% Triton X-100, and stained with primary anti-phospho-H2AX (S139) antibody. After 
washing away unbound primary antibody, cells were incubated with AlexaFluor 594-
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conjugated goat anti-rabbit secondary antibody (Jackson ImmunoResearch 
Laboratories). 4',6-diamidino-2-phenylindole (DAPI) was used for nuclear 
counterstaining. Immunostained cells were analyzed using an Olympus IX-81 
microscope fitted with a SPOT camera and software. 
	
Luciferase	Assay	
Luciferase assays were conducted using the Dual Light Luciferase Assay kit from 
Applied Biosystems (Cat #BC100L) according to the protocol suggested by the 
manufacturer. Briefly, H1299 cells were plated in six-well plates 24 h prior to 
transfection with pGL3 basic (PFKFB3 mutant assay). The next day, cell extracts were 
prepared using 125 μL per well of lysis solution (100 mM potassium phosphate (pH 7.8), 
0.2% Triton X-100, and 0.5 M DTT) after 2 PBS washes. Cell debris was removed by 
centrifugation, and 10μL of the cell lysates were transferred to a 96-well plate in 
triplicate. Twenty-five microliters of Buffer A were added to each well and incubated at 
room temperature for 10 minutes before adding 100μL of Buffer B. Luminescence was 
measured using a BioTek Synergy 2 plate reader. The plate was then incubated at 
room temperature for 1 h to decrease the luminescent signal before adding 100μL of 
Accelerator II buffer and measuring the β-galactosidase signal using a BioTek Synergy 
2 plate reader. Luminescence is shown as the relative firefly luciferase signal 
normalized to the β-galactosidase control. 
 
Antibodies 
The following antibodies were purchased commercially: mouse anti-MDM2 2A10 
(University of North Carolina Tissue Culture and Molecular Biology Support Facility), 
mouse anti-actin (Neomarkers), mouse anti-p53 DO.1 (Neomarkers), goat anti-p53 
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FL393 (Santa Cruz) and mouse anti-mp53 NCL-p53-505 (Leica microsystems). Rabbit 
anti-PFKFB3 antibody (ProteinTech Group 13763-1-AP) and rabbit anti phospho-H2AX 
(S139) #9718S were purchased from Cell Signaling Technologies. Rabbit anti-p21 (C-
19) was generously provided by Dr. Yue Xiong (UNC). 
 
DNA Damage Repair Efficiency Assay 
Cells were treated with the caspase inhibitor QVD-OPh prior to additional 
treatments for 30 minutes. UV treatment (<40 J/m2 for U2OS cells and <15 J/m2 for 
MEF cells) was performed to induce DNA damage. Medium containing QVD-OPh and 
the indicated treatment was added, and the cells were incubated at 37°C. Cells were 
then fixed 0, 24, and 48 hours after treatment and then stained for the DNA damage 
marker g-H2AX (Mah et al., 2010) and counterstained for DAPI. g-H2AX-positive cells 
were counted and normalized to the total cell count as determined by DAPI staining. 
 
Lactate Assay 
Extracellular lactate levels were measured using the Lactate 
Colorimetric/Fluorometric Assay kit according to the protocol suggested by the 
manufacturer (Biovision (Catalog # K607-100). Two microliters of culture medium were 
obtained from cells that were in culture for 24 hours. The absorbance (OD 570 nm) of 
the samples were measured using a BioTek Synergy 2 microplate reader. 
 
Measurement of Cellular Nucleotide Levels (Figure 5) 
An AKTA FPLC (GE Healthcare Life Sciences #18-1900-26) was used to 
quantify methanol-soluble extracts. Five hundred-microliter samples were injected onto 
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a Partisil 5 SAX anion-exchange column (4.6 mm × 250 mm; Whatman #4222-227). 
The nucleotides were separated using a gradient of 50% Buffer A (5 mM 
(NH4)H2PO4 pH 3.8) and 50% Buffer B (0.25 M (NH4)H2PO4, 0.5 M KCl pH 4.5) to 100% 
Buffer B for 30 min followed by an isocratic elution with 100% Buffer B for 15 min at a 
flow rate of 1.5 ml/min. The column was allowed to re-equilibrate to initial conditions for 
5 min prior to the next injection. The absorbance of the nucleotides was determined at 
280 nm. 
 
Measurement of Cellular Nucleotide Levels (Figure 4) 
Nucleotides were extracted from MEF cells using 100% methanol. Briefly, cells 
were washed twice with PBS buffer before the addition of methanol, then the cells were 
scraped into an Eppendorf tube and vortexed. This extract was incubated on ice for 15 
minutes prior to another short vortex, centrifuged at maximum speed for 5 minutes to 
remove cell debris, and dried using a speed-vac at room temperature. Dried extract was 
re-suspended in 60 μl of 1:1 acetonitrile/water solution containing 10 μg/ml of 13C-
labeled standards (13C ATP, 13C CTP, 13C GTP, and 13C UTP (Sigma-Aldrich, St. Louis, 
MO, USA)), vortexed, and 10 μL was used for LC-MS analysis. 
 
Liquid chromatography separation was conducted using an HILIC column (Venusil 
HILIC Column, 3 μm, 100 Å, 2.1x100 mm, Agela Technologies Inc., Wilmington DE, 
USA) optimized for both nucleotide, amino acid, and organic matter separation using 
10-minute cycles based on the following solvent gradients. Solvent A: 100 mM 
ammonium acetate (Fisher Chemicals, Fair Lawn, NJ, USA), 20 mM ammonium 
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hydroxide (Fisher Chemicals, Fair Lawn, NJ, USA) in HPLC grade water (Fluka, Sigma-
Aldrich, St. Louis, MO, USA). Solvent B: 100% HPLC-grade acetonitrile (Fluka, Sigma-
Aldrich, St. Louis, MO, USA). LC gradient: Starting with 98% Solvent B, 1 minute – 
starting gradient, 6 minutes – 50% Solvent B, 6.01 minutes – 2% Solvent B, 7 minutes – 
2% Solvent B, 8 minutes – 98% Solvent B, 10 minutes – stop. Total flow rate of 0.4 
ml/min (binary flow). 
  
Mass spectrometry was performed in positive mode using an ABSciex 5600 with 
following parameters: Ion source gas 1 – 45, Ion source gas 2 – 30, Curtain gas – 20, 
Temperature – 450, Ion spray voltage – 4500 V, Declustering potential – 80 V, Collision 
energy 5 (35 – for product ion fragmentation). TOF mass detection 5 to 1050 Da. MS-
MS was performed for the 10 most abundant products. Scheduled MRM was performed 
for 15 target metabolites (11 phosphonucleotides + 4 13C-labeled internal standards). 
Relative nucleotide levels were calculated by measuring the peak area under the curve 
for each nucleotide species using 13C-labeled NTPs to account for ionization variance 
between runs. Valine was used to normalize for cell number, and 100% was defined 
based on the untreated control samples. Data were analyzed using Peakview software 
to determine nucleotide levels. 
 
Lentivirus-based shRNA and siRNA Treatment 
Lentivirus-based shRNA constructs were purchased from Open Biosystems for 
human PFKFB3 (TRCN0000007338 NM_004566 RHS3979-9576297, 
TRCN0000007340 NM_004566 RHS3979-9576299, TRCN0000007341 NM_004566 
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RHS3979-9576300, TRCN0000007342 NM_004566 RHS3979-9576301) and mouse 
PFKFB3 (TRCN0000025414 NM_133232 RMM3981-9592822, TRCN0000025415 
NM_133232 RMM3981-9592823, TRCN0000025416 NM_133232 RMM3981-9592824, 
TRCN0000025417 NM_133232 RMM3981-9592825, TRCN0000025418 NM_133232 
RMM3981-9592826). shRNA constructs were cloned into the lentivirus-based pLKO.1 
vector and were co-transfected into HEK293T cells along with the appropriate 
packaging vectors to produce infective virions. siRNA constructs targeting human and 
mouse PFKFB3 were as follows: siPFKFB3a: F-GCTGACTCGCTACCTCAACTT 




Total RNA was isolated from WT and p53-/- MEF cells using the RNeasy Mini kit, 
and cDNA was generated using Superscript III reverse transcriptase. qRT-PCR was 
performed using SYBR green master mix in conjunction with a 7900HT Fast Real-Time 
PCR System according to the protocol suggested by the manufacturer. Relative 
expression was normalized to actin. The following primers were used: Figure 1F 
mPFKFB3F: 5’ - TGATGGTGGGGCTCCCAGCC – 3’ mPFKFB3R: 5’ -  
GTGGTCCTGCACTCTGTTCACC – 3’ mActinF: 5’ - 
GCCAGGACCATCAATGAAGTGGAG – 3’ mActinR: 5’ - 
GTTAGAGGTCGCTCTCGCCATAC – 3’ mMdm2F: 5’ – 
CCAACCATCGACTTCCAGCAGCATT – 3’ mMdm2R: 5’ – 
GATTGGCTGTCTGCACACTGGG – 3’ mp21F: 5’ – CCTGGTGATGTCCGACCTG – 3’ 
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mp21R: 5’ – CCATGAGCGCATCGCAATC – 3’ Figure 1 B&D mActin F 5’ –
CCACAGCTGAGAGGGAAATCGTGC- 3’ mActin R 5’ –
CCAGGATGGAGCCACCGATCC- 3’ mPFKFB3 F 5’-CACTGCGTGAACAGGACAAG- 




All statistical comparisons were performed using GraphPad 5.0 software based 
on two-tailed unpaired t-tests with n being greater than or equal to 3. The symbol * 





(4.1) p53 activation in p53ER/- MEF cells correlates with PFKFB3 repression 
(A) p53-/-, Mdm2+/+;p53ER/-, Mdm2-/-;p53ER/-, and WT MEF cells were treated (+/-) 100 nM 4-OHT 
for 24 h prior to lysis and immunoblotting. Densitometry analysis using Image J software was 
used to compare PFKFB3 expression after normalization to actin for 3 independent 
experiments. The PFKFB3 expression level observed in the (-)4OHT sample for each cell line 
was set to 1 for normalization. 
(B) Relative mRNA levels of Pfkfb3 were determined by qRT-PCR in p53-/-, Mdm2+/+;p53ER/-, 
Mdm2-/-;p53ER/- and WT MEF cells 12 h after treatment with 100 nM 4-OHT. Levels were 
normalized to actin, and the levels of Pfkfb3 detected in the vehicle-treated samples for each 








(4.2) PFKFB3 exhibits a dose-dependent decrease specifically in the presence of 4-OHT. 
Mdm2+/+;p53ER/- MEF cells were treated with or without 100 nM 4-OHT for 12 h followed by 
treatment with both 4-OHT and nutlin-3 at the indicated concentrations for 12 h. Cell lysates 







(4.3) p53 activation in response to Nutlin-3 and 5-FU results in PFKFB3 repression 
(A) WT and p53-/- MEF cells were treated (+/-) 10 μM nutlin-3 or 10 μM 5-FU for 24 h prior to 
immunoblotting for the indicated proteins. 
(B) Relative mRNA levels of Pfkfb3 were determined by qRT-PCR in p53-/- and WT MEF cells 
12 h after treatment with DMSO, 10 μM nutlin-3 or 10 μM 5-FU. Levels were normalized to 
actin, and the levels of Pfkfb3 observed in the DMSO-treated samples for each cell line were set 





(4.4) Pfkfb3 decreases in response to UV-induced DNA damage specifically in WT but not 
p53-/- MEF cells 
(A) WT and p53−/− MEF cells were treated with 30 J/m2 UV for 24 h followed by immunoblotting 
for protein expression. 
(B) Relative mRNA levels of Pfkfb3, p21, and Mdm2 were determined by qRT-PCR in WT and 
p53-/- MEF cells 24 h after treatment with 40 J/m2 UV. Levels were normalized to actin, and the 




(4.5) Putative p53 response element in PFKFB3 intron 1 
(A) Conserved p53 response elements (p53RE) have been defined by the following sequence: 
RRRCWWGYYY (N0-13) RRRCWWGYYY (R=purine, Y=pyrimidine, W=adenine or thymine, 
N=any base)  
(B) putative p53RE in the first intron of PFKFB3 exhibits various alterations from this structure 
that may explain why p53 suppresses rather than activates this p53RE, which includes base 






(4.6) p53 binds in Intron 1 of PFKFB3 
(A) Chromatin immunoprecipitation of the putative Pfkfb3 p53RE located within intron 1 and the 
p21 p53RE in U2OS cells 12 h after 10 μM nutlin-3 treatment. (PFKFB3 p=0.002 ; p21 p<0.001 
n=3) (B) Exogenous overexpression of Pfkfb3 Intron 1 p53RE-luciferase (Pfkfb3) and mutant 
Pfkfb3 Intron 1 p53RE-luciferase (Pfkfb3m) in H1299 cells. Relative luminescence is the 





(4.7) PFKFB3 expression is directly correlated with fructose-(2,6)-bisphosphate 
production 
(A) Fructose-(2,6)-bisphosphate (F2,6BP) levels were determined in WT, Mdm2+/+;p53ER/- and 
Mdm2-/-;p53ER/- MEF cells in the presence or absence of 4-OHT after 24 h. The amount of 
F2,6BP detected in the vehicle-treated WT MEF cells was set at 100%. (WT ER p=0.0218; -/- 
ER p=0.0006 n=5) 
(B) Fructose-(2,6)-bisphosphate (F2,6BP) levels were assayed in WT and p53-/- MEF cells 24 h 
after treatment with 40 J/m2 UV, and the amount of F2,6BP detected in the untreated samples 






(4.8) PFKFB3 expression is directly correlated with lactate production 
(A) Expression levels of PFKFB3 were determined by western blot for p53-/- MEF cells stably 
infected with 4 different shRNA constructs targeting Pfkfb3.  
(B) Lactate levels were measured in WT and p53-/- MEF cells 24 h after treatment with 0 J/m2, 
25 J/m2, or 40 J/m2 UV, and the amount of lactate detected in the untreated samples for each 
cell line was set to 100%. (WT 0/25J p<0.0001; WT 0/40J p<0.0001; -/- 0/25J p=0.0308 n=3) 
(C) Extracellular lactate levels were measured in p53-/- MEF cells transduced with 3 unique 
shRNA constructs specifically targeting Pfkfb3 (sh-PFKFB3) and compared with cells 
transduced with the non-specific scrambled control. The non-specific scrambled control samples 
were designated as 100% (#1 p<0.0001; #2 p<0.0001, #3 p<0.0001 n=3). 
(D) Lactate levels were measured 24 h after exogenous overexpression of PFKFB3 in U2OS 








(4.9) PFKFB3 expression inversely correlates with g-H2AX accumulation in response to 
UV induced DNA damage 
si-NS and si-PFKFB3 pretreated U2OS cells were treated with 15 J/m2 UV for varying amounts 





(4.10) shRNA-mediation decreases in PFKFB3 expression decreases g-H2AX signal and 
increases survival 
(A) U2OS cells infected with lentiviral particles expressing shRNA constructs specific for 
PFKFB3 (sh-PFKFB3) and non-specific scrambled control (sh-NS) were treated with caspase 
inhibitor QVD-OPh for 30 minutes prior to treatment with 25 J/m2 UV to prevent apoptosis. Fresh 
medium containing QVD-OPh was added after treatment, and the cells were incubated at 37°C 
for 48 hours prior to fixation and staining for the DNA damage marker g-H2AX along with DAPI 
to visualize the total number of nuclei present. (p<0.0001, n=6)   
(B) U2OS cells infected with lentiviral particles expressing shRNA constructs specific for 
PFKFB3 (sh-PFKFB3) and non-specific scrambled control (sh-NS) were irradiated with UV 40 
J/m2. Twenty-four hours after treatment, the cells were trypsinized and counted using a Bio-Rad 






(4.11) Overexpression of PFKFB3 increases g-H2AX signal and decreases survival 
(A) Mdm2+/+;p53ER/- MEF cells stably infected with lentiviral particles harboring PFKFB3-GFP or 
GFP constructs were treated with caspase inhibitor QVD-OPh for 30 minutes prior to treatment 
with UV 10 J/m2 to prevent apoptosis. Fresh medium containing QVD-OPh was added after 
treatment, and the cells were incubated at 37°C for 48 hours prior to fixation and staining for the 
DNA damage marker g-H2AX along with DAPI to visualize the total number of nuclei present. 
(p<0.0001 n=5)  
(B) U2OS cells overexpressing PFKFB3 by adenoviral infection were irradiated with UV 40 J/m2. 
Twenty-four hours after treatment, the cells were trypsinized and counted using a Bio-Rad TC20 





(4.12) p53 activation decreases g-H2AX signal, but the g-H2AX effect is lost upon 
exogenous expression of PFKFB3 
(A) Mdm2+/+;p53ER/- MEF cells treated with caspase inhibitor QVD-OPh for 30 minutes prior to 
treatment with UV 10 J/m2 to prevent apoptosis. Fresh medium containing QVD-OPh was added 
after treatment, and the cells were incubated at 37°C for 48 hours prior to fixation and staining 
for the DNA damage marker g-H2AX along with DAPI to visualize the total number of nuclei 
present. (+/-) 4-OHT were (p=0.0041 n=7)   
(B) Mdm2+/+;p53ER/- MEF cells stably infected with lentiviral particles harboring PFKFB3-GFP or 
GFP constructs were treated with caspase inhibitor QVD-OPh for 30 minutes prior to treatment 
with UV 10 J/m2 to prevent apoptosis. Fresh medium containing QVD-OPh was added after 
treatment, and the cells were incubated at 37°C for 48 hours prior to fixation and staining for the 
DNA damage marker g-H2AX along with DAPI to visualize the total number of nuclei present. 






(4.13) Down-regulation of PFKFB3 increases cell survival.  
Mdm2+/+;p53ER/- MEF cells infected with lentiviral particles expressing scrambled (NS) or 
sh-PFKFB3 constructs were treated with UV 10 J/m2. Fresh medium was added after 
treatment, and the cells were incubated at 37°C for 24 hours prior to fixation and 
staining for DAPI to visualize the total number of nuclei present. A cell counting plugin 
for ImageJ was used to count surviving cells in each image. Western blot analysis of 






(4.14) p53 is activated by nucleotide shortage and p53-mediated repression of PFKFB3 is 
dependent upon nucleotide levels. 
(A) WT and p53-/- MEF cells were treated with the pyrimidine synthesis inhibitor leflunomide (25 
μM) 24 h prior to immunoblotting for protein expression. 
(B) WT MEF cells were treated with UV 15 J/m2 and incubated for 24 h (+/-) 0.2 mM nucleoside 
supplementation prior to immunoblotting for protein expression. 
(C) WT MEF cells were treated with 10 μM 5-FU and incubated for 24 h (+/-) 0.2 mM nucleoside 
supplementation prior to immunoblotting for protein expression. 
  
A B C 
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(4.15) Nucleoside supplementation reverses UV-induced suppression of PFKFB3 
expression. 
U2OS cells were treated with UV 40 J/m2 and incubated for 24 h with or without 0.2 mM 




(4.16) WT and p53-/- MEF cells exhibit no significant change in nucleotide levels 6h post 
UV treatment. 
(A) WT MEF cells were treated with UV 20 J/m2 and incubated for 6 h prior to methanol 
extraction of nucleotides. Extracts were analyzed by LC-MS for relative nucleotide levels 
between UV-treated and untreated control cells, and untreated cell nucleotide levels were 
normalized to 100% for each experiment (Error bars represent the SEM n=4). 
(B) p53-/- MEF cells were treated with UV 20 J/m2 and incubated for 6 h prior to methanol 
extraction of nucleotides. Extracts were analyzed by LC-MS for relative nucleotide levels 
between UV-treated and untreated control cells, and the untreated cell nucleotide levels were 






(4.17) WT but not p53-/- MEF cells exhibit significant increases in nucleotide levels 12h 
post UV treatment. 
(A) WT MEF cells were treated with UV 20 J/m2 and incubated for 12 h prior to methanol 
extraction of nucleotides. Extracts were analyzed by LC-MS for relative nucleotide levels 
between UV-treated and untreated control cells, and untreated cell nucleotide levels were 
normalized to 100% for each experiment (Error bars represent the SEM n=4). 
(B) p53-/- MEF cells were treated with UV 20 J/m2 and incubated for 12 h prior to methanol 
extraction of nucleotides. Extracts were analyzed by LC-MS for relative nucleotide levels 
between UV-treated and untreated control cells, and the untreated cell nucleotide levels were 





(4.18) PFKFB3 expression inversely correlates with PPP activity and inhibition of the PPP 
abolishes PFKFB3 effects on DNA damage and survival. 
(A) NADPH/NADP+ ratios were determined in p53-/- MEF cell lines stably expressing scrambled 
or sh-PFKFB3 constructs. (#1 p=0.007 #2 p=0.0341 n=3 for each sample)  
(B) U2OS cells stably expressing scrambled or sh-PFKFB3 constructs were treated with QVD-
OPh and (+/-) the PPP inhibitor DHEA (0.25 mM) for 30 minutes prior to 20 J/m2 UV treatment. 
After 48 h, the cells were fixed and stained for g-H2AX and DAPI. (p=0.0044 n=3)  
(C) U2OS cells stably expressing scrambled or sh-PFKFB3 lentiviral constructs were treated 
with 40 J/m2 UV (+/-) DHEA (0.25 mM) for 24 h, after which the cells were trypsinized and 
counted using a Bio-Rad TC20 automated cell counter. (p=0.0002 n=3)   
  
C B A 
	 183	
 
(4.19) Nucleotides rather than NADPH appear to be the PPP product required for DNA 
damage and survival benefit. 
(A) U2OS cells were treated with QVD-OPh and an equimolar nucleoside mixture or NADPH (0 
mM, 0.1 mM, or 0.3 mM) for 30 minutes. Cells were then treated with 40 J/m2 UV 48 h prior to 
fixation and then were stained for g-H2AX and DAPI. (0.1mM p=0.0016;0.3mM p<0.001 n=3)  
(B) U2OS cells were treated with a 0 mM, 0.1 mM, or 0.3 mM equimolar nucleoside mixture for 
30 minutes, after which the cells were treated with UV 40 J/m2. Surviving cells were imaged and 






(4.20) Decreased PFKFB3 expression results in higher nucleotide content and survival 
(A) Nucleotide abundance was assessed by HPLC in p53-/- MEF cells stably expressing 
scrambled or sh-PFKFB3 lentiviral constructs. (p=0.01 n=3)   
(B) U2OS cells stably expressing scrambled or sh-PFKFB3 constructs were treated (+/-) 0.2 
mM equimolar nucleoside mixture for 30 minutes. After nucleoside treatment, cells were 







(4.21) Increased PFKFB3 expression results in lower nucleotide content and survival 
(A) Nucleotide abundance was assessed by HPLC in p53-/- MEF cells stably expressing GFP or 
PFKFB3-GFP. (p=0.0242 n=3) 
(B) HCT116 cells stably expressing GFP or PFKFB3-GFP were treated with QVD-OPh (+/-) 0.2 
mM equimolar nucleoside mixture for 30 minutes. Cells were treated with 25 J/m2 UV 48 h prior 
to fixation and then were stained for g-H2AX and DAPI (Vector vs. PFK p=0.0002; PFK vs. PFK 





(4.22) Overexpression of PFKFB3 decreases nucleotide production. 
p53-/- MEF cells infected with lentiviral GFP or GFP-PFKFB3 constructs were analyzed by HPLC 
for nucleotide abundance. When normalized for protein content detailed analysis shows that in 





(4.23) Model representation of p53-PFKFB3 regulation   
Exhibiting the role of p53 in the concomitant regulation of glycolysis, the PPP, and nucleotide 
production through PFKFB3 as well as through the regulation of DNA damage repair target 




CHAPTER 5: CONCLUSIONS AND FUTURE DIRECTIONS 
PFKFB3 
p53 has been studied extensively over the last three decades leading to the 
discovery of hundreds of target genes, but surprisingly no significant p53 targeted 
therapies have been developed. Building on recent research that p53 elicits tumor 
suppression through less well-studied functions, I sought to identify and characterize 
novel p53-regulated metabolic genes in an effort to identify new targets for cancer 
therapy. From this work, I have established that p53 directly regulates the transcription 
of PFKFB3 and CROT in response to various stresses to regulate glycolysis and lipid 
metabolism, respectively.  
p53 regulation of PFKFB3, while novel in both the target and its responsiveness 
to DNA damage, is not a novel area of biology for p53 regulation, as p53 has been 
shown to regulate glycolysis at multiple steps (Madan et al., 2011). p53 also positively 
regulates the transcription of TIGAR, which directly competes with PFKFB3 to regulate 
PFK1 and glycolysis (Bensaad et al., 2006). These findings suggest that regulation of 
PFK1 activity may be vital for p53-mediated tumor suppression. As mentioned 
previously, it is unclear whether glycolysis is a result of cancerous growth or a driver of 
cancer. To determine the effects of decreased PFKFB3 expression on cancer cell 
proliferation, I utilized the shPFKFB3 constructs from our study to perform both colony 
formation assays and tumor xenografts. Our initial experiments using non-cancerous 
	 189	
p53-null MEF cells stably expressing shPfkfb3 exhibited decreased proliferation 
compared to control cells using 2D colony formation assays (Fig 5.1). This finding is in 
agreement with the hypothesis first suggested by Warburg that cancer cells are 
dependent upon high rates of glycolysis for rapid proliferation (Warburg, 1956). While 
p53-/- MEF cells are capable of reaching significantly higher passage numbers than WT 
MEF cells, MEF cells do not efficiently form tumors in nude mice. Therefore, we utilized 
additional shPFKFB3 expressing lentiviruses to knockdown PFKFB3 expression in the 
A375 melanoma cell line. Initial 2D colony formation assays using shPFKFB3 A375 
cells exhibited decreased proliferation compared to control cells suggesting that, similar 
to p53-/- MEF cells, A375 cancer cells depend on glycolysis for proliferation (Fig 5.2). 
This finding correlates well with previous research that suggests that V600E BRAF 
malignant melanoma cells are particularly dependent upon glycolysis for energy and 
survival (Hall et al., 2013). Next, we injected mice with shPFKFB3 A375 cells to 
determine the effects of decreased PFKFB3 expression on cell proliferation and tumor 
growth in vivo. Unexpectedly, the shPFKFB3 A375 cells resulted in significantly larger 
tumors than the control cells (Fig 5.3). This result was so surprising that I repeated the 
experiment using newly generated cells and mice only to get the same result. This 
suggests that, at least for A375 melanoma cells, increased glucose flux through the 
PPP rather than glycolysis is more conducive to cancer cell proliferation. A possible 
explanation for this PPP dependence could be that A375 cells are more susceptible to 
ROS, and therefore, the increased NADPH produced from the PPP could promote 
survival. Secondly, PFKFB3 has been shown to localize to the nucleus and affect the 
expression of cell cycle regulating genes which could also contribute to the increased 
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growth for PFKFB3 knockdown cells (Yalcin et al., 2009). Additionally, the majority of 
cell proliferation assays are conducted on plastic with an excess availability of nutrients, 
whereas forming a solid tumor in a mouse exposes the cells to varied nutrient and 
oxygen availability along with secreted cues from neighboring cells. Considering the 
changes noted between these models, it is not surprising that plastic and in vivo 
xenografts give different results. Since tumor xenografts model the development of 
cancer better than plastic, the potential dependence upon the PPP observed in these 
shPFKFB3 A375 cells requires further study. First, the finding should be validated for 
other cell lines to minimize the possibility that a unique mutation in the A375 line is 
causing this dependence. If additional melanoma cells are found to be dependent upon 
the PPP, this would be surprising as two p53 target genes positively affect PPP flux 
(Bensaad et al., 2006; Franklin et al., 2016). Nonetheless, p53 can also inhibit the PPP 
by directly binding to G6PD in the cytoplasm (Jiang et al., 2011). While the bulk of 
activated p53 is nuclear upon activation, it is possible that under certain conditions 
cytoplasmic p53 could simultaneously act as a tumor suppressor by binding G6PD to 
prevent PPP-dependent growth. 
In addition to the surprising proliferation and tumorigenesis phenotype, further 
exploration of the role of glycolysis and the PPP in the generation of nucleotides in 
response to DNA damage is an exciting future direction. Many glycolytic enzymes have 
been studied in the context of proliferation and inhibitors have already been developed 
to target some of the more well-studied enzymes such as the glucose transporters 
(Shibuya et al., 2015). These compounds along with novel G6PD inhibitors should be 
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tested in combination with radiation treatment to further explore the novel p53-PFKFB3-
nucleotide pathway identified by my work.  
CROT 
CROT and peroxisomal lipid catabolism are much less well-studied than PFKFB3 
and glycolysis. Yet, cancer cells exhibit a lipid metabolism phenotype that is similarly 
widespread as the Warburg Effect in that cancer cells preferentially favor lipogenesis 
instead of fatty acid oxidation (Menendez and Lupu, 2007). With this relative lack of 
previous research, very little is known about the relationship between peroxisomal lipid 
catabolism and cancer. Moreover, the methodologies and techniques required to study 
lipid metabolism were historically limited compared to the advances made in other 
aspects of biomedical research. From this study, I have identified a novel p53 target 
gene that is involved in a new area of biological regulation for p53. The effects of this 
target gene extend to lipid raft microdomains and affect cell signaling through 
oncogenes including AKT. Since disruption of lipid rafts would target multiple oncogenic 
cell signaling pathways simultaneously, I hypothesize that this could form an effective 
therapeutic strategy once more information about the relationship between lipids, lipid 
raft microdomains, and cancer becomes available. 
While the initial finding CROT knockdown increases AKT activation is exciting, 
my work on the p53-CROT project is incomplete until we have a better understanding of 
the effects of the increased CROT expression mediated by p53 activation. I hypothesize 
that increased CROT expression will exert tumor suppressive effects, but new 
techniques in addition to siRNA and CRISPR will need to be implemented for these 
studies. To address this uncertainty, I am currently in the process of generating lentiviral 
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constructs expressing either WT CROT or H327A CROT, which is predicted to be 
catalytically dead, as overexpression mimics p53-mediated CROT expression. 
Moreover, the previous study on CROT-mediated fatty acid profiling in HepG2 cells 
indicated that overexpression of CROT more strongly affects the percentage change of 
both VLCFAs and medium chain fatty acids than CROT knockdown (Le Borgne et al., 
2011). I previously used adenovirus to exogenously express CROT in experiments 
assessing cell signaling, lipid raft fractionation, and survival, but adenovirus treatment 
activates multiple cell signaling pathways independent of CROT expression. 
Additionally, adenoviral CROT expression is transient and not well-suited for long term 
proliferation or xenograft assays. The use of lentivirus to stably increased CROT 
expression in cells will avoid the activation of AKT mediated by adenovirus and also 
facilitate long term growth experiments. Upon generation of these stable cells, I would 
like to complete two unbiased proteomics experiments along with various growth 
assays.  
The current studies identified the CROT-AKT connection by testing the 
hypothesis that CROT expression affects NRAS-mediated cell signaling. Activated 
NRAS (GTP-bound) preferentially localizes to lipid raft microdomains, which could be 
affected by CROT-mediated VLCFA metabolism (Matallanas et al., 2003). Furthermore, 
AKT activity was probed as AKT is a downstream effector of NRAS activation (Eisfeld et 
al., 2014). The CROT-LRP1 connection was identified in a more serendipitous manner 
as LRP1 is the subject of an independent project in our lab with a well-established lipid 
raft association (Laudati et al., 2016). To avoid selection bias in my additional studies, I 
will complete two proteomics experiments. First, I will assess the effects of CROT 
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expression on cell signaling by starving the cells of FBS for 12 h prior to stimulation with 
EGF for 10 min before lysis and enrichment of phosphorylated peptides, using titanium 
dioxide pulldown, followed by peptide identification and quantification using mass 
spectrometry. One advantage of this system compared to the previous preliminary 
MIB/MS experiment are that titanium dioxide pulldown requires less protein than 
MIB/MS. Furthermore, titanium dioxide pulldown minimizes the potential for bias from 
using various combinations of the multiplexed inhibitor bead cocktails. Secondly, I want 
to assess the effects of exogenous CROT expression on the localization of proteins to 
lipid raft microdomains. The previous data shown in Figure 3.20 suggests that increased 
CROT expression significantly displaces FLOT1 from the lipid raft fraction. If I am able 
to detect localization differences of either FLOT1 or LRP1 by western blot, I could then 
isolate lipid rafts from control and CROT overexpressing cells in response to stimulation 
to assess lipid raft localization by quantitative proteomics. Interesting hits from this 
assessment will then be validated by western blotting and potentially lipid raft 
fractionation experiments.  
In addition to the experiments focusing on assessing cell signaling, I will 
complete cell proliferation and tumor xenograft assays using these CROT 
overexpressing cells. I hypothesize that the effects of exogenous CROT expression on 
proliferation will be greater than our CROT knockdown data because multiple redundant 
enzymes such as ACOT4 likely compensate for decreased CROT expression. 
I have also been working to improve our stable knockdown of CROT by using 
CRISPR-Cas9. The polyclonal knockout cell population exhibits a clear but incomplete 
CROT knockdown and the monoclonal populations will be selected/evaluated soon. 
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These cells will be used in similar experiments to those described for the lentiviral 
CROT cells with one important exception. I would also like to use these CROT knockout 
cells to probe what p53-mediated changes in cell signaling or lipid raft localization are 
CROT-dependent. This will be accomplished by activating p53 by nutlin-3 treatment in 
control or CROT-KO HepG2 cells prior to lysis and lipid raft fraction. p53 regulates 
hundreds of target genes that could contribute to the strong decrease in lipid raft 
associated proteins shown in Figures 3.21 and 3.22 (Fischer, 2017). For example, an 
independent group at UNC recently published that p53 regulates ceramide synthase 6, 
which could also affect lipid raft composition and the localization of cell signaling 
proteins (Fekry et al., 2016). Completing the experiments proposed in this section 
should more conclusively show the p53- and CROT-mediated effects on cell 
proliferation, tumorigenesis, protein localization to lipid raft microdomains, and 
associated cell signaling.  
As there is minimal knowledge available for CROT structure or enzymatic 
activity, it is not feasible to target CROT or the lipid raft signaling pathways that have 
been identified in the previous study without additional study. Moreover, the effects of 
CROT knockdown, which partially mimics small molecule inhibition, on cell signaling 
and cell growth shown in this work are novel but relatively modest. Importantly, small 
molecule inhibitors of fatty acid synthase (FASN) have been developed and have 
already been shown to affect lipid raft composition in recent reports (Ventura et al., 
2015). In order to move our research closer to the clinic, I treated HepG2 cells with a 
high concentration of the FASN inhibitor orlistat to determine whether inhibition of 
lipogenesis activated p53 and/or CROT expression. While orlistat treatment exhibited 
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significant inhibition of cell growth that was similar to p53 activation (data not shown), 
orlistat treatment did not significantly activate p53 or CROT (Fig 5.4). The fact that 
orlistat induced cell cycle arrest independent of p53 activation suggests that lipid 
metabolism could be targeted independent of p53. Future studies focusing on lipid raft-
mediated cell signaling in response to orlistat or additional FASN inhibitors will be 
important for exploring lipid metabolism and lipid raft microdomains as novel targets in 
cancer treatment. Beyond FASN, the elongase ELOVL1, the enzyme responsible for 
VLCFA synthesis, has been shown to affect Lyn activation (Ohno et al., 2010). Taken 
together, the novel biological findings from this work and other studies suggest that 
targeting VLCFAs through FASN or ELOVL1 inhibition could be therapeutically 
beneficial by inhibiting multiple cell signaling pathways associated with cancer 
maintenance.  
All in all, the studies presented here clearly show that p53 can be activated by 
ribosomal proteins in response to nutrient excess, and that p53 regulates both 
glycolysis and lipid metabolism through the regulation of PFKFB3 and CROT. This work 
clearly establishes p53 as a central metabolic regulator and further identifies novel p53-
regulated pathways. Furthermore, these are exciting biological insights with clear 
connections to human diseases such as cancer.  
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(5.1) shPfkfb3 MEF cells exhibit decreased colony formation  
shPfkfb3 MEF cells were plated at 200 cells/well and grown for 2 weeks. Colonies were 







(5.2) shPFKFB3 A375 cells exhibit decreased proliferation and colony formation.  
(A) shPFKFB3 A375 cells exhibit slightly decreased proliferation at normoxia. 
(B) shPFKFB3 A375 cells exhibit slightly decreased proliferation at 3% O2. 
(C) Western blot evaluation of shPFKFB3 A375 cells, C2 & C5 are shPFKFB3 1 & 2. 
(D) Quantitation of colony formation assays grown at either normoxia or 3% O2 










(5.3) shPFKFB3 A375 cells form significantly larger tumors in mouse xenografts.  
(A) Tumor measurements taken in the nine days prior to sacrificing the mice exhibiting 
rapid growth for the shPFKFB3 A375 tumors. 









(5.4) Orlistat treatment does not activate p53 or induce CROT expression.  
A375 cells treated with vehicle (DMSO & Ethanol), orlistat (30 µM), ActD (5 nM), Nutlin-
3 (10 µM) or Etoposide (5 µg/mL) for 24 h prior to lysis and evaluation by western blot. 
 
	
DMSO		EtOH Orlistat			ActD			Nutlin Etoposide
MDM2
CROT
Actin
p21
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